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Introduction
Our Financial Review is provided in addition to the accompanying
consolidated financial statements and footnotes to assist readers
in understanding Pfizer’s results of operations, financial condition
and cash flows. The Financial Review is organized as follows:
• Overview of Consolidated Operating Results. This section
provides a general description of Pfizer’s business; an overview
of our 2005 performance; a summary of our new productivity
initiative; information about our operating environment; and
a discussion of our expectations for 2006.
• Accounting Policies. This section, beginning on page 5, discusses
those accounting policies that are considered important in
understanding Pfizer’s financial statements. For additional
accounting policies, including those considered to be critical
accounting policies, see Notes to Consolidated Financial
Statements—Note 1, Significant Accounting Policies.
• Acquisitions and Dispositions. This section, beginning on page
9, discusses significant acquisitions and dispositions made by
Pfizer during 2005, 2004 and 2003.
• Analysis of the Consolidated Statement of Income. This section,
beginning on page 11, provides an analysis of our products and
revenues for the three years ended December 31, 2005; an
overview of important product developments; a discussion
about our costs and expenses; an analysis of the financial
statement impact of our discontinued operations and
dispositions during the period; and a discussion of Adjusted
income, an alternative view of performance used by
management.
• Financial Condition, Liquidity and Capital Resources. This
section, beginning on page 27, provides an analysis of our
balance sheet as of December 31, 2005 and 2004, and cash flows
for the three years ended December 31, 2005, as well as a
discussion of our outstanding debt and commitments that
existed as of December 31, 2005. Included in the discussion of
outstanding debt is a discussion of the amount of financial
capacity available to fund Pfizer’s future commitments.
• Recently Issued Accounting Standards. This section, beginning
on page 30, discusses accounting standards that we have not
yet adopted and the expected impact to Pfizer upon adoption.
• Forward-Looking Information and Factors That May Affect
Future Results. This section, beginning on page 31, provides a
description of the risks and uncertainties that could cause
actual results to differ materially from those discussed in
forward-looking statements set forth in this report relating to
the financial results, operations and business prospects of the
Company. Such forward-looking statements are based on
management’s current expectations about future events, which
are inherently susceptible to uncertainty and changes in
circumstances. Also included in this section are discussions of
Financial Risk Management, Foreign Exchange Risk, Interest
Rate Risk and Legal Proceedings and Contingencies.
Overview of Consolidated Operating Results
Our Business
We are a research-based, global pharmaceutical company that
discovers, develops, manufactures and markets leading
prescription medicines for humans and animals, as well as many
of the world’s best known consumer healthcare products. Our
longstanding value proposition has been to prove that our
medicines cure or treat disease, including symptoms and suffering,
and this remains our core mission. We have expanded our value
proposition to also show that not only can our medicines cure or
treat disease, but that they can also markedly improve health
systems by reducing overall healthcare costs, improving societies’
economic well-being and increasing effective prevention and
treatment of disease. We generate revenue through the sale of
our products, as well as through alliance agreements by co-
promoting products discovered by other companies.
Our Human Health segment represented 86% of our total
revenues in 2005 and, therefore, developments relating to the
pharmaceutical industry can have a significant impact on our
operations.
Our 2005 Performance
Our performance in 2005 was impacted by the loss of exclusivity
in the U.S. of certain key medicines (Diflucan, Neurontin,
Accupril/Accuretic and Zithromax), uncertainty related to Celebrex
and the suspension of Bextra sales, which collectively reduced our
worldwide revenues by $5.7 billion compared with 2004. Partially
offsetting these impacts was the solid aggregate performance of
the balance of our portfolio of patent-protected medicines.
Specifically, in 2005,
• Our total revenues decreased 2% to $51.3 billion from 2004.
Revenues of major products with lost exclusivity in the U.S.
(Diflucan, Neurontin and Accupril/Accuretic during 2004 and
Zithromax in November 2005) declined by 44% from 2004.
These four products represented 8% of our Human Health
revenues and 7% of our total revenues for the year ended
December 31, 2005 compared to 13% of our Human Health
revenues and 12% of our total revenues for the year ended
December 31, 2004. Uncertainty related to Celebrex and the
suspension of Bextra sales have resulted in a significant decline
in prescription volume in the arthritis and pain market, resulting
in a 63% decline in revenues in those products from 2004.
These declines were partially offset by an aggregate revenue
increase of 11% in the balance of our portfolio of our patent-
protected products. Our portfolio of medicines includes four of
the world’s 25 best-selling medicines, with six medicines that
lead their therapeutic areas (see further discussion in the
“Human Health-Selected Product Descriptions” section of this
Financial Review).
• Our net income was $8.1 billion compared with $11.4 billion in
2004. Our 2005 results reflect in-process research and
development (IPR&D) charges of $1.7 billion, primarily related
to our acquisitions of Vicuron Pharmaceuticals, Inc. (Vicuron)
and Idun Pharmaceuticals, Inc. (Idun); asset impairment and
other charges of $1.2 billion associated with the suspension of
sales of Bextra; restructuring charges and merger-related costs
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of $943 million associated with our integration of Pharmacia
Corporation (Pharmacia), an acquisition in 2003; restructuring
and implementation costs of $780 million associated with our
new productivity initiative; increased pressure on our cost of
sales; and an effective tax rate of 29.7%, reflecting our
repatriation of foreign earnings; partially offset by $800 million
in cost savings from our new productivity initiative. Our 2004
results reflect IPR&D charges of $1.1 billion, primarily related
to our acquisition of Esperion Therapeutics, Inc. (Esperion); an
asset impairment charge of $691 million related to the Depo-
Provera brand; restructuring charges and merger-related costs
of $1.2 billion associated with the integration of Pharmacia;
$369 million in connection with certain litigation-related
charges; and an effective tax rate of 19%. Both years benefited
from the cost savings associated with the Pharmacia acquisition.
• We launched a company-wide productivity initiative, called
Adapting to Scale (AtS), which involves a comprehensive review
of our processes, organizations, systems and decision-making.
We achieved annual cost savings under the AtS productivity
initiative of approximately $800 million in 2005 and expect this
program to yield annual cost savings of about $4 billion by 2008.
We also achieved approximately $4.2 billion in annual cost
savings as a result of our integration of Pharmacia. See further
discussion in the “Our Adapting to Scale Productivity Initiative
and Merger-Related Synergies” section of this Financial Review.
• We acquired Vicuron, a biopharmaceutical company focused on
the development of novel anti-infectives, for approximately $1.9
billion in cash and Idun, a biopharmaceutical company focused
on the discovery and development of therapies to control
apoptosis (cell death), for approximately $298 million in cash.
We expect that these strategic acquisitions will strengthen
and broaden our existing pharmaceutical capabilities.
Our Adapting to Scale Productivity Initiative and
Merger-Related Synergies
Our multi-year productivity initiative, called Adapting to Scale
(AtS), to increase efficiency and streamline decision-making across
the Company, was launched in the first quarter of 2005. It follows
the integration of Warner-Lambert and Pharmacia, which resulted
in the tripling of Pfizer’s revenues over the past six years. The
integration of those two companies resulted in a combined expense
reduction of approximately $6 billion, inclusive of $4.2 billion in
Pharmacia-related synergies that were achieved through 2005.
The new AtS productivity initiative is expected to yield $4 billion
in cost savings on an annual basis by 2008, based on a top-to-bottom
business review completed during the first half of 2005.
During 2005, cost savings from our AtS productivity initiative
were approximately $800 million, mainly attributable to the
Human Health business. We expect annual cost savings to
accelerate over the next three years, with about $2 billion in 
savings targeted for 2006, about $3.5 billion in 2007 and about
$4 billion upon completion in 2008. These savings are expected
to be realized in procurement, operating expenses and facilities,
among other sources. We plan to use the cost savings we generate,
in part, to fund key investments, including new product launches
and the development of the many promising new medicines in
our pipeline. The Company expects that the aggregate cost of
implementing this initiative through 2008 will be approximately
$4 billion to $5 billion on a pre-tax basis. 
Projects in various stages of implementation include:
• Reorganizing Pfizer Global Research & Development (PGRD) to
increase efficiency and effectiveness in bringing new therapies
to patients-in-need while reducing the cost of research and
development. PGRD is being reorganized into eleven
therapeutic areas—cardiovascular, metabolic, and endocrine;
central nervous system; inflammation; allergy and respiratory;
infectious diseases; pain; gastrointestinal and hepatitis;
oncology; urology and sexual health; ophthalmology; and
dermatology. Each therapeutic area will have three co-leaders:
a Research leader whose expertise is in preclinical compounds;
a Development leader whose expertise is in clinical studies; and
a Commercial leader whose expertise is in marketing. Discovery
Research will retain its existing structure of six drug-candidate-
discovery sites. Development will move toward single sites for
most therapeutic areas.
• The continuation of our optimization of Pfizer Global
Manufacturing’s plant network, which began with the
acquisition of Pharmacia, to ensure that the Company’s
manufacturing facilities are aligned with current and future
product needs. During 2005, 14 sites were identified for
rationalization (Angers and Val de Reuil, France; Arecibo and
Cruce Davila, Puerto Rico; Augusta, Georgia; Corby and
Morpeth, U.K.; Holland, Michigan; Jakarta, Indonesia;
Orangeville, Canada; Parsippany, New Jersey; Tsukuba, Japan;
Stockholm and Uppsala-Fyrislund, Sweden). In addition, there
have been extensive reductions in site operations in Sandwich,
U.K. (the planned closure of drug product, distribution and
fermentation operations); Lincoln and Omaha, Nebraska sites;
and Puerto Rico sites (staff reductions), with smaller staff
reductions in Groton, Connecticut and Lititz, Pennsylvania.
• Realigning our European marketing teams and implementing
initiatives designed to improve the effectiveness of our field
force in Japan. During the third quarter of 2005, we completed
a major reorganization of the U.S. field force, reshaping the
management structure to be more responsive to commercial
trends as the Medicare Modernization Act takes effect and
driving greater sales-force accountability in preparation for
the upcoming launch of new medicines.
• Pursuing savings in information technology resulting from
significant reductions in application software (already reduced
from over 8,000 at the time of the Pharmacia acquisition in 2003
to fewer than 3,000) and data centers (to be reduced from 17
to 4), as well as rationalization of service providers, while
enhancing our ability to invest in innovative technology
opportunities to further propel our growth.
• Reducing costs in purchased goods and services. Purchasing
initiatives will focus on rationalizing suppliers, leveraging the
approximately $16 billion of goods and services that Pfizer
purchases annually, improving demand management to
optimize levels of outside services needed and strategic sourcing
from lower-cost sources. For example, savings from demand
management will be derived in part from reductions in travel,
entertainment, consulting and other external service expenses.
Facilities savings are being found in site rationalization, energy
conservation, and renegotiated service contracts.
Our Business Environment
There are a number of industry-wide factors that may affect our
business and should be considered along with the information
presented in the section “Forward-Looking Information and
Factors That May Affect Future Results.” Such industry-wide
factors include continuing pricing pressures both in the U.S. and
internationally, pressures on selective COX-2 inhibitor products,
the increasing regulatory scrutiny of drug safety, the adoption of
new direct-to-consumer (DTC) advertising guidelines, lower
prescription growth rates and increased branded and generic
competition in certain therapeutic areas. It is important to
recognize that our near-term future products reflect investments
we made approximately ten years ago through our in-house
research and development operations or reflect more recent
investments in development and acquisitions or collaborations.
Looking beyond our portfolio of leading medicines, we are
positioning Pfizer to fulfill our vision to serve the public’s health
needs more fully, not just through the treatment of diseases,
but also through the promotion of health.
We believe that there are future opportunities for revenue
generation for our products, including:
• Current demographics of developed countries that indicate
that people are living longer and, therefore, will have a greater
need for the most effective medicines;
• The large number of untreated patients within our various
therapeutic categories. For example, of the tens of millions of
Americans who need medical therapy for high cholesterol, we
estimate only about one-fourth are actually receiving treatment;
• Refocusing the debate on health policy to address the cost of
disease that remains untreated and the benefits of investing
in prevention and wellness to not only improve health, but save
money;
• The promise of technology to improve upon existing therapies
and to introduce treatments where none currently exist;
• Developments and growth in Pfizer’s presence in emerging
markets worldwide; and
• Worldwide emphasis on the need to find solutions to difficult
problems in healthcare systems.
We have known that we would face loss of exclusivity in the U.S.
of several key products in a very short period of time. As a result,
we have been remaking our Company to meet changing times and
we are addressing our challenges through the following actions:
• Enhancing a product portfolio intended to transcend the
volatility of individual products or markets;
• Pursuing a large number of new product launches, indications
and completed clinical trials;
• Increasing our research and development (R&D) productivity;
• Emphasizing the clinical benefits of our medicines;
• Launching new global positionings of our products, where
necessary;
• Acquiring the rights to promising medicines;
• Defending our patents aggressively;
• Marketing generic versions of certain of our products after our
compounds face generic competition;
• Guarding the integrity of our products in an increasingly
predatory atmosphere evidenced by the growing problem of
counterfeit drugs;
• Addressing the wide array of patient populations through our
innovative access and affordability programs;
• Aligning our research, development and marketing functions
in search of new medical opportunities as part of a fully
integrated portfolio-planning process; and
• Streamlining many of our basic functions to capitalize on our
unmatched size and reach.
Continuing Pricing Pressures
A rise in Consumer Directed Health Plans has increased consumer
sensitization to the cost of healthcare. Consumers are aware of
global price differences resulting from price controls imposed
by foreign governments and have become more willing to seek
less expensive alternatives, such as switching to generics and
sourcing medicines across national borders. Both U.S. and
international governmental regulations mandating prices or price
controls can impact our revenues, and we continue to work
within the current legal and pricing structures to minimize the
impact on our revenues. For example, we have taken steps to
assure that medicines intended for Canadian consumption are in
fact used for that purpose. Managed care organizations, as well
as government agencies, with their significant purchasing power,
continue to seek discounts on our products which has served to
slow our revenue growth.
The enactment of the Medicare Prescription Drug Improvement
and Modernization Act of 2003 (which went into effect in 2006)
regarding prescription drug benefits for Medicare beneficiaries
expands access to medicines that patients need. While expanded
access may potentially result in increased sales of our products,
such increases may be offset by increased pricing pressures due
to the enhanced purchasing power of the private sector providers
that will negotiate on behalf of Medicare beneficiaries in the
future. We believe that our medicines provide significant value
for both providers and patients not only from the improved
treatment of diseases, but also from a reduction in other
healthcare costs such as hospitalization or emergency room costs,
increased patient productivity and a better quality of life.
Defending Our Intellectual Property Rights
The loss of patent protection with respect to any of our major
products can have a material adverse effect on future revenues
and our results of operations. Our performance in 2005 was
impacted by loss of U.S. exclusivity of four major products—
Diflucan, Neurontin, and Accupril/Accuretic during 2004 and
Zithromax in November 2005. In addition, we face the loss of U.S.
exclusivity for Zoloft during 2006 and Norvasc and Zyrtec during
2007. These seven products represented 33% of our Human
Health revenues and 29% of our total revenues for the year
ended December 31, 2004. Zithromax, Zoloft, Norvasc and Zyrtec
represented 26% of our Human Health revenues and 22% of our
total company revenues for the year ended December 31, 2005.
Intellectual property legal protections and remedies are a
significant factor in our business. Many of our products have a
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composition-of-matter or compound patent and may also have
additional patents. Additional patents can include additional
composition-of-matter patents, processes for making the
compound or additional indications or uses. As such, each of our
products has varying patents expiring at varying dates, thereby
strengthening our patent protection. However, once the patent
protection period has expired, generic pharmaceutical
manufacturers generally produce similar products and sell those
products for a lower price. This price competition can substantially
decrease our revenues.
Patents covering our products are subject to challenges from
time to time. Increasingly, generic pharmaceutical manufacturers
are launching their products “at-risk”—before the final resolution
of legal proceedings challenging their generic products. Wherever
appropriate, we aggressively defend our patent rights against 
such challenges (details of these matters are described in Notes
to the Consolidated Financial Statements—Note 18, Legal
Proceedings and Contingencies).
Product Competition
We face the loss of U.S. exclusivity for Zoloft during 2006 and
Norvasc and Zyrtec during 2007. In addition, some of our products
face competition in the form of new branded products or generic
drugs, which treat similar diseases or indications. We have been
able to limit the impact on revenues by highlighting the proven
track record of safety and efficacy of our products. For example,
the success of Lipitor is the result of an unprecedented array of
clinical data supporting both efficacy and safety.
Expansion and Productivity of Development Pipeline
Discovery and development of new products, as well as the
development of additional uses for existing products, are
imperative for the continued strong operation of our businesses.
The numerous filings, approvals and launches of new Pfizer
products and product enhancements during 2005 and in early 2006
evidenced a productive period of R&D. The opportunities for
improving human health remain abundant. As the world’s largest
privately funded biomedical operation, and through our global
scale, we are developing and delivering innovative medicines
that will benefit patients around the world. We will continue to
make the investments necessary to serve patients’ needs and to
generate long-term growth. A good example of this is our
torcetrapib/atorvastatin (Lipitor) development program whose
objective is to provide clear evidence that substantially raising HDL-
cholesterol and further lowering LDL-cholesterol can reduce
cardiovascular risk beyond what can be currently achieved with
existing treatments.
During 2005, we continued to successfully introduce new products,
including Macugen, Revatio, Zmax and Lyrica in the U.S. In
December 2004 and during 2005, we or our development partners
submitted six New Drug Applications (NDAs) to the U.S. Food and
Drug Administration (FDA) for important new drug candidates:
Exubera, indiplon, Sutent (Sunitinib Malate), Zeven (dalbavancin),
Eraxis (anidulafungin) and Champix (varenicline). We continue to
make progress toward our goal of filing 20 major new medicines
in the U.S. in the five-year period ending in 2006. However, we
now believe we will achieve 19 of those filings by the end of 2006.
Even so, we believe that our track record of 19 NDA filings in five
years evidences one of the highest levels of productivity in our
industry. In February 2006, the FDA approved Eraxis for treatment
of candidemia and invasive candidiasis, and for treatment of
esophageal candidiasis. In January 2006, the FDA and the
European Commission approved Exubera (inhaled human insulin)
for treatment of type 1 and type 2 diabetes in adults, and the FDA
approved Sutent for advanced kidney cancer and gastrointestinal
stromal tumors.
Our financial strength enables us to conduct research on a scale that
can help redefine medical practice. We have combined that ability
with a fully integrated portfolio-planning approach that aligns
our research, development, and marketing functions in the search
for new medical opportunities. We have over 200 novel concepts
in development across multiple therapeutic areas, and we are
leveraging our status as the industry’s partner of choice to expand
our licensing operations. This is enabling us to strengthen our core
cardiovascular and neuroscience portfolios, as well as to expand
other therapeutic areas, including oncology and ophthalmology.
Our R&D pipeline included, as of February 10, 2006, 235 projects
in development: 152 new molecular entities and 83 product-line
extensions. In addition, we have more than 400 projects in
discovery research. During 2005, 47 new compounds were
advanced from discovery research into preclinical development,
30 preclinical development candidates progressed into Phase 1
human testing and 12 Phase 1 clinical development candidates
advanced into Phase 2 proof-of-concept trials.
Reducing attrition has been a key focus on our R&D productivity
improvement effort. For several years, we have been revising the
quality hurdles for candidates entering development and
throughout the development process. As the quality of candidates
has improved, the development attrition rate has begun to fall. At
our current internal discovery output of chemical entities and at the
attrition rates we are seeing for these high quality candidates, we
believe we will improve our overall success rates to 1 in 11 versus
the historical industry rate of 1 in 20 to 25. This would allow us to
double our productivity without doubling our R&D investment.
Given the multi-year nature of pharmaceutical R&D, it will take
some time before the full impact of these changes is realized.
While a significant portion of R&D is done internally, we do enter
into agreements with other companies to co-develop promising
compounds. These co-development and alliance agreements
allow us to capitalize on these compounds to expand our pipeline
of potential future products. We have more than 1,000 alliances
across the entire spectrum of the discovery, development and
commercialization process. Our R&D covers a wide spectrum of
therapeutic areas as discussed in the “Product Developments”
section of this Financial Review. Due to our strength in marketing
and our global reach, we are able to attract other organizations
that may have promising compounds and can benefit from our
strength and skills. Over the past two years, we have invested $4.4
billion in acquisitions for these purposes. For example, in 2005, the
acquisition of Vicuron builds on Pfizer’s extensive experience in
anti-infectives and demonstrates our commitment to strengthen
and broaden our pharmaceutical business through strategic
product acquisitions. By acquiring Vicuron, Pfizer looks forward
to bringing to patients around the world two important new
medicines that at the date of the acquisition were under review
by the FDA. In February 2006, Eraxis was approved by the FDA.
Our Expectations for 2006
While our revenue and income will likely continue to be tempered
in the near term due to patent expirations and other factors, we
will continue to make the investments necessary to sustain long-
term growth. We remain confident that Pfizer has the
organizational strength and resilience, as well as the financial
depth and flexibility, to succeed in the long term. However, no
assurance can be given that the industry-wide factors described
above or other significant factors will not have a material adverse
effect on our business and financial results.
Given these and other factors, at current exchange rates and
reflecting management’s current assessment, for 2006 we expect
Adjusted income of approximately $15 billion, Adjusted diluted EPS
of approximately $2.00, reported Net income of approximately 
$11.4 to $11.7 billion, reported diluted EPS of approximately
$1.52 to $1.56 and over $16 billion in cash flow from operations,
all of which do not reflect the purchase accounting impacts of a
pending business-development transaction, as well as any potential
impacts in connection with a business for which we are exploring
strategic options. We expect 2006 revenues to be comparable to
2005. The growth of three key products—Lipitor, Celebrex and
Lyrica—is expected to contribute significantly to our 2006 revenues.
Our forecasted financial performance in 2006 is subject to a
number of factors and uncertainties—as described in the “Forward
Looking Information and Factors That May Affect Future Results”
section below. Some of these factors and uncertainties may persist
over our planning horizon.
A reconciliation of forecasted 2006 Adjusted income and Adjusted
diluted EPS to forecasted 2006 reported Net income and reported
diluted EPS follows:
($ BILLIONS, EXCEPT PER-SHARE AMOUNTS) NET INCOME(a) DILUTED EPS(a)
Forecasted Adjusted 
income/diluted EPS ~$15.0 ~$2.00
Intangible amortization, 
net of tax (2.3) (0.31)
Adapting to scale costs(b) (1.4-1.7) (0.19-0.23)
Resolution of certain tax 
positions 0.4 0.06
Forecasted reported Net 
income/diluted EPS ~$11.4 – $11.7 ~$1.52 – $1.56
(a) Does not reflect the purchase accounting impacts of a pending
business-development transaction, as well as any potential
impacts in connection with a business for which we are exploring
strategic options.
(b) About 15% is expected to be incurred in Selling, informational
and administrative expense (SI&A), about 10% in Research and
development expense and about 5% in Cost of sales with the
balance in Restructuring charges and merger-related costs.
Accounting Policies
We consider the following accounting policies important in
understanding our operating results and financial condition. For
additional accounting policies, see Notes to the Consolidated
Financial Statements—Note 1, Significant Accounting Policies.
Estimates and Assumptions
In preparing the consolidated financial statements, we use certain
estimates and assumptions that affect reported amounts and
disclosures. For example, estimates are used when accounting for
deductions from revenues (such as rebates, discounts, incentives and
product returns), depreciation, amortization, employee benefits,
contingencies and asset and liability valuations. Our estimates are
often based on complex judgments, probabilities and assumptions
that we believe to be reasonable, but that are inherently uncertain
and unpredictable. Assumptions may be incomplete or inaccurate
and unanticipated events and circumstances may occur. It is also
possible that other professionals, applying reasonable judgment to
the same facts and circumstances, could develop and support a
range of alternative estimated amounts. We are also subject to
other risks and uncertainties that may cause actual results to
differ from estimated amounts, such as changes in the healthcare
environment, competition, foreign exchange, litigation, legislation
and regulations. These and other risks and uncertainties are
discussed throughout this Financial Review, particularly in the
section “Forward-Looking Information and Factors That May
Affect Future Results.”
Contingencies
We and certain of our subsidiaries are involved in various patent,
product liability, consumer, commercial, securities, environmental
and tax litigations and claims; government investigations; and
other legal proceedings that arise from time to time in the
ordinary course of our business. We record accruals for such
contingencies to the extent that we conclude their occurrence is
probable and the related damages are estimable. We consider
many factors in making these assessments. Because litigation
and other contingencies are inherently unpredictable and
excessive verdicts do occur, these assessments can involve a series
of complex judgments about future events and can rely heavily
on estimates and assumptions (see Notes to the Consolidated
Financial Statements—Note 1B, Significant Accounting Policies:
Estimates and Assumptions). We record anticipated recoveries
under existing insurance contracts when assured of recovery.
Acquisitions
Our consolidated financial statements and results of operations
reflect an acquired business after the completion of the acquisition
and are not restated. We account for acquired businesses using
the purchase method of accounting which requires that the
assets acquired and liabilities assumed be recorded at the date of
acquisition at their respective fair values. Any excess of the
purchase price over the estimated fair values of the net assets
acquired is recorded as goodwill. Amounts allocated to acquired
IPR&D are expensed at the date of acquisition. When we acquire
net assets that do not constitute a business under generally
accepted accounting principles in the U.S. (GAAP), no goodwill is
recognized.
The judgments made in determining the estimated fair value
assigned to each class of assets acquired and liabilities assumed,
as well as asset lives, can materially impact our results of
operations. Accordingly, for significant items, we typically obtain
assistance from third party valuation specialists.The valuations are
based on information available near the acquisition date and are
based on expectations and assumptions that have been deemed
reasonable by management.
There are several methods that can be used to determine the fair
value of assets acquired and liabilities assumed. For intangible
assets, including IPR&D, we typically use the “income method.”
This method starts with a forecast of all of the expected future
net cash flows. These cash flows are then adjusted to present value
by applying an appropriate discount rate that reflects the risk
factors associated with the cash flow streams. Some of the more
significant estimates and assumptions inherent in the income
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method or other methods include: the amount and timing of
projected future cash flows; the amount and timing of projected
costs to develop the IPR&D into commercially viable products; the
discount rate selected to measure the risks inherent in the future
cash flows; and the assessment of the asset’s life cycle and the
competitive trends impacting the asset, including consideration
of any technical, legal, regulatory, or economic barriers to entry,
as well as expected changes in standards of practice for indications
addressed by the asset.
Determining the useful life of an intangible asset also requires
judgment as different types of intangible assets will have different
useful lives and certain assets may even be considered to have
indefinite useful lives. For example, the useful life of the right
associated with a pharmaceutical product’s exclusive patent will
be finite and will result in amortization expense being recorded
in our results of operations over a determinable period. However,
the useful life associated with a brand that has no patent
protection but that retains, and is expected to retain, a distinct
market identity could be considered to be indefinite and the
asset would not be amortized.
Revenues
Revenue Recognition—We record revenue from product sales
when the goods are shipped and title passes to the customer. At
the time of sale, we also record estimates for a variety of sales
deductions, such as rebates, discounts and incentives, and product
returns.
Deductions from Revenues—Our gross product sales are subject
to a variety of deductions, primarily representing rebates and
discounts to government agencies, wholesalers and managed
care organizations with respect to our pharmaceutical products.
These deductions represent estimates of the related obligations
and, as such, judgment is required when estimating the impact
of these sales deductions on gross sales for a reporting period.
Specifically:
• In the U.S., we record provisions for pharmaceutical Medicaid and
contract rebates based upon our actual experience ratio of
rebates paid and actual prescriptions written during prior quarters.
We apply the experience ratio to the respective period’s sales to
determine the rebate accrual and related expense. This experience
ratio is evaluated regularly to ensure that the historical trends are
as current as practicable. As appropriate, we will adjust the ratio
to better match our current experience or our expected future
experience. In assessing this ratio, we consider current contract
terms, such as changes in formulary status and discount rates. If
our ratio is not indicative of future experience, our results could
be materially affected.
• Provisions for pharmaceutical chargebacks (primarily discounts
to federal government agencies) closely approximate actual as
we settle these deductions generally within 2-3 weeks of
incurring the liability.
• Outside of the U.S., the majority of our pharmaceutical rebates
are contractual or legislatively-mandated and our estimates are
based on actual invoiced sales within each period; both of these
elements help to reduce the risk of variations in the estimation
process. Some European countries base their rebates on the
government’s unbudgeted pharmaceutical spending and we use
an estimated allocation factor against our actual invoiced sales
to project the expected level of reimbursement. We obtain third
party information that helps us monitor the adequacy of these
accruals. If our estimates are not indicative of actual unbudgeted
spending, our results could be materially affected.
• We record sales incentives as a reduction of revenues at the time
the related revenues are recorded or when the incentive is
offered, whichever is later. We estimate the cost of our sales
incentives based on our historical experience with similar
incentives programs.
Historically, our adjustments to actual have not been material; on
a quarterly basis, they generally have been less than 0.5% of net
sales and can result in a net increase to income or a net decrease
to income. The sensitivity of our estimates can vary by program,
type of customer and geographic location. However, estimates
associated with U.S. Medicaid and contract rebates are most at-
risk for material adjustment because of the extensive time delay
between the recording of the accrual and its ultimate settlement,
an interval that can range up to one year. Because of this time lag,
in any given quarter, our adjustments to actual can incorporate
revisions of several prior quarters.
Alliances—We have agreements to co-promote pharmaceutical
products discovered by other companies. Revenue is earned when
our co-promotion partners ship the related product and title
passes to their customer. Alliance revenue is primarily based upon
a percentage of our co-promotion partners’ net sales. Generally,
expenses for selling and marketing these products are included
in Selling, informational and administrative expenses.
Long-lived Asset Impairment Analysis
We review all of our long-lived assets, including goodwill and
other intangible assets, for impairment indicators at least annually
and we perform detailed impairment testing for goodwill and
indefinite-lived assets annually and for all other long-lived assets
whenever impairment indicators are present. Examples of those
events or circumstances that may be indicative of impairment
include:
• A significant adverse change in legal factors or in the business
climate that could affect the value of the asset. For example,
a successful challenge of our patent rights resulting in generic
competition earlier than expected.
• A significant adverse change in the extent or manner in which
an asset is used. For example, restrictions imposed by the FDA
or other regulatory authorities that affect our ability to
manufacture or sell a product.
• A projection or forecast that demonstrates losses associated
with an asset. For example, a change in a government
reimbursement program that results in an inability to sustain
projected product revenues and profitability.
Our impairment review process is as follows:
• For finite-lived intangible assets, such as developed technology
rights, whenever impairment indicators are present, we will
perform an in-depth review for impairment. We will calculate
the undiscounted value of the projected cash flows associated
with the asset and compare this estimated amount to the
carrying amount of the asset. If the carrying amount is found
to be greater, we will record an impairment loss for the excess
of book value over the asset’s fair value. Fair value is generally
calculated by applying an appropriate discount rate to the
undiscounted cash flow projections to arrive at net present
value. In addition, in all cases of an impairment review, we will
re-evaluate the remaining useful life of the asset and modify
it, as appropriate.
• For indefinite-lived intangible assets, such as brands, each year
and whenever impairment indicators are present, we will
calculate the fair value of the asset and record an impairment
loss for the excess of book value over fair value, if any. Fair value
is generally measured as the net present value of projected cash
flows. In addition, in all cases of an impairment review, we will
re-evaluate the remaining useful life of the asset and determine
whether continuing to characterize the asset as having an
indefinite life is appropriate.
• For goodwill, which includes amounts related to our Human
Health, Consumer Healthcare and Animal Health segments,
each year and whenever impairment indicators are present, we
will calculate the fair value of each business segment and
calculate the implied fair value of goodwill by subtracting the
fair value of all the identifiable net assets other than goodwill
and record an impairment loss for the excess of book value of
goodwill over the implied fair value, if any.
• For other long-lived assets, such as property, plant and
equipment, we apply procedures similar to those for finite-lived
intangible assets to determine if an asset is impaired. Long-term
investments and loans are subject to periodic impairment
reviews and whenever impairment indicators are present. For
these assets, fair value is typically determined by observable
market quotes or the expected present value of future cash
flows. When necessary, we record charges for impairments of
long-lived assets for the amount by which the fair value is less
than the carrying value of these assets.
• For non-current deferred tax assets, we provide a valuation
allowance when we believe that the assets are not recoverable
based on an assessment of estimated future taxable income that
incorporates ongoing, prudent, feasible tax planning strategies.
The value of intangible assets is determined primarily using the
“income method,” which starts with a forecast of all the expected
future net cash flows (see “Acquisitions” above). Accordingly,
the potential for impairment for these intangible assets may
exist if actual revenues are significantly less than those initially
forecasted or actual expenses are significantly more than those
initially forecasted.
Some of the more significant estimates and assumptions inherent
in the intangible asset impairment estimation process include: the
amount and timing of projected future cash flows; the discount
rate selected to measure the risks inherent in the future cash flows;
and the assessment of the asset’s life cycle and the competitive
trends impacting the asset, including consideration of any
technical, legal, regulatory, or economic barriers to entry as well
as expected changes in standard of practice for indications
addressed by the asset.
The implied fair value of goodwill is determined by first estimating
the fair value of the associated business segment. To estimate the
fair value of each business segment, we generally use the “market
approach,” where we compare the segment to similar businesses
or “guideline” companies whose securities are actively traded in
public markets or which have recently been sold in a private
transaction; or the ”income approach,” where we use a discounted
cash flow model in which cash flows anticipated over several
periods, plus a terminal value at the end of that time horizon, are
discounted to their present value using an appropriate rate of
return. 
Some of the more significant estimates and assumptions inherent
in the goodwill impairment estimation process using the “market
approach” include: the selection of appropriate guideline
companies; the determination of market value multiples for the
guideline companies and the subsequent selection of an
appropriate market value multiple for the business segment
based on a comparison of the business segment to the guideline
companies; and the determination of applicable premiums and
discounts based on any differences in ownership percentages,
ownership rights, business ownership forms, or marketability
between the segment and the guideline companies; and/or
knowledge of the terms and conditions of comparable
transactions; and when considering the ”income approach,”
include: the required rate of return used in the discounted cash
flow method, which reflects capital market conditions and the
specific risks associated with the business segment. Other estimates
inherent in the ”income approach” include long-term growth rates
and cash flow forecasts for the business segment.
A single estimate of fair value results from a complex series of
judgments about future events and uncertainties and relies
heavily on estimates and assumptions (see “Estimates and
Assumptions” above). The judgments made in determining an
estimate of fair value can materially impact our results of
operations. As such, for significant items, we often obtain
assistance from third party valuation specialists. The valuations are
based on information available as of the impairment review date
and are based on expectations and assumptions that have been
deemed reasonable by management.
Share-Based Payments
Our compensation programs can include share-based payments.
Stock options, which entitle the holder to purchase shares of
Pfizer stock at a pre-determined price at the end of a vesting term,
are accounted for under Accounting Principles Board Opinion No.
25, Accounting for Stock Issued to Employees, an elective
accounting policy permitted by SFAS No. 123, Accounting for
Stock-Based Compensation. Under this policy, since the exercise
price of stock options granted is set equal to the market price on
the date of the grant, we do not record any expense to the
income statement related to the grants of stock options, unless
certain original grant-date terms are subsequently modified.
For disclosure purposes only, we estimate the fair value of
employee stock options, as required under GAAP, using the Black-
Scholes-Merton option-pricing model. We believe that it is difficult
to accurately measure the value of an employee stock option (see
“Estimates and Assumptions” above). Our estimates of employee
stock option values rely on estimates of factors we input into the
model. The key factors involve an estimate of future uncertain
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events. The key factors influencing the estimation process, among
others, are the expected term of the option, the expected stock
price volatility factor and the expected dividend yield.
In the first quarter of 2005, we changed our method of estimating
expected dividend yield from historical patterns of dividend
payments to a method that reflects a constant dividend yield
during the expected term of the option. In the first quarter of
2004, we began using quoted implied volatility to determine the
expected stock price volatility factor. We believe that these
market-based inputs provide a better estimate of our future
stock price movements and are consistent with emerging
employee stock option valuation considerations. Also, of
significance, is our expected term until exercise factor. We continue
to use historical exercise patterns as our best estimate of future
exercise patterns. Once employee stock option values are
determined, current accounting practices do not permit them to
be changed, even if the estimates used are different from actual.
The pro forma effect on net income and diluted earnings per
common share for the years ended 2005, 2004 and 2003 is set forth
in Notes to the Consolidated Financial Statements—see Note 1P,
Significant Accounting Policies: Share-Based Payments.
Additionally, see our discussion in the “Recently Issued Accounting
Standards” section of this Financial Review.
Beginning in 2006, we will report the value of stock options in our
income statement. See our discussion in “Recently Issued
Accounting Standards” section of this Financial Review.
Benefit Plans
We provide defined benefit pension plans and defined
contribution plans for the majority of our employees worldwide.
In the U.S., we have both qualified and supplemental (non-
qualified) defined benefit plans and defined contribution plans,
as well as other postretirement benefit plans, consisting primarily
of healthcare and life insurance for retirees.
A U.S. qualified plan meets the requirements of certain sections of
the Internal Revenue Code and, generally, contributions to qualified
plans are tax deductible. It typically provides benefits to a broad
group of employees and may not discriminate in favor of highly
compensated employees in its coverage, benefits or contributions.
We also provide benefits through non-qualified U.S. retirement
plans to certain employees. These supplemental plans, which
generally are not funded, will provide, out of our general assets,
an amount substantially equal to the amounts that would have
been payable under the defined benefit qualified pension plans,
in the absence of legislation limiting pension benefits and earnings
that may be considered in calculating pension benefits. In addition,
we provide medical and life insurance benefits to retirees and their
eligible dependents through our postretirement plans, which, in
general, are also unfunded obligations.
In 2005, we made required U.S. qualified plan contributions of $3
million and voluntary tax-deductible contributions in excess of
minimum requirements of $49 million to our U.S. pension plans.
In 2004, we made required U.S. qualified plan contributions of $29
million and voluntary tax-deductible contributions in excess of
minimum requirements of $52 million to our U.S. pension plans.
In the aggregate, the U.S. qualified pension plans are overfunded
on an accumulated benefit obligation measurement basis as of
December 31, 2005 and 2004.
Outside the U.S., in general, we fund our defined benefit plans
to the extent that tax or other incentives exist and we have
accrued liabilities on our consolidated balance sheets to reflect
those plans that are not fully funded.
The accounting for benefit plans is highly dependent on actuarial
estimates, assumptions and calculations which result from a
complex series of judgments about future events and uncertainties
(see “Estimates and Assumptions” above). The assumptions and
actuarial estimates required to estimate the employee benefit
obligations for the defined benefit and postretirement plans,
include discount rate; expected salary increases; certain employee-
related factors, such as turnover, retirement age and mortality (life
expectancy); expected return on assets; and healthcare cost trend
rates. Our assumptions reflect our historical experiences and our
best judgment regarding future expectations that have been
deemed reasonable by management. The judgments made in
determining the costs of our benefit plans can materially impact
our results of operations. As such, we often obtain assistance from
actuarial experts to aid in developing reasonable assumptions and
cost estimates.
Our assumption for the expected long-term rate of return-on-
assets in our U.S. pension plans, which determines net periodic
benefit cost, is 9% for 2006 and 2005. The assumption for the
expected return-on-assets for our U.S. and international plans
reflects our actual historical return experience and our long-term
assessment of forward-looking return expectations by asset
classes, which is used to develop a weighted-average expected
return based on the implementation of our targeted asset
allocation in our respective plans. The expected return for our U.S.
plans and the majority of our international plans is applied to the
fair market value of plan assets at each year end. For our
international plans that use a market-related value of plan assets
to calculate net periodic pension cost, shifting to fair market
value of plan assets would serve to decrease our 2006 international
pension plans’ pre-tax expense by approximately $29 million. As
a sensitivity measure, holding all other assumptions constant,
the effect of a one-percentage-point decline in the return-on-
assets assumption would be an increase in our 2006 U.S. qualified
pension plan pre-tax expense of approximately $71 million.
The following table shows the expected versus actual rate of
return on plan assets for the U.S. qualified pension plans:
2005 2004 2003
Expected annual rate of return 9.0% 9.0% 9.0%
Actual annual rate of return 10.1 11.5 21.4
The discount rate used in calculating our U.S. pension benefit
obligations at December 31, 2005, is 5.8%, which represents a 0.2
percentage-point decline from our December 31, 2004, rate of
6.0%. The discount rate for our U.S. defined benefit and
postretirement plans is based on a yield curve constructed from
a portfolio of high quality corporate bonds rated AA or better 
for which the timing and amount of cash flows approximate 
the estimated payouts of the plans. For our international plans,
the discount rates are set by benchmarking against investment
grade corporate bonds rated AA or better. Holding all other
assumptions constant, the effect of this 0.2 percentage-point
decrease in the discount rate assumption is an increase in our 2006
U.S. qualified pension plan pre-tax expense of approximately
$25 million and an increase in the U.S. qualified pension plans’




On April 16, 2003, we acquired Pharmacia in a stock-for-stock
transaction valued at approximately $56 billion. For the year
ended December 31, 2003, about 71⁄2 months of results of
operations of Pharmacia’s international operations (which
conformed to Pfizer’s international operations fiscal year end of
November 30th) and about 81/2 months of results of operations of
Pharmacia’s U.S. operations were included in our consolidated
financial statements.
Our operating results for the years ended December 31, 2005 and
2004, reflect the impact of the acquisition of Pharmacia
throughout the entire period, as compared to the year ended
December 31, 2003, which reflects the impact of the acquisition
of Pharmacia from April 16, 2003.
The impact of purchase accounting relating to the Pharmacia
acquisition resulted in a number of significant non-cash charges
to the income statement for the years ended December 31, 2005,
2004 and 2003. The non-cash charges for 2005 and 2004 include
incremental amortization of about $3.3 billion relating to
intangible assets adjusted to fair value. The non-cash charges in
2003 include non-recurring IPR&D ($5.1 billion); incremental cost
of sales (non-recurring $2.7 billion) from the sale of acquired
inventory adjusted to fair value; and incremental amortization
($2.3 billion) of tangible and intangible assets adjusted to fair
value. See also the discussions under the heading “Merger-Related
In-Process Research and Development Charges” in the “Costs
and Expenses” section of this Financial Review.
In connection with the acquisition, we took actions to integrate
and restructure the Pharmacia operations in order to increase
our profitability through cost savings and operating efficiencies.
To achieve the savings, we incurred certain merger-related
expenditures of about $5.4 billion through December 31, 2005. See
also the discussions under the heading “Merger-Related Costs” in
the “Costs and Expenses” section of this Financial Review. As a
result of these activities and the combining of operations, it is not
possible to provide separate results of operations for Pharmacia
for the period after the acquisition date.
As a result of the acquisition of Pharmacia, regulatory authorities
required us to divest several products and a product candidate.
In April 2003, we sold Cortaid, an anti-itch cream, for $35.8
million in cash. Also in April 2003, we sold the product candidate
for overactive bladder, darifenacin, for $225 million. We received
$50 million in cash upon closing in April 2003 and an additional
$100 million in 2004 (with an additional $75 million contingent
upon when, and if, darifenacin receives regulatory approvals).
These net proceeds are included in Other income/(deductions)—
net, in the respective years.
Other Acquisitions
On September 14, 2005, we completed the acquisition of all of the
outstanding shares of Vicuron, a biopharmaceutical company
focused on the development of novel anti-infectives, for
approximately $1.9 billion in cash (including transaction costs). At
the date of acquisition, Vicuron had two products under NDA
review by the FDA: Eraxis (anidulafungin) for fungal infections and
Zeven (dalbavancin) for Gram-positive infections. The allocation
of the purchase price includes IPR&D of approximately $1.4 billion,
which was expensed in Merger-related in-process research and
development charges, and goodwill of $243 million, which has
been allocated to our Human Health segment. Neither of these
items is deductible for tax purposes. In February 2006, Eraxis was
approved by the FDA.
On April 12, 2005, we completed the acquisition of all outstanding
shares of Idun, a biopharmaceutical company focused on the
discovery and development of therapies to control apoptosis,
and on August 15, 2005, we completed the acquisition of all
outstanding shares of Bioren Inc. (Bioren), which focuses on
technology for optimizing antibodies. The aggregate cost of
these and other smaller acquisitions was approximately $340
million in cash (including transaction costs) for 2005. In connection
with these transactions, we expensed $262 million of IPR&D,
which was included in Merger-related in-process research and
development charges.
On September 30, 2004, we completed the acquisition of
Campto/Camptosar (irinotecan), from sanofi-aventis for
approximately $525 million in cash (including transaction costs).
Additional payments of up to $63 million will be payable upon
obtaining regulatory approvals for additional indications in
certain European countries. In connection with the acquisition, we
recorded an intangible asset for developed technology rights of
$445 million.
On February 10, 2004, we completed the acquisition of all the
outstanding shares of Esperion, a biopharmaceutical company, for
$1.3 billion in cash (including transaction costs). The allocation of
the purchase price includes IPR&D of approximately $920 million,
which was expensed in Merger-related in-process research and
development charges, and goodwill of $239 million, which was
allocated to our Human Health segment. Neither of these items
was deductible for tax purposes.
In 2004, we also completed several other acquisitions. The total
purchase price associated with these transactions was
approximately $430 million. In connection with these transactions,
we expensed $151 million of IPR&D, which was included in
Merger-related in-process research and development charges,
and recorded $206 million in intangible assets, primarily brands
(indefinite-lived) and developed technology rights.
In January 2006, we announced an agreement to acquire the
sanofi-aventis worldwide rights, including patent rights and
production technology, to manufacture and sell Exubera, an
inhaled form of insulin for use in adults with type 1 and type 2
diabetes, and the insulin-production business and facilities located
in Frankfurt, Germany, previously jointly owned by Pfizer and
sanofi-aventis, for approximately $1.3 billion.
2005 Financial Report 9
Financial Review
Pfizer Inc and Subsidiary Companies
10 2005 Financial Report
Financial Review
Pfizer Inc and Subsidiary Companies
Dispositions
We evaluate our businesses and product lines periodically for
strategic fit within our operations. As a result of our evaluation,
we decided to sell a number of businesses and product lines and
we recorded certain of these results in Discontinued operations
for 2005, 2004 and 2003, as appropriate. All of these sales were
completed as of December 31, 2005. The more significant disposals
include:
• In the third quarter of 2005, we sold the last of three European
generic pharmaceutical businesses which we had included in our
Human Health segment and had become a part of Pfizer in April
2003 in connection with our acquisition of Pharmacia, for 4.7
million euro (approximately $5.6 million) and recorded a loss
of $3 million ($2 million, net of tax) in Gains on sales of
discontinued operations—net of tax in the consolidated
statement of income for 2005.
• In the first quarter of 2005, we sold the second of three
European generic pharmaceutical businesses which we had
included in our Human Health segment and had become a part
of Pfizer in April 2003 in connection with our acquisition of
Pharmacia, for 70 million euro (approximately $93 million)
and recorded a gain of $57 million ($36 million, net of tax) in
Gains on sales of discontinued operations—net of tax in the
consolidated statement of income for 2005. In addition, we
recorded an impairment charge of $9 million ($6 million, net
of tax) related to the third European generic business in
(Loss)/income from discontinued operations—net of tax in the
consolidated statement of income for 2005.
• In the fourth quarter of 2004, we sold the first of three
European generic pharmaceutical businesses which we had
included in our Human Health segment and had become a part
of Pfizer in April 2003 in connection with our acquisition of
Pharmacia, for 53 million euro (approximately $65 million). In
addition, we recorded an impairment charge of $61 million ($37
million, net of tax), relating to a European generic business
which was later sold in 2005, and is included in (Loss)/income
from discontinued operations—net of tax in the consolidated
statement of income for 2004.
• In the third quarter of 2004, we sold certain non-core consumer
product lines marketed in Europe by our Consumer Healthcare
segment for 135 million euro (approximately $163 million) in
cash. We recorded a gain of $58 million ($41 million, net of tax)
in Gains on sales of discontinued operations—net of tax in
the consolidated statement of income for 2004. The majority
of these products were small brands sold in single markets
only and included certain products that became a part of Pfizer
in April 2003 in connection with our acquisition of Pharmacia.
• In the second quarter of 2004, we sold our surgical ophthalmic
business for $450 million in cash. The surgical ophthalmic business
was included in our Human Health segment and became a part
of Pfizer in April 2003 in connection with our acquisition of
Pharmacia. The results of this business were included in
(Loss)/income from discontinued operations—net of tax.
• In the second quarter of 2004, we sold our in-vitro allergy and
autoimmune diagnostics testing (Diagnostics) business, formerly
included in the “Corporate/Other” category of our segment
information, for $575 million in cash. The Diagnostics business
was acquired in April 2003 in connection with our acquisition
of Pharmacia. The results of this business were included in
(Loss)/income from discontinued operations—net of tax.
• In the second quarter of 2003, we completed the sale of the
hormone replacement therapy femhrt, formerly part of our
Human Health segment, for $160 million in cash with a right
to receive up to $63.8 million contingent on femhrt retaining
market exclusivity until the expiration of its patent. We recorded
a gain on the sale of this product of $139 million ($83 million,
net of tax) in Gains on sales of discontinued operations—net
of tax in the consolidated statement of income for 2003.
• In the first quarter of 2003, we sold the oral contraceptives
Estrostep and Loestrin, formerly part of our Human Health
segment, for $197 million in cash with a right to receive up to
$47.3 million contingent on Estrostep retaining market
exclusivity until the expiration of its patent. We recorded a gain
on the sale of these two products of $193 million ($116 million,
net of tax) in Gains on sales of discontinued operations—net
of tax in the consolidated statement of income for 2003.
• In the first quarter of 2003, we sold the Adams confectionery
products business, formerly part of our Consumer Healthcare
segment, for $4.2 billion in cash. We recorded a gain on the sale
of this business of $3.1 billion ($1.8 billion, net of tax) in Gains
on sales of discontinued operations—net of tax in the
consolidated statement of income for 2003.
• In the first quarter of 2003, we sold the Schick-Wilkinson Sword
shaving products business, formerly part of our Consumer
Healthcare segment, for $930 million in cash. We recorded a
gain on the sale of this business of $462 million ($262 million,
net of tax) in Gains on sales of discontinued operations—net
of tax in the consolidated statement of income for 2003.
In 2005, we earned $29 million of income ($18 million, net of tax)
and in 2004, we earned $17 million of income ($10 million, net
of tax), both amounts relating to the 2003 sale of the femhrt,
Estrostep and Loestrin product lines, which was recorded in Gains
on sales of discontinued operations—net of tax in the consolidated
statement of income for the applicable year.
Net cash flows of our discontinued operations from each of the
categories of operating, investing and financing activities were
not significant for 2005, 2004 and 2003.
Analysis of the Consolidated Statement 
of Income
YEAR ENDED DEC. 31, % CHANGE__________________________________________ _________________
(MILLIONS OF DOLLARS) 2005 2004 2003(a) 05/04 04/03
Revenues $51,298 $52,516 $44,736 (2) 17
Cost of sales 8,525 7,541 9,589 13 (21)
% of revenues 16.6% 14.4% 21.4%
SI&A expenses 16,997 16,903 15,108 1 12
% of revenues 33.1% 32.2% 33.8%
R&D expenses 7,442 7,684 7,487 (3) 3
% of revenues 14.5% 14.6% 16.7%
Amortization of 
intangible assets 3,409 3,364 2,187 1 54
% of revenues 6.6% 6.4% 4.9%
Merger-related 
IPR&D charges 1,652 1,071 5,052 54 (79)
% of revenues 3.2% 2.0% 11.3%
Restructuring charges 
and merger-related 
costs 1,392 1,193 1,058 17 13
% of revenues 2.7% 2.3% 2.4%
Other (income)/
deductions—net 347 753 1,009 (54) (25)
Income from 
continuing 
operations(b) 11,534 14,007 3,246 (18) 332
% of revenues 22.5% 26.7% 7.3%
Provision for taxes 
on income 3,424 2,665 1,614 28 65
Effective tax rate 29.7% 19.0% 49.7%
Minority interest 16 10 3 59 222
Discontinued 
operations— 
net of tax 16 29 2,311 (45) (99)
Cumulative effect of 
a change in 
accounting 
principles—net 
of tax (25) — (30) * *
Net income $ 8,085 $11,361 $3,910 (29) 191
% of revenues 15.8% 21.6% 8.7%
(a) The results of operations in 2003 include Pharmacia’s product
sales and expenses from the acquisition date (April 16, 2003).
(b) Represents income from continuing operations before provision
for taxes on income, minority interests, discontinued operations
and cumulative effect of a change in accounting principles.
* Calculation not meaningful.
Percentages in this table and throughout the Financial Review
may reflect rounding adjustments.
Revenues
Total revenues decreased 2% to $51.3 billion in 2005 primarily due
to the loss of U.S. exclusivity of certain key products, the suspension
of the sales of Bextra and the uncertainty related to Celebrex.
These decreases were partially offset by the solid aggregate
performance in the balance of our broad portfolio of patent-
protected medicines. In 2005, Lipitor, Norvasc, Zoloft and
Zithromax each delivered at least $2 billion in revenues, while
Celebrex, Viagra, Xalatan/Xalacom and Zyrtec each surpassed 
$1 billion.
Total revenues increased 17% to $52.5 billion in 2004 primarily due
to the inclusion of Pharmacia results from the full year 2004
(2003 reflected only 81/2 months of domestic and 71/2 months of
international Pharmacia product sales), strong performances by
a number of our in-line products and newly launched products
across major businesses and regions and the weakening of the U.S.
dollar relative to many foreign currencies. In 2004, the Company’s
top five medicines—Lipitor, Norvasc, Zoloft, Celebrex and
Neurontin—each delivered at least $2 billion in revenues, while
Zithromax, Viagra, Zyrtec, Bextra and Xalatan/Xalacom each
surpassed $1 billion.
Changes in foreign exchange rates increased total revenues in 2005
by $945 million or 1.8% compared to 2004 and increased total
revenues in 2004 by $1.4 billion or 3.2% compared to 2003. The
foreign exchange impact on 2005 and 2004 revenue growth was
due to the weakening of the U.S. dollar relative to many foreign
currencies, especially the euro, which accounted for about 35%
of the impact in 2005 and about 50% in 2004. The revenues of
legacy Pharmacia products, recorded from the acquisition date of
April 16, 2003, until the anniversary date of the transaction in
2004, were treated as incremental volume and did not have a
foreign exchange impact.
Revenues exceeded $500 million in each of 12 countries outside
the U.S. in 2005 and in each of ten countries outside the U.S. in
2004. The U.S. was the only country to contribute more than
10% of total revenues in each year.
Pfizer’s policy relating to the supply of pharmaceutical inventory
at domestic wholesalers, and in major international markets, is to
maintain stocking levels under one month on average and to keep
monthly levels consistent from year to year based on patterns of
utilization. Pfizer has historically been able to closely monitor these
customer stocking levels by purchasing information from our
customers directly or by obtaining other third party information.
Pfizer believes its data sources to be directionally reliable, but
cannot verify its accuracy. Further, as Pfizer does not control this
third party data, we cannot be assured of continuing access.
Unusual buying patterns and utilization are promptly investigated.
We completed the harmonization of Pharmacia’s trade-inventory
practices in 2003. However, such harmonization of trade-inventory
practices with those of legacy Pfizer negatively impacted revenues
by approximately $500 million in 2003.
Rebates under Medicaid and related state programs reduced
revenues by $1.3 billion in 2005, $1.4 billion in 2004 and $800
million in 2003. Performance-based contract rebates reduced
revenues by $2.3 billion in 2005, $2.2 billion in 2004 and $1.9 billion
in 2003. These contracts are with managed care customers,
including health maintenance organizations and pharmacy benefit
managers, who receive rebates based on the achievement of
contracted performance terms for products. Rebates are product-
specific and, therefore, for any given year are impacted by the mix
of products sold. Chargebacks (primarily discounts to U.S. federal
government agencies) reduced revenues by $1.3 billion in both
2005 and 2004, and $874 million in 2003. Medicaid rebates,
contract rebates and chargebacks in 2003 only include Pharmacia
as of April 16, 2003. In addition, chargebacks were impacted by
the launch of certain generic products in 2005 and 2004 by our
Greenstone subsidiary.
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Our accruals for Medicaid rebates, contract rebates and
chargebacks totaled $1.8 billion and $1.7 billion at December 31,
2005 and 2004.
Revenues by Business Segment
We operate in the following business segments:
• Human Health
—The Human Health segment, which represents our
pharmaceutical business, includes treatments for cardiovascular
and metabolic diseases, central nervous system disorders,
arthritis and pain, infectious and respiratory diseases,
urogenital conditions, cancer, eye disease, endocrine disorders
and allergies.
• Consumer Healthcare
—The Consumer Healthcare segment includes self-medications
for oral care, upper-respiratory health, tobacco dependence,
gastrointestinal health, skin care, eye care and hair growth.
• Animal Health
—The Animal Health segment includes treatments for diseases
in livestock and companion animals.









HUMAN HEALTH ANIMAL HEALTH
CONSUMER HEALTHCARE CORPORATE/OTHER
Change in Geographic Revenues
YEAR ENDED DEC. 31, % CHANGE
U.S. INTERNATIONAL U.S. INTERNATIONAL
(MILLIONS OF DOLLARS) 2005 2004 2003 2005 2004 2003 05/04 04/03 05/04 04/03
Revenues:
Human Health $23,443 $26,583 $24,100 $20,841 $19,550 $15,325 (12) 10 7 28
Consumer Healthcare 1,941 1,780 1,649 1,937 1,736 1,300 9 8 12 34
Animal Health 993 878 738 1,213 1,075 860 13 19 13 25
Other 287 298 308 643 616 456 (4) (3) 4 35
Total Revenues $26,664 $29,539 $26,795 $24,634 $22,977 $17,941 (10) 10 7 28
Human Health
Revenues of our Human Health segment were as follows:
YEAR ENDED DEC. 31, % CHANGE__________________________________________ _________________
(MILLIONS OF DOLLARS) 2005 2004 2003 05/04 04/03
Human Health $44,284 $46,133 $39,425 (4) 17
Our pharmaceutical business is the largest in the world. Revenues
from this segment contributed 86% of our total revenues in 2005
and 88% in each of 2004 and 2003. At the end of 2005, six of our
pharmaceutical products were number one in their respective
therapeutic categories based on revenue.
We recorded product sales of more than $1 billion for each of
eight products in 2005, each of ten products in 2004 and each of
nine products in 2003. These products represented 64% in 2005,
69% in 2004 and 70% in 2003 of our Human Health business.
In 2005, Human Health revenues declined. The loss of U.S.
exclusivity on certain key products (primarily Neurontin) has
resulted in a decline in 2005 worldwide revenues for those
products of approximately $2.8 billion in comparison to 2004. In
addition, the uncertainty and patient concerns relating to selective
COX-2 inhibitors and the suspension of sales of Bextra have
resulted in a decline in our selective COX-2 inhibitor worldwide
revenues of $2.9 billion (down 63%) in comparison to 2004.
Despite these events, we were able to offset approximately $4.0
billion of those declines through our in-line products coupled with
new product launches.
2005 was also impacted by increased competition and the overall
market decline as branded prescriptions in the U.S. declined 5%
in 2005 compared to 2004. An example is the erectile-dysfunction
market, with total prescriptions declining 3% in 2005 versus 10%
growth in 2004. The second half of 2005 also exhibited significant
change in growth trends relative to the first half of the year in a
number of U.S. therapeutic markets.
Effective January 1, 2006, January 1, 2005 and January 2, 2004, we
increased the published prices for certain U.S. pharmaceutical
products. These price increases had no material effect on
wholesaler inventory levels in comparison to the prior year.
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Revenues — Major Human Health Products
(MILLIONS OF DOLLARS) YEAR ENDED DEC. 31, % CHANGE________________________________________________ ______________________
PRODUCT PRIMARY INDICATIONS 2005 2004 2003 05/04 04/03
Cardiovascular 
and metabolic diseases:
Lipitor Reduction of LDL cholesterol $12,187 $10,862 $9,231 12 18
Norvasc Hypertension 4,706 4,463 4,336 5 3
Cardura Hypertension/Benign prostatic hyperplasia 586 628 594 (7) 6
Accupril/Accuretic Hypertension/Congestive heart failure 294 665 706 (56) (6)
Caduet Reduction of LDL cholesterol and hypertension 185 50 — 272 —
Central nervous system 
disorders:
Zoloft Depression and certain anxiety disorders 3,256 3,361 3,118 (3) 8
Neurontin Epilepsy and post-herpetic neuralgia 639 2,723 2,702 (77) 1
Geodon/Zeldox Schizophrenia and acute manic or mixed episodes 
associated with bipolar disorder 589 467 353 26 32
Xanax/Xanax XR Anxiety/Panic disorders 409 378 238 8 59
Aricept(a) Alzheimer’s disease 346 308 254 12 22
Lyrica Epilepsy, post-herpetic neuralgia and 
diabetic peripheral neuropathy 291 13 — M+ *
Relpax Migraine headaches 233 169 85 38 99
Arthritis and pain:
Celebrex(b) Arthritis pain and inflammation, acute pain 1,730 3,302 1,883 (48) 75
Bextra(b) Arthritis pain and inflammation (61) 1,286 687 * 87
Infectious and respiratory 
diseases:
Zithromax/Zmax Bacterial infections 2,025 1,851 2,010 9 (8)
Zyvox Bacterial infections 618 463 181 33 156
Diflucan Fungal infections 498 945 1,176 (47) (20)
Vfend Fungal infections 397 287 200 38 44
Urology:
Viagra Erectile dysfunction 1,645 1,678 1,879 (2) (11)
Detrol/Detrol LA Overactive bladder 988 904 544 9 66
Oncology:
Camptosar Metastatic colorectal cancer 910 554 299 64 86
Ellence Breast cancer 367 344 216 7 59
Aromasin Breast cancer 247 143 58 73 145
Ophthalmology:
Xalatan/Xalacom Glaucoma and ocular hypertension 1,372 1,227 668 12 84
Endocrine disorders:
Genotropin Replacement of human growth hormone 808 736 481 10 53
All other:
Zyrtec/Zyrtec-D Allergies 1,362 1,287 1,338 6 (4)
Alliance revenue(c) Alzheimer’s disease (Aricept), neovascular (wet) 
age-related macular degeneration (Macugen), 
Parkinson’s disease (Mirapex), hypertension 
(Olmetec), multiple sclerosis (Rebif) and 
chronic obstructive pulmonary disease (Spiriva) 1,065 721 759 48 (5)
(a) Represents direct sales under license agreement with Eisai Co., Ltd.
(b) Includes direct sales under license agreement with Pharmacia prior to the acquisition.
(c) Includes alliance revenue for Celebrex and Bextra under co-promotion agreements with Pharmacia prior to the acquisition.
M+ Change greater than one-thousand percent.
* Calculation not meaningful.
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Human Health — Selected Product
Descriptions
• Lipitor, for the treatment of elevated cholesterol levels in the
blood, is the most widely used treatment for lowering
cholesterol and the best-selling pharmaceutical product of any
kind in the world reaching over $12 billion in sales in 2005, an
increase in worldwide sales of 12% compared to 2004. Despite
the substantial growth in 2005, Lipitor performance has slowed,
particularly in the second half of 2005. This performance reflects
a slowdown in the lipid-lowering market as a whole and
increased competition. Despite this market slowdown, Lipitor
still accounts for more than 39% of all lipid-lowering
prescriptions, more than 2.5 times larger than its nearest
competitor. Lipitor will face competition in the U.S. from
generic pravastatin (Pravachol) beginning in April 2006 and
generic simvastatin (Zocor) beginning in June 2006. While we
cannot predict what will happen in any specific market, we have
found that in certain European countries, Lipitor has continued
to grow despite the introduction of generic simvastatin.
In September 2005, the FDA approved the use of Lipitor to
reduce the risk of stroke and myocardial infarction in patients
with type 2 diabetes and multiple risk factors for coronary heart
disease. The FDA’s decision was based on the findings of the
Collaborative Atorvastatin Diabetes Study (CARDS), a landmark
trial of more than 2,800 patients with type 2 diabetes, near-
normal cholesterol, and at least one other risk factor, such as high
blood pressure or smoking. CARDS showed that patients using
Lipitor experienced 48% fewer strokes than those on placebo.
The CARDS study’s steering committee stopped the trial nearly
two years earlier than planned because of the clinical benefits
among patients who took Lipitor.
In addition, the FDA expanded the Lipitor label to include
data on the reduction in the incidence of stroke in patients with
multiple risk factors, as shown in the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT) clinical trial. The ASCOT trial
found that Lipitor reduced the relative risk of stroke by 26%
compared to placebo. The study involved people with normal
or borderline cholesterol and no prior history of heart disease
with controlled high blood pressure and at least three other risk
factors for heart disease, such as family history, age over 55,
smoking, diabetes, and obesity. Patients with multiple risk
factors, including diabetes, face a greater threat of heart attack
and stroke. Reducing their risk of such cardiovascular events is
extremely important.
In March 2005, the Treating to New Targets (TNT) clinical study/
trial was presented at the American College of Cardiology
meeting and was published simultaneously in the New England
Journal of Medicine. TNT was the first large-scale study to
show that patients with established coronary disease who
reduce and maintain their cholesterol with Lipitor well below
currently recommended levels experience significantly fewer
heart attacks and strokes than those who lower their cholesterol
to recommended levels. The results of TNT, the longest and
largest study to date of Lipitor 80 mg efficacy and safety, were
achieved safely and build upon the well-established safety
profile of Lipitor’s highest dose. Over the course of the following
eight months, a total of eight TNT sub-group analyses were
presented at the scientific sessions of the American Heart
Association and American Diabetes Association, further
demonstrating the efficacy and safety of long-term therapy with
Lipitor 80 mg in specific patient populations.
The recently published IDEAL study, involving 8,888 patients
with established coronary heart disease, assessed the efficacy
of Lipitor 80 mg for secondary prevention of cardiovascular
events compared with simvastatin (Zocor) 20/40 mg. On the
primary endpoint, reduction in the risk of a major coronary
event, Lipitor 80 mg achieved an 11% risk reduction compared
with simvastatin 20/40 mg. This difference fell short of statistical
significance, however (p=0.07 vs. significance at p=0.05). Lipitor
achieved statistically significant improvements in major
secondary endpoints compared with simvastatin, including a
13% reduction in major cardiovascular events and a 17%
reduction in non-fatal heart attacks.
In December 2005, the U.S. District Court for the District of
Delaware determined that two U.S. patents covering atorvastatin,
the active ingredient in Lipitor, are valid and infringed by the
product of generic manufacturer Ranbaxy Laboratories Limited,
thus protecting Lipitor’s exclusivity until June 2011. In addition,
in October 2005, the United Kingdom’s High Court of Justice
upheld the exclusivity of the basic patent covering atorvastatin.
The ruling prevents Ranbaxy from introducing a generic version
of atorvastatin in the U.K. until the patent expires in November
2011. Both the U.S. and the U.K. decisions have been appealed.
(See Notes to Consolidated Financial Statments—Note 18. Legal
Proceedings and Contingencies.)
• Norvasc is the world’s most-prescribed branded medicine for
treating hypertension. It achieved a 5% growth in sales in
2005 compared to 2004, despite patent expirations in many
European Union (E.U.) countries. Norvasc maintains exclusivity
in many major markets globally, including the U.S., Japan,
Canada and Australia.
In January 2006, the U.S. District Court for the Northern District
of Illinois upheld Pfizer’s U.S. patent covering amlodipine
besylate, the active ingredient in Norvasc, which had been
challenged by the generic manufacturer Apotex Inc. The
decision is subject to possible appeal. (See Notes to Consolidated
Financial Statements—Note 18, Legal Proceedings and
Contingencies.)
• Zoloft, which will lose U.S. market exclusivity in June 2006, is
the most-prescribed antidepressant in the U.S. It is indicated for
the treatment of major depressive disorder, panic disorder,
obsessive-compulsive disorder (OCD) in adults and children,
post-traumatic stress disorder (PTSD), premenstrual dysphoric
disorder (PMDD) and social anxiety disorder (SAD). Zoloft is
approved for acute and long-term use in all of these indications,
with the exception of PMDD. It is the only approved agent for
the long-term treatment of PTSD and SAD, an important
differentiating feature as these disorders tend to be chronic.
In the U.S., in February 2005, Pfizer implemented FDA
instructions that require the makers of all currently marketed
antidepressants, including tricyclic agents, monoamine oxidase
(MAO) inhibitors, selective reuptake inhibitors such as Zoloft,
selective norepinephrine reuptake inhibitors and atypical
antidepressants, to include a black-box warning that
antidepressants increased the risk of suicidal thinking and
behavior in children and adolescents in pooled, short-term
studies. In the nine completed clinical trials of Zoloft involving
children and adolescents, which included studies of Zoloft in
children diagnosed with depression, OCD, or both, no suicides
occurred. The trials found no statistically significant differences
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between Zoloft-treated children and adolescents and placebo
controls in their rates of suicide attempts or ideation.
• Neurontin, for use in adjunctive therapy for epilepsy, is also
approved in more than 60 markets for the treatment of a
range of neuropathic pain conditions. Neurontin has also been
approved for the management of post-herpetic neuralgia
(PHN), a painful condition that affects many people in the
aftermath of the viral infection commonly known as shingles.
Neurontin was the first oral medication approved in the U.S.
for the treatment of PHN. The introduction of generic versions
of gabapentin in the U.S. in late 2004 caused a 77% reduction
in Neurontin sales for 2005 as compared to 2004.
• Geodon/Zeldox, a psychotropic agent, is a dopamine and
serotonin receptor antagonist indicated for the treatment of
schizophrenia and acute manic or mixed episodes associated
with bipolar disorder. Available in both an oral capsule and
rapid-acting intramuscular formulation, Geodon has been
launched in 59 countries, where more than 7 million
prescriptions have been written for more than 1.3 million
patients worldwide. In the U.S., Geodon hit an all-time new
prescription share weekly high of 6.1% during December 2005
and is now the second-fastest-growing atypical anti-psychotic
medication. In 2005, total Geodon prescriptions grew 23%
compared to 2004.
The Clinical Antipsychotic Trials of Intervention Effectiveness
schizophrenia study, supported by the National Institute of
Mental Health and recently published in the New England Journal
of Medicine, confirms that Geodon is an effective anti-psychotic
and is less likely to worsen weight, lipids, and glucose metabolism
than other agents. In fact, Geodon was associated with some
improvement in these metabolic parameters. These findings are
noteworthy because of the higher prevalence of metabolic issues
among patients with schizophrenia and are consistent with
previous Pfizer-sponsored clinical trials involving Geodon.
• Lyrica was approved by the FDA in June 2005 for adjunctive
therapy for adults with partial onset seizures. This latest
indication builds on the earlier FDA approval of Lyrica for two
of the most common forms of neuropathic pain—diabetic
peripheral neuropathy, a chronic neurologic condition affecting
nearly three million Americans, and post-herpetic neuralgia.
Lyrica was launched in the U.S., Canada, and Italy in September
2005 and is now approved in more than 50 countries and is
currently available in more than 30 markets. Market penetration
has been rapid; after one and a half years of Lyrica sales,
Germany and the U.K. posted Lyrica sales shares of 14.5% and
11.5%, respectively, in the anti-epileptic drug market, surpassing
those of many established competitors in both countries. Since
its September 2005 launch in the U.S., more than 500,000
prescriptions have been written for Lyrica as of December 23,
2005. Lyrica has already gained more than a 7% new-
prescription share of the U.S. anti-epileptic market as of
December 23, 2005, continuing its performance as one of
Pfizer’s most successful pharmaceutical launches.
Clinical evidence favorable to Lyrica continues to accumulate.
The September 2005 edition of Epilepsia focused on the
medication’s lack of interactions with other drugs. The
December 2005 edition of Epilepsia published a study showing
a significant seizure reduction in line with that seen in the three
previously published pivotal epilepsy studies.
• Celebrex and Bextra
On April 7, 2005, the FDA announced a decision to require
boxed warnings of potential cardiovascular risk for all COX-2
pain relievers and all prescription NSAIDs, including older non-
specific drugs such as ibuprofen and naproxen. On July 29,
2005, Pfizer and the FDA finalized the label changes for Celebrex.
The final U.S. label contains a boxed warning of potential
serious cardiovascular and gastrointestinal risks for Celebrex that
are consistent with warnings for all other prescription NSAIDs.
The boxed warning provides that Celebrex is contraindicated for
patients who recently have undergone coronary artery bypass
graft surgery. The label recommends that Celebrex be prescribed
at the lowest effective dose for the shortest duration consistent
with individual patient treatment goals. Pfizer is continuing to
conduct additional clinical studies evaluating the benefits and
risks of Celebrex. Pfizer is supporting Cleveland Clinic’s 20,000
patient prospective study to definitively evaluate the relative
safety of Celebrex and two older pain medications in patients
with heart disease or at high risk of heart disease.
In June 2005, the Committee for Human Medicinal Products
(CHMP) concluded its COX-2 referral process and recommended
that both Celebrex and Dynastat (parecoxib) remain available
to patients. The European Medicines Evaluation Agency (EMEA)
has required new labeling for all COX-2 drugs that includes a
restriction on use for patients with established heart disease or
stroke and additional warnings to physicians regarding use in
patients with cardiovascular risk factors. This new labeling was
implemented for all COX-2 medicines across the E.U. in July of 2005.
The market for pain relievers has changed since the withdrawal
of Vioxx in September 2004. Sales of Celebrex began to decline
in late 2004 due to physician and patient concerns surrounding
selective COX-2 inhibitors. Also contributing to the decline in
sales of Celebrex was the voluntary suspension of DTC
advertising in the U.S. beginning in December 2004. Pfizer
plans to reintroduce branded advertising in 2006, in alignment
with our new DTC advertising principles, highlighting Celebrex’s
unique clinical profile and benefits.
In September 2005, with full implementation of revised labeling,
Pfizer began to focus renewed attention on Celebrex, with the
goal of making the pain reliever available to increased numbers
of patients. In July 2005, the FDA approved a sixth indication
for Celebrex—ankylosing spondylitis—a form of spinal arthritis
that affects more than one million people in the U.S.
In April 2005, the FDA decided that while Bextra’s cardiovascular
risk could not be differentiated from other NSAIDs, the
additional, increased risk of rare but serious skin reactions
associated with Bextra, already described in its label, warranted
its withdrawal from the market. In 2004, we recorded $1.3
billion in revenue for Bextra. We respectfully disagree with the
FDA’s position regarding the relative risk/benefit profile of
Bextra. However, in deference to the regulatory agency’s view,
we suspended sales of the medicine. In addition, at the request
of European and other regulators, we suspended sales of Bextra
in the E.U., Canada and many other markets around the world.
In connection with the decision to suspend sales of Bextra in
the U.S., the E.U., and certain other markets, we recorded
certain charges totaling $1.2 billion ($769 million, net of tax)
in 2005. These pre-tax charges included $1.1 billion related to
the impairment of developed technology rights associated
with Bextra and $5 million related to the write-off of machinery
and equipment, both of which are included in Other
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(income)/deductions—net; $73 million in write-offs of inventory
and exit costs, included in Cost of sales; $8 million related to
the costs of administering the suspension of sales, included in
Selling, informational and administrative expenses; and $212
million for an estimate of customer returns, primarily included
against Revenues.
• Zithromax, whose composition of matter patent in the U.S.
expired in November 2005, remained the number-one
prescribed oral antibiotic during 2005, despite the end of active
sales promotion in July, when the U.S. sales force began
promoting Zmax. During the fourth quarter of 2005, four
generic versions of oral solid azithromycin were launched,
including one authorized generic by Pfizer’s Greenstone
subsidiary. The generics launched two weeks later than
expected, which led to higher than expected sales of Zithromax
in the fourth quarter of 2005. After seven weeks of generic
availability, generic azithromycin constituted 90% of the total
oral solid azithromycin adult prescription volume. Pfizer’s
generic had captured 49% of total generic prescriptions.
• Zmax, a single-dose, sustained-release form of azithromycin for
adults, was introduced in the U.S. in August 2005 for treatment
of mild-to-moderate acute bacterial sinusitis and community-
acquired pneumonia in adult patients appropriate for oral
therapy due to susceptible pathogens. Single-dose Zmax delivers
higher azithromycin serum concentrations during the first 24
hours than Zithromax and assures complete compliance
compared to multi-dose regimes, demonstrating a clear benefit
of the new medication.
• Diflucan is a systemic antifungal. The decrease in sales in 2005
compared to 2004 is mainly due to loss of exclusivity in the U.S.
in July 2004.
• Viagra remains the leading treatment for erectile dysfunction
and one of the world’s most recognized pharmaceutical brands,
with more than 60% of U.S. sales in its market of
phosphodiesterase-5 (PDE5) inhibitors through November 2005.
2005 Viagra sales declined 2% worldwide from 2004, reflecting
aggressive competition, as well as negative growth for oral
erectile dysfunction treatments in several major markets. We
expect to see continued pressure on sales in the U.S. More
than 35 states have enacted “Preferred Drug Lists” that have
the potential to limit Pfizer sales to state Medicaid programs
and Medicare coverage will end in 2007. Effective January 1,
2006, federal funds may not be used for reimbursement of
erectile dysfunction medications by the Medicaid program.
Pfizer has begun to introduce new branded advertising
compliant with our DTC advertising guidelines to highlight the
unique clinical profile for Viagra, as well as new unbranded
advertising to address the needs of potential new patients who
may be hesitant to try any medication for erectile dysfunction.
On July 8, 2005, the FDA approved an update to the Viagra label
to reflect rare post-marketing reports of non-arteritic anterior
ischemic optic neuropathy (NAION) in patients taking PDE5
inhibitor medications. The updated label notes that in rare
instances, men taking PDE5 inhibitors, including Viagra,
reported a sudden decrease or loss of vision in one or both eyes
and that it is not possible to determine whether these events
are related directly to these medicines, to the patient’s
underlying vascular risk factors, to a combination of these
factors, or other factors. Most of the reported NAION cases
occurred in Viagra users with underlying anatomic or vascular
risk factors associated with the development of NAION.
• Camptosar is a semisynthetic camptothecin derivative that
works by inhibiting the topoisomerase 1 enzyme, which is
involved in cancer cell replication. Camptosar is indicated as first-
line therapy for metastatic colorectal cancer in combination with
5-fluorouracil and leucovorin. It is also indicated as second-line
therapy for patients in whom metastatic colorectal cancer has
recurred or progressed despite following initial fluorouracil-
based therapy. Camptosar is for intravenous use only. Revenue
growth of 64% in 2005 compared to 2004 was impacted in part
by Pfizer’s acquisition of marketing rights to Campto/Camptosar
in Europe and Asia (except Japan) in late 2004. Among current
oncology medications, the National Comprehensive Cancer
Network, an alliance of 19 of the world’s leading cancer centers,
has issued guidelines recommending Camptosar as an option
across all lines of treatment for advanced colorectal cancer.
• Xalatan/Xalacom, a prostaglandin analogue used to lower the
intraocular pressure associated with glaucoma and ocular
hypertension, is the most-prescribed branded glaucoma
medicine in the world. Clinical data showing its advantages in
treating intra-ocular pressure compared with beta blockers
should support the continued growth of this important
medicine. Xalacom, the only fixed combination prostaglandin
(Xalatan) and beta blocker, is available primarily in European
markets. In 2005, Xalatan/Xalacom experienced sales growth of
12% compared to 2004.
• Zyrtec provides strong, rapid and long-lasting relief for seasonal
and year-round allergies and hives with once-daily dosing.
Zyrtec continues to be the most-prescribed antihistamine in the
U.S. in a challenging market. The increase in sales in 2005
compared to 2004 is attributable to stabilization in the
prescription antihistamine market subsequent to the Rx to
over-the-counter switch of loratadine as the majority of the
managed care plans have completed their formulary tier
changes in this category.
• Caduet, a single pill combining Lipitor and Norvasc, has
successfully completed the Mutual Recognition Procedure
(MRP) in the E.U. and is the first multi-target combination
product to receive a broad approval for prevention of
cardiovascular events in the E.U. Caduet is now approved in the
following E.U. countries: France, Spain, Portugal, Austria,
Iceland, Luxembourg, Cyprus, the Czech Republic, Hungary,
Latvia, Lithuania, Malta, Poland, Slovakia and Slovenia. It is
indicated for prevention of cardiovascular events in
hypertensive patients with three concomitant cardiovascular risk
factors, normal to mildly elevated cholesterol levels, without
clinically evident coronary heart disease, where combined use
of amlodipine and low dose atorvastatin is considered
appropriate, and in accordance with current treatment
guidelines. The Caduet Marketing Authorization application has
been officially withdrawn from the MRP in Belgium, Denmark,
Estonia, Ireland, Italy, Netherlands, Norway, the U.K., Sweden,
Germany, Finland and Greece. These countries had reservations
as to whether the benefit of Caduet, the first cardiovascular,
multi-target, fixed combination product, had been
demonstrated, based upon current European regulatory
guidelines for fixed combination products. As a result, these
countries did not mutually recognize the proposed label and
Pfizer decided to withdraw the application from these countries.
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Pfizer will continue to explore regulatory approval
opportunities for Caduet.
• Alliance revenue reflects revenue primarily Inc. (OSI), associated
with our co-promotion of Aricept, Macugen, Rebif and Spiriva.
—Aricept, discovered and developed by our alliance partner
Eisai Co., Ltd, is the world’s leading medicine to treat
symptoms of Alzheimer’s disease.
—Macugen, discovered and developed by our alliance partner
OSI Pharmaceuticals, Inc. (OSI), for the treatment of
neovascular (wet) age-related macular degeneration (AMD).
—Rebif, discovered and developed by Serono S.A. (Serono), is
used to treat symptoms of relapsing forms of multiple
sclerosis. Pfizer co-promotes Rebif with Serono in the U.S.
—Spiriva, discovered and developed by our alliance partner
Boehringer Ingelheim (BI), is used to treat chronic obstructive
pulmonary disease, a chronic respiratory disorder that
includes chronic bronchitis and emphysema.
Alliances allow us to co-promote or license these products for sale
in certain countries. Under the co-promotion agreements, these
products are marketed and promoted with our alliance partners.
We provide funding through cash, staff and other resources to sell,
market, promote and further develop these products.
Recent Product Launches
We continue to invest in clinical research for our in-line medicines,
increasing the value of our medicines to patients and their
healthcare providers. We are also reinvigorating our portfolio by
launching a series of new medicines or existing medicines in new
markets. The following highlights the achievements for several
of these products in 2005:
• Macugen, for treatment of AMD, the leading cause of blindness
in people over 60, was launched in the U.S. in January 2005 and
approved in the E.U. in 2006. While new competitors are expected
to enter the market, Macugen has a strong foothold with more
than 40,000 patients treated to date. Macugen’s favorable safety
profile has been maintained for more than two years of clinical
testing and marketing. 
• Revatio, for treatment of pulmonary arterial hypertension
(PAH) was approved by the FDA in June 2005 and by the EMEA
in November 2005.
• Zmax, for treatment of mild-to-moderate acute bacterial
sinusitis and community acquired pneumonia in adult patients
appropriate for oral therapy due to susceptible pathogens
was launched in the U.S. in August 2005.
• Lyrica, for add-on therapy for adult epilepsy patients with
partial onset seizures, as well as neuropathic pain due to
diabetic neuropathy and post-herpetic neuralgia, was launched
in the U.S. in September 2005 with more than 500,000
prescriptions written as of December 23, 2005. Lyrica has
already gained more than a 7% new-prescription share of the
U.S. anti-epileptic market as of December 23, 2005.
Consumer Healthcare
Revenues of our Consumer Healthcare business follow:
YEAR ENDED DEC. 31, % CHANGE__________________________________________ _________________
(MILLIONS OF DOLLARS) 2005 2004 2003 05/04 04/03
Consumer Healthcare $3,878 $3,516 $2,949 10 19
Our Consumer Healthcare business is one of the largest in the
world.
On February 7, 2006, we announced that we are exploring
strategic options for our Consumer Healthcare business, including
a possible sale or spin-off of the business.
The increase in Consumer Healthcare revenues in 2005, as
compared to 2004, was attributable to:
• the 11% increase in 2005 in sales of Listerine mouthwash,
which benefited from the U.S. launch of Listerine Whitening in
April 2005, as well as continued strong performance in
international markets;
• the 13% growth from upper-respiratory products, 55% growth
from Zantac, and 15% growth from tobacco dependence
products;
• inclusion of Purell sales in 2005 following the acquisition of the
Purell brand in November 2004; and
• the favorable impact of the weakening of the U.S. dollar
relative to many foreign currencies.
The increase in Consumer Healthcare revenues in 2004, as
compared to 2003, was attributable to:
• the 22% increase in 2004 in sales of Listerine mouthwash,
which benefited from the U.S. launch of Natural Citrus flavor
in September 2003 and the launch of Listerine Advanced in
September 2004;
• the favorable impact of the weakening of the U.S. dollar
relative to many foreign currencies; and
• the inclusion of Pharmacia product revenues for a full year in
2004.
Animal Health
Revenues of our Animal Health business follow:
YEAR ENDED DEC. 31, % CHANGE__________________________________________ _________________
(MILLIONS OF DOLLARS) 2005 2004 2003 05/04 04/03
Livestock products $1,379 $1,200 $970 15 24
Companion animal 
products 827 753 628 10 20
Total Animal Health $2,206 $1,953 $1,598 13 22
Our Animal Health business is one of the largest in the world.
The increase in Animal Health revenues in 2005, as compared to
2004, was attributable to:
• in livestock, the continued performance of Excede (long acting
anti-infective) in the U.S. and Draxxin (for treatment of
respiratory disease in cattle and swine) in Europe and in the U.S.,
as well as Spectramast (antibiotic formulated to treat clinical
mastitis), which was launched in the U.S. in May 2005;
• in companion animal, increased promotional activities
throughout our markets resulted in Revolution (a parasiticide
for dogs and cats) and Clavamox (an antibiotic for dogs and cats)
growing at double-digit rates in 2005, and the launch of
Simplicef (small animal anti-infective) in the U.S. in the fourth
quarter of 2004; and
• the favorable impact of the weakening of the U.S. dollar
relative to many foreign currencies.
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The increase in Animal Health revenues in 2004, as compared to
2003, despite the impact on the cattle industry following the
discovery of BSE (bovine spongiform encephalopathy or mad
cow disease) in the U.S., was attributable to:
• in livestock, the launch of a new claim for Bovishield (protects
pregnant cows and fetal and nursing calves against viral
diseases) in the U.S. during the fourth quarter of 2003; the
launch of Draxxin in Europe during the first quarter of 2004;
and the third quarter of 2004 launch of Excede in the U.S.;
• in companion animal, Rimadyl (for relief of arthritis pain in dogs
and for post-operative treatment), Revolution and Clavamox
all grew at double-digit rates in 2004;
• the favorable impact of the weakening of the U.S. dollar
relative to many foreign currencies; and
• the inclusion of Pharmacia product revenues, which are
reflected in both product categories, for a full year in 2004.
Product Developments
We continue to invest in R&D to provide future sources of revenue
through the development of new products, as well as through
additional uses for existing in-line and alliance products. We have
a broad and deep pipeline of medicines in development. We have
10 new products (Lyrica, Macugen, Revatio, Zmax, Champix, Sutent,
Eraxis, Exubera, indiplon and Zeven) that recently have been
approved or are undergoing regulatory review in the U.S. and/or
the E.U. We launched, or intend to launch, these new products in
markets once regulatory approvals are received. However, there
are no assurances as to when, or if, we will receive regulatory
approval for these or any of our other products in development.
Significant regulatory actions by, and filings pending with, the FDA
and other regulatory authorities follow:
Recent FDA Approvals
PRODUCT INDICATION DATE APPROVED
Eraxis Treatment of candidemia and February 2006
invasive candidiasis
Treatment of esophageal February 2006
candidiasis
Exubera Inhaled form of insulin for January 2006
use in adults with type 1 and 
type 2 diabetes
Sutent Treatment of metastatic renal January 2006
cell carcinoma (mRCC) and 
malignant gastrointestinal 
stromal tumors (GIST)
Aromasin Treatment of early breast October 2005
cancer in post-menopausal 
women
Lipitor Reduce the risk of stroke and September 2005
myocardial infarction in 
patients with type 2 diabetes




Celebrex For the relief of the signs and July 2005
symptoms associated with 
ankylosing spondylitis
Lyrica Add-on therapy for adult June 2005
epilepsy patients with partial 
onset seizures
Revatio Oral treatment for adult PAH June 2005
Zmax Single dose version of June 2005
Zithromax for acute bacterial 
sinusitis and community-
acquired pneumonia
Zyvox For the treatment of bacterial May 2005
infections in pediatric patients
Depo-SubQ Subcutaneous formulations to March 2005
Provera treat pain associated with 
endometriosis
Ellence Adjuvant long-term cancer March 2005
treatment
Pending U.S. New Drug Applications (NDAs) 
and Supplemental Filings
PRODUCT INDICATION DATE SUBMITTED
Champix Nicotine-receptor partial November 2005
agonist for smoking cessation
Aricept Treatment of severe August 2005
Alzheimer’s disease
Genotropin Treatment of short stature and June 2005
growth problems resulting 
from Turner’s syndrome
Vfend Pediatric filing June 2005
Indiplon Modified-release tablets for May 2005
treatment of multiple 
aspects of insomnia
Immediate-release capsules April 2005
for treatment of multiple 
aspects of insomnia
Zeven Treatment of Gram-positive December 2004
bacterial infections
Norvasc Reduction of cardiovascular August 2004
risk, including risk of 




Fragmin Use in oncology patients to March 2004
reduce cardiac toxicity 
associated with 
chemotherapy
In September 2005, we received “not-approvable” letters from the
FDA for Oporia for the prevention of post-menopausal
osteoporosis, and Dynastat (parecoxib), an injectable prodrug for
valdecoxib for the treatment of acute pain. In January 2006, we
received a “not-approvable” letter from the FDA for Oporia for
the treatment of vaginal atrophy. Pfizer is currently in discussions
with the FDA regarding these “not-approvable” letters and we
continue to develop both of these compounds.
On September 14, 2005, Pfizer completed the acquisition of
Vicuron. Zeven (dalbavancin), one of the key product candidates
acquired in the Vicuron acquisition, is a new injectable antibiotic
to treat Gram-positive infections. The FDA has designated as
approvable the NDA for Zeven. We anticipate a rapid and
successful resolution of outstanding issues to allow final NDA
approval in the coming months. Eraxis (anidulafungin), also
acquired in the Vicuron acquisition, was approved by the FDA in
February 2006. The addition of these two medications will broaden
Pfizer’s existing portfolio of anti-infectives, where the Company
has a long history of providing patients and physicians with life-
saving medicines.
An NDA for Champix (varenicline), a nicotine-receptor partial
agonist for smoking cessation was submitted to the FDA in
November 2005. In December 2005, the FDA granted Champix
priority-review status.
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Other Regulatory Approvals and Filings:
PRODUCT DESCRIPTION OF EVENT DATE APPROVED DATE SUBMITTED
Exubera Approved in the E.U. as an inhaled form of insulin for use in January 2006 —
adults with type 1 and type 2 diabetes
Macugen Approved in the E.U. for AMD January 2006 —
Approval in Canada and Brazil for AMD May 2005 —
Application submitted in Switzerland for AMD — January 2005
Application submitted in Australia for AMD — September 2004
Zoloft Approval in Japan for treatment of depression January 2006 —
Detrol/Detrol LA Approval in Japan for treatment of overactive bladder January 2006 —
Revatio Approval in the E.U. for treating PAH November 2005 —
Application submitted in Canada for treating PAH — December 2004
Caduet Approval in Canada for cardiovascular event prevention November 2005 —
Approval in certain E.U. countries for cardiovascular event July 2005 —
prevention
Champix Application submitted in the E.U. for smoking cessation — November 2005
Sutent Application submitted in Canada for mRCC and GIST — November 2005
Application submitted in the E.U. for mRCC and GIST — August 2005
Geodon/Zeldox Approval in the E.U. for treating manic or mixed episodes of October 2005 —
moderate severity in bipolar disorder
Somavert Approval in Canada for Acromegaly October 2005 —
Application submitted in Japan for Acromegaly — May 2005
Aromasin Approval in the E.U. for treating early breast cancer in August 2005 —
post-menopausal women
Aricept Approval in Canada for fast dissolving tablet July 2005 —
Lyrica Approval in Canada for neuropathic pain June 2005 —
Application submitted in the E.U. for treatment of generalized — June 2005
anxiety disorder (GAD) in adults
Fragmin Approval in the E.U. for treatment of deep vein thrombosis in April 2005 —
cancer patients
Vfend Approval in Japan for treatment of aspergillosis April 2005 —
Approval was granted in the E.U. for treatment of serious, January 2005 —
invasive, fluconazole-resistant candida infections and first-line 
treatment of candidemia in non-neutropenic patients.
Zmax Application submitted in the E.U. for sustained release — October 2004
Genotropin Application submitted in Japan for treatment of short stature — July 2004
and growth problems
Neurontin Application submitted in Japan for epilepsy — April 2004
In January 2006, the CHMP, the scientific committee of the EMEA, finalized its scientific assessment and issued a positive opinion
recommending that marketing authorization be granted by the European Commission for Lyrica for the treatment of GAD in adults.
The approval requires final authorization from the European Commission.
Ongoing or planned clinical trials for additional uses and dosage forms for our products include:
PRODUCT INDICATION
Celebrex Sporadic adenomatous polyposis—a precancerous condition caused by growths (polyps) in the intestines
Camptosar IV Adjuvant colorectal cancer
Gastric cancer
Geodon/Zeldox Bipolar relapse prevention
Macugen Diabetic macular edema
Xalatan (new 
delivery device) Ocular hypertension
Zyvox Catheter-related infections
Bone and joint infections
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Drug candidates in late-stage development include maraviroc
(UK-427,857), a CCR-5 receptor antagonist for HIV; torcetrapib/
atorvastatin, a combination CETP inhibitor/statin for heart disease;
asenapine, for schizophrenia and bipolar disorder, under 
co-development with Akzo Nobel’s Organon healthcare unit;
Zithromax/chloroquine for treatment of malaria; PF-3512676, a
toll-like receptor 9 agonist for non-small cell lung cancer developed
in partnership with Coley Pharmaceutical Group, Inc. (Coley);
and ticilimumab (CP-675,206), an anti-CTLA4 monoclonal antibody
for melanoma. The FDA has granted fast-track designation for
maraviroc’s clinical development program.
Torcetrapib/atorvastatin, which combines the new chemical entity
torcetrapib (a CETP inhibitor discovered by Pfizer that raises HDL-
cholesterol) with atorvastatin (Lipitor), is continuing in global
Phase 3 clinical trials. This comprehensive 12,000-subject
development program includes three comparative atherosclerotic
imaging trials (a coronary intravascular ultrasound study and
two carotid ultrasound studies), as well as a full range of blood-
lipid efficacy studies comparing torcetrapib/atorvastatin to Lipitor,
other statins and fibrates. In addition to these Phase 3 studies, the
development program includes a definitive mortality and
morbidity trial that is enrolling 13,000 patients.
Despite effective treatments, cardiovascular disease remains the
number one killer worldwide with a residual relative risk of 60%
to 70% after treatment with statins. Therefore, the primary
objective of the torcetrapib/atorvastatin development program
is to provide clear evidence that substantially raising HDL-
cholesterol and further lowering LDL-cholesterol can reduce
cardiovascular risk beyond what can be achieved with current
treatments. Torcetrapib will be developed with atorvastatin in
order to rigorously test this hypothesis and the new CETP
inhibition mechanism of action. This development program
represents a major commitment by Pfizer to significantly advance
the understanding of lipids and atherosclerosis in order to provide
an important new tool for patients and prescribers in preventing
and treating the global burden of cardiovascular disease.
On November 21, 2005, Pfizer announced an agreement to
purchase development, manufacturing and marketing rights of
drugs to treat chronic inflammatory conditions from Incyte
Corporation (Incyte). Milestone payments of up to $803 million
could potentially be made to Incyte. Under the collaborative
research and license agreement, Pfizer will receive exclusive rights
to Incyte’s portfolio of CCR2 antagonist compounds. The
agreement is subject to regulatory approval.
In May 2005, we announced an agreement to collaborate with
Renovis Pharmaceuticals, Inc. (Renovis) for the research and
development of antagonists of vanilloid receptor 1 for the
treatment of neuropathic and other types of chronic pain. Under
the terms of the agreement, we expensed a payment of $10
million made in the second quarter of 2005, which was included
in Research and development expenses. Additional milestone
payments of $175 million could potentially be made to Renovis
based upon clinical trials, regulatory filing and approvals, as well
as the attainment of certain agreed upon sales levels.
In March 2005, we announced a license agreement with Coley for
ProMune, ProMune combination products and ProMune vaccine
products for the treatment, control and prevention of cancer.
Under the terms of the agreement, we expensed a payment of
$50 million made in the first quarter of 2005, which was included
in Research and development expenses, and purchased $10 million
of Coley’s common stock. Additional milestone payments of $455
million could potentially be made to Coley based upon clinical
trials, regulatory approvals and the launch of a ProMune product
by Pfizer.
In January 2005, we entered into a collaborative research and
license agreement with Rigel Pharmaceuticals, Inc. (Rigel) to
identify, develop and commercialize Syk tyrosine kinase inhibitors
for the use in diagnosis, treatment and prevention of certain
allergy and respiratory conditions. Under the terms of the
agreement we expensed a payment of $10 million made in the
first quarter of 2005, which was included in Research and
development expenses, and purchased $5 million of Rigel’s
common stock. Additional milestone payments of $130 million
could potentially be made to Rigel based upon development
stages, clinical trials, regulatory approvals and the successful
commercialization of a product.
In October 2003, we announced a global agreement to collaborate
with Organon for asenapine, a treatment for schizophrenia and
bipolar disorder. Under the terms of the agreement, we expensed
a payment of $100 million made in the fourth quarter of 2003,
which was included in Research and development expenses.
Additional milestone payments of $270 million could potentially
be made to Organon based upon regulatory approvals and launch
of asenapine in the U.S., E.U., and Japan, as well as the attainment
of certain agreed-upon sales levels.
In December 2002, we announced an agreement with Neurocrine
for indiplon, for the treatment of insomnia. Under the terms of
the agreement, we expensed a payment of $100 million made in
the first quarter of 2003, which was included in Research and
development expenses. Additional milestone payments of $300
million could potentially be made to Neurocrine based on
worldwide regulatory submissions and approvals. In 2005 and
2004, we expensed $70 million and $21 million in milestone
payments (of the $300 million), which were included in Research
and development expenses.
Also in December 2002, we announced an agreement with Eyetech
Pharmaceuticals, Inc. (Eyetech) for Macugen (pegaptanib sodium),
a treatment for AMD, which was approved by the FDA in
December 2004 and by the E.U. in January 2006, and diabetic
macular edema (DME), both leading causes of blindness. Eyetech
was subsequently acquired by OSI. Under the terms of the
agreement we expensed a payment of $100 million in the first
quarter of 2003, which was included in Research and development
expenses. Additional milestone payments up to $195.5 million
could potentially be made to OSI based on worldwide regulatory
submissions and approvals. OSI also has the potential to receive
an additional $450 million in milestone payments, which are
contingent upon successful commercialization of Macugen and
attainment of agreed-upon sales levels. In 2004, based on certain
regulatory submissions and approvals, we expensed $16 million
in milestone payments, which were included in Research and
development expenses and in connection with the approval, we
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capitalized as an intangible asset, a $90 million milestone payment
(all amounts were included in the $195.5 million).




Cost of sales increased 13% in 2005 and decreased 21% in 2004
while revenues decreased 2% in 2005 and increased 17% in 2004.
Cost of sales in 2005 compared to 2004 increased as a result of:
• unfavorable geographic, segment and product mix, and adverse
changes in production volume, among other factors, which
reflect the loss of U.S. exclusivity for certain of our
pharmaceutical products and the uncertainty regarding the
selective COX-2 inhibitors;
• $124 million related to implementation costs of our new AtS
productivity initiative; and
• $73 million in write-offs of inventory and exit costs related to
suspension of sales and marketing of Bextra.
Cost of sales in 2004 (which includes legacy Pharmacia’s product
portfolio for the entire period) compared to 2003 decreased as
a result of:
• impact of purchase accounting in 2003, which reflected the
incremental charge of $2.7 billion from the sale of inventory
acquired from Pharmacia, adjusted to fair value;
• merger-related cost savings; and
• favorable product mix,
partially offset by:
• higher product costs attributable to legacy Pharmacia products;
and
• the unfavorable impact of the weakening of the U.S. dollar
relative to many foreign currencies.
Selling, Informational and Administrative (SI&A)
Expenses
SI&A expenses increased 1% in 2005 which reflects the unfavorable
impact of foreign exchange and $156 million in AtS expenses,
partially offset by an increase in merger-related synergies and the
impact of the Company’s AtS productivity initiative. Marketing
expenses of our pharmaceutical products decreased compared to
2004, due primarily to lower spending on products which have lost
exclusivity and the withdrawal of Bextra.
In 2004, SI&A expenses increased 12%, mainly due to the full year
inclusion of Pharmacia SI&A-related activities, partially offset by
cost synergies from Pharmacia-related restructuring activities.
Marketing expenses of our pharmaceutical products included
costs in 2004 primarily for supporting new product introductions
such as Caduet, Lyrica, Inspra and Somavert and increased
promotion due to new product competition largely offset by the
realization of merger synergies.
Research and Development (R&D) Expenses
R&D expenses decreased 3% in 2005 and increased 3% in 2004.
The decline in 2005 reflects the initial benefits associated with the
AtS productivity initiative, partially offset by increased portfolio
support and $50 million in AtS expenses. We have consolidated
our infrastructure support systems into global centers of excellence
that now support the entire R&D enterprise. More importantly,
the mix of expenses has changed over the past three years. For
example, while our capital expenditures and information
technology expenses were approximately one-third of our budget
in 2002, our 2006 budget will be less than 17% of the R&D
budget. As a result, we are taking funds previously used to
support R&D and utilizing them in our development of
compounds. In 2004, year-over-year growth of R&D expenses is
attributable to the inclusion of Pharmacia-related activities and
increased support of the advanced-stage development portfolio,
partially offset by cost synergies from Pharmacia-related
restructuring activities.
R&D expense also includes payments for intellectual property
rights of $156 million in 2005, $160 million in 2004 and $380
million in 2003. Additionally, see our discussion in the “Product
Developments” section of this Financial Review.
Merger-Related In-Process Research and 
Development Charges
The estimated value of merger-related IPR&D is expensed at the
acquisition date. In 2005, we expensed $1.7 billion of IPR&D,
primarily related to our acquisition of Vicuron on September 14,
2005 ($1.4 billion) and our acquisition of Idun on April 12, 2005
($250 million). In 2004, we expensed $1.1 billion of IPR&D,
primarily related to our acquisition of Esperion ($920 million). In
2003, we expensed $5.1 billion of IPR&D related to our acquisition
of Pharmacia.
Merger-Related Costs
We incurred the following merger-related costs, primarily in
connection with our acquisition of Pharmacia which was
completed on April 16, 2003:
YEAR ENDED DEC. 31,________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
Integration costs(a):
Pharmacia $538 $ 475 $ 838
Other 12 21 33
Restructuring costs(a):
Pharmacia 390 704 177
Other 3 (7) 10
Total merger-related 
costs—expensed $943 $1,193 $1,058
Total merger-related 
costs—capitalized $ — $ 581 $1,578
(a) Included in Restructuring charges and merger-related costs.
Integration costs represent external, incremental costs directly
related to an acquisition, including expenditures for consulting
and systems integration.
In connection with the acquisition of Pharmacia, Pfizer
management approved plans to restructure and integrate the
operations of both legacy Pfizer and legacy Pharmacia to combine
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operations, eliminate duplicative facilities and reduce costs. As of
December 31, 2005, the restructuring of our operations as a
result of our acquisition of Pharmacia is substantially complete.
Restructuring charges included severance, costs of vacating
duplicative facilities, contract termination and other exit costs.
Total merger-related expenditures (income statement and balance
sheet) incurred during 2002-2005 to achieve these synergies were
$5.4 billion, on a pre-tax basis.
The restructuring of our operations resulting from our merger with
Warner-Lambert was substantially complete as of December 31,
2003. Accordingly, we did not incur significant integration or
restructuring charges in 2005 and 2004 directly related to our
merger with Warner-Lambert.
Cost synergies from the Pharmacia acquisition were $4.2 billion
in 2005, $3.6 billion in 2004 and $1.3 billion in 2003. Synergies
come from a broad range of sources, including a streamlined
organization, reduced operating expenses, and procurement
savings.
Restructuring Costs Associated with Legacy 
Pharmacia — Capitalized
We recorded, through April 15, 2004, restructuring costs associated
primarily with employee terminations and exiting certain activities
of legacy Pharmacia. These costs were recognized as liabilities
assumed in the purchase business combination. Accordingly, these
costs were considered part of the purchase price of Pharmacia and
have been recorded as an increase to goodwill (see Notes to
Consolidated Financial Statements—Note 2A, Acquisitions:
Pharmacia Corporation). At December 31, 2005, liabilities for
restructuring costs incurred but not paid totaled $132 million
and are included in Other current liabilities. Restructuring charges
after April 15, 2004 associated with legacy Pharmacia are charged
to the results of operations. Changes to previous estimates of
restructuring charges that were included as part of the purchase
price allocation of Pharmacia are recorded as a reduction of
goodwill or as an expense to operations, as appropriate.
The majority of the restructuring costs related to employee
terminations (see Notes to Consolidated Financial Statements—
Note 5B, Merger-Related Costs: Restructuring Costs—Pharmacia).
Through December 31, 2005, employee termination costs totaling
$1.5 billion represent the approved reduction of the legacy
Pharmacia work force by 12,768 employees mainly in corporate,
manufacturing, distribution, sales and research. We notified
affected individuals and 12,589 employees were terminated as of
December 31, 2005. Employee termination costs include accrued
severance benefits and costs associated with change-in-control
provisions of certain Pharmacia employment contracts.
Restructuring Costs Associated with Legacy Pfizer 
and Legacy Pharmacia — Expensed
Through December 31, 2005, we have recorded, in total, $1.3
billion of restructuring costs ($390 million recorded in 2005).
These restructuring costs were associated with exiting certain
activities of legacy Pfizer and legacy Pharmacia (from April 16,
2004), including severance, costs of vacating duplicative facilities,
contract termination and other exit costs. At December 31, 2005,
liabilities for restructuring costs incurred but not paid totaled $119
million and are included in Other current liabilities.
The majority of the restructuring costs related to employee
terminations (see Notes to Consolidated Financial Statements—
Note 5B, Merger-Related Costs: Restructuring Costs—Pharmacia).
Through December 31, 2005, employee termination costs totaling
$625 million ($108 million recorded in 2005) represent the
approved reduction of the legacy Pfizer and legacy Pharmacia
(from April 16, 2004) work force by 4,476 employees, mainly in
corporate, manufacturing, distribution, sales and research. We
notified affected individuals and 4,082 employees were terminated
as of December 31, 2005. Employee termination costs include
accrued severance benefits and costs associated with change-in-
control provisions of certain Pharmacia employment contracts.
Adapting to Scale Initiative
In connection with the AtS productivity initiative, Pfizer
management has performed a comprehensive review of our
processes, organizations, systems and decision-making procedures,
in a company-wide effort to improve performance and efficiency.
We expect the costs associated with this multi-year effort to
continue through 2008 and to total approximately $4 billion to
$5 billion, on a pre-tax basis. The actions associated with the AtS
productivity initiative will include restructuring charges, such as
asset impairments, exit costs and severance costs (including any
related impacts to our benefit plans, including settlements and
curtailments) and associated implementation costs, such as
accelerated depreciation charges, primarily associated with plant
network optimization efforts, and expenses associated with
system and process standardization and the expansion of shared
services.
We incurred the following costs in connection with our AtS
initiative, which was launched in the first quarter of 2005:
YEAR ENDED 
DEC. 31,______________
(MILLIONS OF DOLLARS) 2005
Implementation costs(a) $330
Restructuring charges(b) 450
Total AtS costs $780
(a) Included in Cost of sales ($124 million), Selling, informational and
administrative expenses ($156 million), and Research and
development expenses ($50 million).
(b) Included in Restructuring charges and merger-related costs.
Through December 31, 2005, the restructuring charges primarily
relate to employee termination costs at our manufacturing
facilities in North America and in our U.S. marketing and
worldwide research and development operations, and the
implementation costs primarily relate to system and process
standardization, as well as the expansion of shared services.
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The components of restructuring charges associated with AtS
follow:
UTILIZATION ACCRUAL
COSTS THROUGH AS OF 
INCURRED DEC. 31, DEC. 31,__________ ___________ ___________
(MILLIONS OF DOLLARS) 2005 2005 2005(a)
Employee termination costs $305 $166 $139
Asset impairments 131 131 —
Other 14 3 11
$450 $300 $150
(a) Included in Other current liabilities.
Through December 31, 2005, Employee termination costs
represent the approved reduction of the workforce by 2,602
employees, mainly in manufacturing, sales and research. We
notified affected individuals and 2,425 employees were terminated
as of December 31, 2005. Employee termination costs are recorded
as incurred and include accrued severance benefits, pension and
postretirement benefits. Asset impairments primarily include
charges to write off inventory and write down property, plant and
equipment. Other primarily includes costs to exit certain activities.
Other (Income)/Deductions — Net
In 2005, Pfizer recorded impairment charges of $1.1 billion related
to the developed technology rights for Bextra, a selective COX-
2 inhibitor, and $5 million related to the write-off of machinery
and equipment. In 2004, we recorded an impairment charge of
$691 million related to the Depo-Provera brand and a litigation-
related charge of $369 million related to the resolution of claims
against Quigley Company, Inc., a wholly-owned subsidiary of
Pfizer. In 2003, we recorded charges totaling $1.4 billion to cover
the resolution of two legacy Warner-Lambert legal matters
relating to Rezulin personal injury claims and a government
investigation of marketing practices relating to Neurontin. See also
Notes to Consolidated Financial Statements—Note 6, Other
(Income)/Deductions—Net.
Taxes on Income
In 2005, we recorded an income tax charge of $1.7 billion, included
in Provision for taxes on income, in connection with our decision
to repatriate approximately $37 billion of foreign earnings in
accordance with the American Jobs Creation Act of 2004 (the Jobs
Act). The Jobs Act created a temporary incentive for U.S.
corporations to repatriate accumulated income earned abroad by
providing an 85% dividend-received deduction for certain
dividends from controlled foreign corporations in 2005. In
addition, during 2005, we recorded a tax benefit of $586 million,
primarily related to the resolution of certain tax positions.
Our overall effective tax rate for continuing operations was
29.7% in 2005, 19.0% in 2004 and 49.7% in 2003. The higher tax
rate in 2005 compared to 2004 was attributable to the previously
mentioned tax charge associated with the repatriation of foreign
earnings and higher non-deductible charges for merger-related
IPR&D, primarily relating to our acquisition of Vicuron and Idun
in 2005, partially offset by the tax benefit of $586 million related
to the resolution of certain tax positions. The lower tax rate in
2004 compared to 2003 was attributable to decreased non-
deductible merger-related IPR&D charges.
On January 25, 2006, the Company was notified by the IRS Appeals
Division that a resolution had been reached on one matter that
we were in the process of appealing related to the tax deductibility
of a breakup fee paid by the Warner-Lambert Company in 2000.
As a result, in the first quarter of 2006, we will record favorable
adjustments of approximately $450 million.
On January 23, 2006, the IRS issued final regulations on Statutory
Mergers and Consolidations, which impact certain prior period
transactions. The regulations could result in benefits ranging
from approximately $75 million to $214 million in the first quarter
of 2006 subject to certain management decisions.
Discontinued Operations
See our discussion in the “Acquisitions and Dispositions” section
of this Financial Review for a complete discussion of dispositions.
The following amounts have been segregated from continuing
operations and reported as discontinued operations, and in 2003,
primarily related to the disposition of the Adams confectionery
products business and the Schick-Wilkinson Sword business:
YEAR ENDED DEC. 31,________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
Revenues $ 55 $405 $1,214
Pre-tax (loss)/income (33) (39) 43
(Benefit) from/provision 
for taxes(a) (2) (17) 17
(Loss)/income from 
discontinued operations—
net of tax (31) (22) 26
Pre-tax gains on sales of 
discontinued operations 77 75 3,885
Provision for taxes on gains(b) 30 24 1,600
Gains on sales of 
discontinued operations—
net of tax 47 51 2,285
Discontinued operations—
net of tax $ 16 $ 29 $2,311
(a) Includes a deferred tax expense of $23 million in 2005, a deferred
tax benefit of $15 million in 2004 and a deferred tax expense of
$8 million in 2003.
(b) Includes a deferred tax expense of nil in 2005 and 2004, and $744
million in 2003.
Adjusted Income
General Description of Adjusted Income Measure
Adjusted income is an alternative view of performance used by
management and we believe that investors’ understanding of our
performance is enhanced by disclosing this performance measure.
The Company reports Adjusted income in order to portray the
results of our major operations—the discovery, development,
manufacture, marketing and sale of prescription medicines for
humans and animals, as well as our over-the-counter products—
prior to considering certain income statement elements. We have
defined Adjusted income as Net income before significant impact
of purchase accounting for acquisitions, merger-related costs,
discontinued operations, the cumulative effect of a change in
accounting principles and certain significant items. The Adjusted
income measure is not, and should not be viewed as, a substitute
for U.S. GAAP Net income.
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The Adjusted income measure is an important internal
measurement for Pfizer. We measure the performance of the
overall Company on this basis. The following are examples of how
the Adjusted income measure is utilized.
• Senior management receives a monthly analysis of the
operating results of our Company that is prepared on an
Adjusted income basis;
• The annual budgets of our Company are prepared on an
Adjusted income basis; and
• Annual and long-term compensation, including annual cash
bonuses, merit-based salary adjustments and stock options,
for various levels of management, is based on financial measures
that include Adjusted income. The Adjusted income measure
currently represents a significant portion of target objectives
that are utilized to determine the annual compensation for
various levels of management, although the actual weighting
of the objective may vary by level of management and job
responsibility and may be considered in the determination of
certain long-term compensation plans. The portion of senior
management’s bonus, merit-based salary increase and stock
option awards based on the Adjusted income measure ranges
from 10% to 30%.
Despite the importance of this measure to management in goal
setting and performance measurement, we stress that Adjusted
income is a non-GAAP financial measure that has no standardized
meaning prescribed by U.S. GAAP and, therefore, has limits in its
usefulness to investors. Because of its non-standardized definition,
Adjusted income (unlike U.S. GAAP Net income) may not be
comparable with the calculation of similar measures for other
companies. Adjusted income is presented solely to permit investors
to more fully understand how management assesses the
performance of our Company.
We also recognize that, as an internal measure of performance,
the Adjusted income measure has limitations and we do not
restrict our performance-management process solely to this
metric. A limitation of the Adjusted income measure is that it
provides a view of our Company’s operations without including
all events during a period such as the effects of an acquisition,
merger-related costs or amortization of purchased intangibles and
does not provide a comparable view of our performance to other
companies in the pharmaceutical industry. We also use other
specifically tailored tools designed to ensure the highest levels of
performance in our Company. For example, our R&D organization
has productivity targets, upon which its effectiveness is measured.
In addition, for senior levels of management, a portion of their
long-term compensation is based on U.S. GAAP Net income.
Purchase Accounting Adjustments
Adjusted income is calculated prior to considering certain
significant purchase-accounting impacts, such as those related to
our acquisitions of Pharmacia, Vicuron and Esperion as well as net-
asset acquisitions. These impacts can include charges for purchased
IPR&D, the incremental charge to cost of sales from the sale of
acquired inventory that was written up to fair value and the
incremental charges related to the amortization of finite-lived
intangible assets for the increase to fair value. Therefore, the
Adjusted income measure includes the revenues earned upon the
sale of the acquired products without considering the
aforementioned significant charges.
Certain of the purchase-accounting adjustments associated with
a business combination, such as the amortization of intangibles
acquired in connection with our acquisition of Pharmacia, can occur
for up to 40 years (these assets have a weighted-average useful life
of approximately nine years), but this presentation provides an
alternative view of our performance that is used by management
to internally assess business performance. We believe the
elimination of amortization attributable to acquired intangible
assets provides management and investors an alternative view of
our business results by trying to provide a degree of parity to
internally developed intangible assets for which research and
development costs have been previously expensed.
However, a completely accurate comparison of internally
developed intangible assets and acquired intangible assets cannot
be achieved through Adjusted income. This component of
Adjusted income is derived solely with the impacts of the items
listed in the first paragraph of this section. We have not factored
in the impacts of any other differences in experience that might
have occurred if Pfizer had discovered and developed those
intangible assets on its own and this approach does not intend
to be representative of the results that would have occurred in
those circumstances. For example, our research and development
costs in total, and in the periods presented, may have been
different; our speed to commercialization and resulting sales, if
any, may have been different; or our costs to manufacture may
have been different. In addition, our marketing efforts may have
been received differently by our customers. As such, in total,
there can be no assurance that our Adjusted income amounts
would have been the same as presented had Pfizer discovered and
developed the acquired intangible assets.
Merger-Related Costs
Adjusted income is calculated prior to considering integration and
restructuring costs associated with business combinations because
these costs are unique to each transaction and represent costs that
were incurred to restructure and integrate two businesses as a
result of the acquisition decision. For additional clarity, only
restructuring and integration activities that are associated with
a purchase business combination or a net-asset acquisition are
included in merger-related costs. We have not factored in the
impacts of synergies that would have resulted had these costs not
been incurred.
We believe that viewing income prior to considering these charges
provides investors with a useful additional perspective because the
significant costs incurred in a business combination result primarily
from the need to eliminate duplicate assets, activities or
employees—a natural result of acquiring a fully integrated set of
activities. For this reason, we believe that the costs incurred to
convert disparate systems, to close duplicative facilities or to
eliminate duplicate positions (for example, in the context of a
business combination) can be viewed differently from those costs
incurred in other, more normal business contexts.
The integration and restructuring costs associated with a business
combination may occur over several years with the more
significant impacts ending within three years of the transaction.
Because of the need for certain external approvals for some
actions, the span of time needed to achieve certain restructuring
and integration activities can be lengthy. For example, due to the
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highly regulated nature of the pharmaceutical business, the
closure of excess facilities can take several years as all
manufacturing changes are subject to extensive validation and
testing and must be approved by the FDA. In other situations, we
may be required by local laws to obtain approvals prior to
terminating certain employees. This approval process can delay
the termination action.
Discontinued Operations
Adjusted income is calculated prior to considering gains or losses
on the sale of businesses and product lines included in
discontinued operations as well as the related results of
operations. We believe that this presentation is meaningful to
investors because, while we review our businesses and product
lines periodically for strategic fit with our operations, we do not
build or run our businesses with an intent to sell them.
Cumulative Effect of a Change in Accounting Principles
Adjusted income is calculated prior to considering cumulative
effect of a change in accounting principles. The cumulative effect
of a change in accounting principles is generally one time in
nature and not expected to occur as part of our normal business
on a regular basis.
Certain Significant Items
Adjusted income is calculated prior to considering certain
significant items. Certain significant items represent substantive,
unusual items that are evaluated on an individual basis. Such
evaluation considers both the quantitative and the qualitative
aspect of their unusual nature. Unusual, in this context, may
represent items that are not part of our ongoing business; items
that, either as a result of their nature or size, we would not expect
to occur as part of our normal business on a regular basis; items
that would be non-recurring; or items that relate to products we
no longer sell. While not all-inclusive, examples of items that
could be included as certain significant items would be a major
non-acquisition-related restructuring charge and associated
implementation costs for a program which is specific in nature with
a defined term, such as those related to our AtS initiative; costs
associated with a significant recall of one of our products; charges
related to sales or disposals of products or facilities that do not
qualify as discontinued operations as defined by U.S. GAAP; certain
intangible asset impairments; adjustments related to the resolution
of certain tax positions; the impact of adopting certain significant,
event-driven tax legislation, such as charges attributable to the
repatriation of foreign earnings in accordance with the Jobs Act;
or possible charges related to legal matters, such as certain of those
discussed in Legal Proceedings in our Form 10-K and in Part II: Other
Information; Item 1, Legal Proceedings included in our Form 10-Q
filings. Normal, ongoing defense costs of the Company or
settlements and accruals on legal matters made in the normal
course of our business would not be considered a certain significant
item.
Reconciliation
A reconciliation between Net income, as reported under U.S.
GAAP, and Adjusted income follows:
YEAR ENDED DEC. 31, % CHANGE__________________________________________ _________________
(MILLIONS OF DOLLARS) 2005 2004 2003 05/04 04/03
Reported net income $ 8,085 $11,361 $3,910 (29) 191
Purchase accounting 
adjustments—
net of tax 3,973 3,389 8,666 17 (61)
Merger-related 
costs—net of tax 624 786 659 (21) 19
Discontinued 
operations—
net of tax (16) (29) (2,311) (45) (99)
Cumulative effect of 
a change in 
accounting 
principles—
net of tax 25 — 30 * *
Certain significant 
items—net of tax 2,310 629 1,358 268 (54)
Adjusted income $15,001 $16,136 $12,312 (7) 31
* Calculation not meaningful.
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Adjusted income as shown above excludes the following items:
YEAR ENDED DEC. 31,_______________________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
Purchase accounting adjustments, pre-tax:
In-process research and development charges(a) $1,652 $ 1,071 $ 5,052
Intangible amortization and other(b) 3,295 3,285 2,336
Sale of acquired inventory written up to fair value(c) 4 40 2,747
Total purchase accounting adjustments, pre-tax 4,951 4,396 10,135
Income taxes (978) (1,007) (1,469)
Total purchase accounting adjustments—net of tax 3,973 3,389 8,666
Merger-related costs, pre-tax:
Integration costs(d) 550 496 871
Restructuring costs(d) 393 697 187
Total merger-related costs, pre-tax 943 1,193 1,058
Income taxes (319) (407) (399)
Total merger-related costs—net of tax 624 786 659
Discontinued operations, pre-tax:
Loss/(income) from discontinued operations(e) 33 39 (43)
Gains on sales of discontinued operations(e) (77) (75) (3,885)
Total discontinued operations, pre-tax (44) (36) (3,928)
Income taxes 28 7 1,617
Total discontinued operations—net of tax (16) (29) (2,311)
Cumulative effect of a change in accounting principles—net of tax 25 — 30
Certain significant items, pre-tax:
Asset impairment charges(f) 1,240 702 —
Restructuring charges—Adapting to Scale(d) 450 — —
Implementation costs—Adapting to Scale(g) 330 — —
Gain on disposals of investments(h) (134) — —
Litigation-related charges(h) — 369 1,402
Contingent income earned from the prior year sale of a product-in-development(h) — (100) —
Operating results of divested legacy Pharmacia research facility(i) — 64 —
Total certain significant items, pre-tax 1,886 1,035 1,402
Income taxes (654) (406) (44)
Resolution of certain tax positions(j) (586) — —
Tax impact of the repatriation of foreign earnings(j) 1,664 — —
Total certain significant items—net of tax 2,310 629 1,358
Total purchase accounting adjustments, merger-related costs, discontinued 
operations, cumulative effect of a change in 
accounting principles and certain significant items—net of tax $6,916 $ 4,775 $ 8,402
(a) Included in Merger-related in-process research and development charges. (See Notes to Consolidated Financial Statements—Note 2,
Acquisitions.)
(b) Included primarily in Amortization of intangible assets. (See Notes to Consolidated Financial Statements—Note 12, Goodwill and Other
Intangible Assets.)
(c) Included in Cost of sales. (See Notes to Consolidated Financial Statements—Note 2, Acquisitions.)
(d) Included in Restructuring charges and merger-related costs. (See Notes to Consolidated Financial Statements—Note 4, Adapting to Scale
Initiative and Note 5, Merger-Related Costs.)
(e) Included in Discontinued operations—net of tax. (See Notes to Consolidated Financial Statements—Note 3, Dispositions.)
(f) In 2005, primarily Cost of sales ($73 million), Selling, informational and administrative expenses ($8 million) and Other (income)/deductions—
net ($1.2 billion) related to the suspension of sales of Bextra. In 2004, primarily Other (income)/deductions—net related to an impairment
charge related to the Depo-Provera brand. (See Notes to Consolidated Financial Statements—Note 12B, Goodwill and Other Intangible Assets:
Other Intangible Assets.)
(g) Included in Cost of Sales ($124 million), Selling, informational and administrative expenses ($156 million), and Research and development
expenses ($50 million) for 2005. (See Notes to Consolidated Financial Statements—Note 4, Adapting to Scale Initiative.)
(h) Included in Other (income)/deductions—net. (See Notes to Consolidated Financial Statements—Note 6, Other (Income)/Deductions—Net.)
(i) Included in Research and development expenses.
(j) Included in Provision for taxes on income. (See Notes to Consolidated Financial Statements—Note 7, Taxes on Income.)
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Financial Condition, Liquidity and Capital
Resources
Net Financial Assets
Our net financial asset position as of December 31 follows:
(MILLIONS OF DOLLARS) 2005 2004
Financial assets:
Cash and cash equivalents $ 2,247 $ 1,808
Short-term investments 19,979 18,085
Short-term loans 510 653
Long-term investments and loans 2,497 3,873
Total financial assets 25,233 24,419
Debt:
Short-term borrowings 11,589 11,266
Long-term debt 6,347 7,279
Total debt 17,936 18,545
Net financial assets $ 7,297 $ 5,874
We rely largely on operating cash flow, short-term commercial
paper borrowings and long-term debt to provide for the working
capital needs of our operations, including our R&D activities. We
believe that we have the ability to obtain both short-term and long-
term debt to meet our financing needs for the foreseeable future.
Impact of Repatriation of Foreign Earnings
In 2005, under the Jobs Act, we repatriated to the U.S.
approximately $37 billion in cash from foreign earnings (see the
“Taxes on Income” section of this Financial Review). This cash is
being used for domestic expenditures relating to advertising and
marketing activities, research and development activities, capital
assets and other asset acquisitions and non-executive
compensation in accordance with the provisions of the Jobs Act
(as in effect on December 31, 2005). The repatriation resulted in
a decrease in short-term and long-term investments held overseas
as the cash was repatriated and an increase in short-term
borrowings overseas used to fund the repatriation.
Investments
Our short-term and long-term investments consist primarily of high
quality, liquid investment-grade available-for-sale debt securities.
Our long-term investments include debt securities that totaled
$906 million as of December 31, 2005, which have maturities
ranging substantially from 1 to 10 years. Wherever possible, cash
management is centralized and intercompany financing is used
to provide working capital to our operations. Where local
restrictions prevent intercompany financing, working capital
needs are met through operating cash flows and/or external
borrowings.
Long-Term Debt Issuance 
In November 2005, Pfizer issued $1.0 billion of senior unsecured
floating-rate notes at LIBOR, less a nominal amount, with an
initial maturity of 13 months. The debt holders have the option
to extend the term of the notes by one month, each month,
during the five-year maximum term of the notes. In addition, the
adjustment to LIBOR increases each December by a nominal
amount. The notes are callable by us at par plus accrued interest
to date every six months, with a notice not less than thirty days,
but not more than sixty days. The LIBOR-based floating-rate
notes bear an interest rate of 4.33% as of December 31, 2005. The
floating-rate notes were issued through an international
subsidiary. They are guaranteed as to principal and interest by
Pfizer Inc through the maturity date of the notes. These notes
were issued to fund certain international subsidiaries’ dividends
paid in 2005 to Pfizer in connection with our repatriation strategy.
On February 22, 2006, we issued the following Japanese yen
fixed-rate bonds, which will be used for current general corporate
purposes:
• $508 million equivalent, senior unsecured notes, due February
2011, which pay interest semi-annually, beginning on August 22,
2006, at a rate of 1.2%; and
• $466 million equivalent, senior unsecured notes, due February
2016, which pay interest semi-annually, beginning on August 22,
2006, at a rate of 1.8%.
The notes were issued under a $5 billion debt shelf registration
filed with the SEC in November 2002. Such yen debt is designated
as a hedge of our yen net investments.
Long-Term Debt Redemption
In July 2005, we decided to exercise Pfizer’s option to call, at par-
value plus accrued interest, $1 billion of senior unsecured floating-
rate notes, which were included in Long-term debt at December
31, 2004. Notice to call was given to the Trustees and the notes
were redeemed in September 2005.
Credit Ratings
Two major corporate debt-rating organizations, Moody’s Investors
Services (Moody’s) and Standard & Poor’s (S&P), assign ratings to
our short-term and long-term debt. The following chart reflects
the current ratings assigned to the Company’s senior unsecured
non-credit enhanced long-term debt and commercial paper issued
directly by the Company or by affiliates with a guarantee from the
Company by each of these agencies:
LONG-TERM DEBTNAME OF COMMERCIAL _________________________
RATING AGENCY PAPER RATING OUTLOOK
Moody’s P-1 Aaa Negative
S&P A1+ AAA Stable
In early April 2005, following the market withdrawal of Bextra and
the FDA’s decision requiring new labeling for Celebrex, Moody’s
placed our Aaa rating under review for possible downgrade.The
review was completed in June 2005 when Moody’s removed
Pfizer from review status and reaffirmed our Aaa rating. However,
Moody’s maintained our rating outlook as negative.This reflects
Moody’s overall negative rating outlook for the major
pharmaceutical sector and, specifically, their concern that lower
product sales, potentially unfavorable outcomes of patent
litigation, or a shift towards a more aggressive financial profile
could result in Pfizer’s financial metrics falling below those
appropriate for a Aaa-rated company. 
Our superior credit ratings are primarily based on our diversified
product portfolio, our strong operating cash flow, our substantial
financial assets, our strong late-stage product pipeline and on our
desire to maintain a prudent financial profile. Our access to
financing at favorable rates would be affected by a substantial
downgrade in our credit ratings.
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Debt Capacity
We have available lines of credit and revolving-credit agreements
with a group of banks and other financial intermediaries. We
maintain cash balances and short-term investments in excess of
our commercial paper and other short-term borrowings. At
December 31, 2005, we had access to $3.0 billion of lines of
credit, of which $1.1 billion expire within one year. Of these lines
of credit, $2.8 billion are unused, of which our lenders have
committed to loan us $1.7 billion at our request. $1.5 billion of
the unused lines of credit, which expire in 2010, may be used to
support our commercial paper borrowings.
As of February 24, 2006, we had the ability to borrow
approximately $1 billion by issuing debt securities under our
existing debt shelf registration statement filed with the SEC in
November 2002.
Goodwill and Other Intangible Assets
At December 31, 2005, goodwill totaled $23.8 billion (20% of our
total assets) and other intangible assets, net of accumulated
amortization, totaled $27.8 billion (24% of our total assets).
The components of goodwill and other identifiable intangible
assets, by segment, at December 31, 2005 follow:
HUMAN CONSUMER ANIMAL
(MILLIONS OF DOLLARS) HEALTH HEALTHCARE HEALTH OTHER TOTAL
Goodwill $20,919 $2,789 $ 56 $ 10 $23,774
Finite-lived 
intangible 




assets 2,834 1,342 246 4 4,426
Finite-lived intangible assets, net include $22.0 billion related to
developed technology rights and $1.0 billion related to brands.
Indefinite-lived intangible assets include $3.9 billion related to
brands.
Developed Technology Rights
Developed technology rights represent the amortized value
associated with developed technology, which has been acquired
from third parties, and which can include the right to develop, use,
market, sell and/or offer for sale the product, compounds and
intellectual property that we have acquired with respect to
products, compounds and/or processes that have been completed.
We possess a well-diversified portfolio of hundreds of developed
technology rights across therapeutic categories primarily
representing the amortized value of the commercialized products
included in our Human Health segment that we acquired in
connection with our Pharmacia acquisition in 2003. While the
Arthritis and Pain therapeutic category represents about 28% of
the total amortized value of developed technology rights at
December 31, 2005, the balance of the amortized value is evenly
distributed across the following Human Health therapeutic
product categories: Ophthalmology; Oncology; Urology; Infectious
and Respiratory Diseases; Endocrine Disorders categories; and, as
a group, the Cardiovascular and Metabolic Diseases; Central
Nervous System Disorders and All Other categories. The significant
components include values determined for Celebrex, Detrol,
Xalatan, Genotropin, Zyvox, and Campto/Camptosar. Also included
in this category are the post-approval milestone payments made
under our alliance agreements for certain Human Health products,
such as Rebif, Spiriva, Celebrex (prior to our acquisition of
Pharmacia) and Macugen. These rights are all subject to our
impairment review process explained above.
In 2005, we recorded an impairment charge of $1.1 billion related
to the developed technology rights for Bextra, a selective COX-2
inhibitor (see Notes to Consolidated Financial Statements—Note
6, Other (Income)/Deductions—Net).
Brands
Significant components of brands include values determined for
Depo-Provera contraceptive, Xanax, Medrol and tobacco
dependence products.
In 2004, we recorded an impairment charge of $0.7 billion related
to the Depo-Provera brand (See Notes to Consolidated Financial
Statements—Note 6, Other (Income)/Deductions—Net).
Selected Measures of Liquidity and Capital
Resources
The following table sets forth certain relevant measures of our
liquidity and capital resources as of December 31:
AS OF DECEMBER 31,__________________________________
(MILLIONS OF DOLLARS, EXCEPT RATIOS AND PER COMMON
SHARE DATA) 2005 2004
Cash and cash equivalents and 
short-term investments and loans $22,736 $20,546
Working capital(a) $13,448 $12,630
Ratio of current assets to 
current liabilities 1.47:1 1.48:1
Shareholders’ equity per 
common share(b) $ 8.96 $ 9.19
(a) Working capital includes assets and liabilities held for sale, which
were not significant, as of December 31, 2005 and December 31,
2004.
(b) Represents total shareholders’ equity divided by the actual
number of common shares outstanding (which excludes treasury
shares, and those held by our employee benefit trust).
The increase in working capital in 2005 as compared to 2004 was
primarily due to:
• an increase in net current financial assets of $1.9 billion,
primarily reflecting a shift from long-term investments to short-
term investments, which was effected as part of our repatriation
strategy under the Jobs Act;
• an increase in accounts receivable of $398 million, which is a
result of revenue growth in our international markets, growth
of our generic product sales and the impact of their longer
payment terms, and increased alliance-related receivables due
in part to the launch of Macugen in 2005 and growth in Spiriva
revenues;
partially offset by:
• the timing of tax obligations and payments, reflected in a $1.6
billion increase in income taxes payable.
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Summary of Cash Flows
YEAR ENDED DEC. 31,_____________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
Cash provided by/(used in):
Operating activities $14,733 $16,340 $ 11,727
Investing activities (5,072) (9,422) 4,850
Financing activities (9,222) (6,629) (16,909)
Effect of exchange-rate 
changes on cash and 
cash equivalents — (1) (26)
Net increase/(decrease) in 
cash and cash equivalents $ 439 $ 288 $ (358)
Operating Activities
Our net cash provided by continuing operating activities was
$14.7 billion in 2005 compared to $16.3 billion in 2004. The
decrease in net cash provided by operating activities was primarily
attributable to:
• the payment of $1.7 billion in taxes associated with the
repatriation of approximately $37 billion of foreign earnings
under the Jobs Act; as well as
• the timing of other receipts and payments in the ordinary
course of business.
Our net cash provided by continuing operating activities was
$16.3 billion in 2004 compared to $11.7 billion in 2003. The
increase in net cash provided by operating activities was primarily
attributable to:
• higher current period income from operations, net of non-
cash items, which reflects the increased revenues attributable
to Pharmacia products for the full-year 2004 compared to
recording sales of Pharmacia products in 2003 from the April
16, 2003 acquisition date;
• lower voluntary pension plan contributions; and
• timing of tax payments,
partially offset by:
• litigation-related payments in 2004 related to Rezulin and
Neurontin that were accrued in 2003.
In the cash flow statement, Other non-cash adjustments includes
adjustments for non-cash items such as valuation adjustments.
Investing Activities
Our net cash used by investing activities was $5.1 billion in 2005
compared to $9.4 billion in 2004. The decrease in net cash used
by investing activities was primarily attributable to:
• a decrease in net purchases of investments (a decreased use of
$4.9 billion), due primarily to higher redemptions of investments
in 2005 to provide funds for the repatriation of foreign earnings
in accordance with the Jobs Act; and
• lower purchases of plant, property and equipment (a decreased
use of $495 million),
partially offset by:
• lower proceeds from the sales of business, product lines and
other products (a decreased provision of cash of $1.1 billion).
Our net cash used in investing activities was $9.4 billion in 2004
compared to net cash provided by investing activities of $4.9
billion in 2003. The increase in net cash used in investing activities
was primarily attributable to:
• an increase in net purchases of investments (an increased use
of $6.1 billion);
• net cash paid of $2.3 billion relating to the acquisitions of
Esperion, Campto/Camptosar, and other entities compared to
cash and cash equivalents acquired in the Pharmacia acquisition
of $1.8 billion (an increased use of $4.1 billion); and
• a decrease in the proceeds from the sale of business and
product lines (an increased use of $4.3 billion).
Financing Activities
Our net cash used in financing activities increased to $9.2 billion
in 2005 compared to $6.6 billion in 2004. The increase in net
cash used in financing activities was primarily attributable to:
• net repayments of $321 million on total borrowings in 2005 as
compared to total net borrowings of $4.1 billion in 2004, as
funds from the repatriation of foreign earnings were used to
finance domestic activities, thereby reducing our reliance on
short-term borrowings;
• an increase in cash dividends paid of $473 million as compared
to 2004 due to an increase in the dividend rate; and
• a decrease of $610 million in the proceeds from the exercise of
employee stock options,
partially offset by:
• a decrease of $2.9 billion in purchases of our common stock in
2005 as compared to the same period in 2004.
Our net cash used in financing activities, decreased to $6.6 billion
in 2004 compared to $16.9 billion in 2003. The decrease in net cash
used in financing activities was primarily attributable to:
• a decrease in common stock purchases under our share-purchase
programs of $6.4 billion; and
• an increase in net borrowings of $4.7 billion, due primarily to
an increase in net short-term borrowings of $2.9 billion
(including the November 2004 issuance of $1.0 billion in senior
floating-rate unsecured notes) and net long-term debt of $1.8
billion (including the issuances in February 2004 of $1.5 billion
in senior unsecured notes and in September 2004 of $1.0 billion
in senior unsecured floating-rate notes),
partially offset by:
• an increase in cash dividends paid of $729 million as compared
to 2003 due to an increase in the dividend rate.
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In June 2005, we announced a new $5 billion share-purchase
program which is being funded by operating cash flows. During
2005, we purchased approximately 22 million shares under the
new program.
In October 2004, we announced a $5 billion share-purchase
program, which we completed in the second quarter of 2005 and
was funded from operating cash flows. In total, under the October
2004 program, we purchased approximately 185 million shares.
In December 2003, we announced a $5 billion share-purchase
program, which we completed in October 2004 and was funded
from operating cash flows. In total, under the December 2003
program, we purchased approximately 146 million shares.
A summary of common stock purchases follows:
SHARES OF TOTAL COST OF
COMMON AVERAGE COMMON 
(MILLIONS OF SHARES AND DOLLARS, STOCK PER-SHARE STOCK
EXCEPT PER-SHARE DATA) PURCHASED PRICE PAID PURCHASED
2005:
June 2005 program 22 $22.38 $ 493
October 2004 program 122 27.20 3,304
Total 144 $3,797
2004:
October 2004 program 63 $26.79 $1,696
December 2003 program 145 34.14 4,963
Total 208 $6,659
Contractual Obligations
Payments due under contractual obligations at December 31,
2005 mature as follows:
YEARS___________________________________________________________
OVER 1 OVER 3
(MILLIONS OF DOLLARS) TOTAL WITHIN 1 TO 3 TO 5 AFTER 5
Long-term 






GAAP(b) 3,054 268 561 552 1,673
Lease 
commit-
ments(c) 1,285 240 409 247 389
Purchase 
obligations(d) 1,474 892 379 149 54
(a) Long-term debt consists of senior unsecured notes, floating-rate
unsecured notes, foreign denominated notes and other
borrowings and mortgages.
(b) Includes expected payments relating to our unfunded U.S.
supplemental (non-qualified) pension plans, postretirement plans
and deferred compensation plans.
(c) Includes operating and capital lease obligations.
(d) Purchase obligations represent agreements to purchase goods and
services that are enforceable and legally binding and include
amounts relating to advertising, information technology services
and employee benefit administration services.
In 2006, we expect to spend approximately $2.2 billion on
property, plant and equipment.
Off-Balance Sheet Arrangements
In the ordinary course of business and in connection with the sale
of assets and businesses, we often indemnify our counterparties
against certain liabilities that may arise in connection with a
transaction or related to activities prior to a transaction. These
indemnifications typically pertain to environmental, tax, employee
and/or product-related matters, and patent infringement claims.
If the indemnified party were to make a successful claim pursuant
to the terms of the indemnification, we would be required to
reimburse the loss. These indemnifications are generally subject
to threshold amounts, specified claim periods and other
restrictions and limitations. Historically, we have not paid
significant amounts under these provisions and as of December
31, 2005, recorded amounts for the estimated fair value of these
indemnifications are not material.
Certain of our co-promotion or license agreements give our
licensors or partners the right to negotiate for, or in some cases
to obtain, under certain financial conditions, co-promotion or
other rights in specified countries with respect to certain of our
products.
Dividends on Common Stock
We declared dividends of $6.0 billion in 2005 and $5.2 billion in
2004 on our common stock. In 2005, we increased our annual
dividend to $0.76 per share from $0.68 per share in 2004. In
December 2005, our Board of Directors declared a first-quarter
2006 dividend of $0.24 per share. The 2006 cash dividend marks
the 39th consecutive year of dividend increases.
Our current dividend provides a return to shareholders while
maintaining sufficient capital to invest in growing our businesses.
Our dividends are funded from operating cash flows and short-
term commercial paper borrowings; are based on our profitability;
and are not restricted by debt covenants. To the extent we have
additional capital in excess of investment opportunities, we
typically offer a return to our shareholders through a stock
repurchase program. We believe the Company’s profitability and
access to financial markets provides sufficient capability for the
Company to pay current and future dividends.
Recently Issued Accounting Standards
In December 2004, Financial Accounting Standards Board issued
Statement of Financial Accounting Standards (SFAS) No. 123R,
Share-Based Payment. SFAS 123R replaces SFAS 123, Stock-Based
Compensation issued in 1995. SFAS 123R requires that the fair
value of the grant of employee stock options be reported as an
expense. Historically, we have disclosed in our footnotes the pro
forma expense effect of the grants (see Notes to Consolidated
Financial Statements—Note 1P, Significant Accounting Policies:
Share-Based Payments). We adopted SFAS 123R as of January 1,
2006. The estimated impact of adopting SFAS 123R on operations
for 2006 is $330 million in expense, net of tax. The estimate was
determined in January 2006, and is based, in part, on a projection
of our common stock price and other option valuation
assumptions for the fourth week in February 2006, the expected
time of our largest annual grant of stock option awards.
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The estimated impact of adopting SFAS 123R on our financial
position, including the short-term and long-term deferred tax
assets related to unvested options at adoption date, is expected
to be immaterial.
Forward-Looking Information and Factors
That May Affect Future Results
The Securities and Exchange Commission encourages companies
to disclose forward-looking information so that investors can
better understand a company’s future prospects and make
informed investment decisions. This report and other written or
oral statements that we make from time to time contain such
forward-looking statements that set forth anticipated results
based on management’s plans and assumptions. Such forward-
looking statements involve substantial risks and uncertainties. We
have tried, wherever possible, to identify such statements by
using words such as “will,” “anticipate,” “estimate,” “expect,”
“project,” “intend,” “plan,” “believe,” “target,” “forecast” and
other words and terms of similar meaning in connection with any
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective products or product approvals, future performance
or results of current and anticipated products, sales efforts,
expenses, interest rates, foreign exchange rates, the outcome of
contingencies, such as legal proceedings, and financial results.
Among the factors that could cause actual results to differ
materially are the following:
• the success of research and development activities;
• decisions by regulatory authorities regarding whether and
when to approve our drug applications as well as their decisions
regarding labeling and other matters that could affect the
availability or commercial potential of our products;
• the speed with which regulatory authorizations, pricing
approvals, and product launches may be achieved;
• competitive developments affecting our current growth
products;
• the ability to successfully market both new and existing products
domestically and internationally;
• difficulties or delays in manufacturing;
• trade buying patterns;
• the ability to meet generic and branded competition after the
loss of patent protection for our products or for competitor
products;
• the impact of existing and future regulatory provisions on
product exclusivity;
• trends toward managed care and health care cost containment;
• possible U.S. legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement,
including under Medicaid and Medicare, the importation of
prescription drugs that are marketed outside the U.S. and sold
at prices that are regulated by governments of various foreign
countries, and the involuntary approval of prescription
medicines for over-the-counter use;
• the potential impact of the Medicare Prescription Drug,
Improvement and Modernization Act of 2003;
• legislation or regulations in markets outside the U.S. affecting
product pricing, reimbursement or access;
• contingencies related to actual or alleged environmental
contamination;
• claims and concerns that may arise regarding the safety or
efficacy of in-line products and product candidates;
• legal defense costs, insurance expenses, settlement costs and
the risk of an adverse decision or settlement related to product
liability, patent protection, governmental investigations,
ongoing efforts to explore various means for resolving asbestos
litigation and other legal proceedings;
• the Company’s ability to protect its patents and other
intellectual property both domestically and internationally;
• interest rate and foreign currency exchange rate fluctuations;
• governmental laws and regulations affecting domestic and
foreign operations, including tax obligations;
• changes in U.S. generally accepted accounting principles;
• any changes in business, political and economic conditions due
to the threat of future terrorist activity in the U.S. and other
parts of the world, and related U.S. military action overseas;
• growth in costs and expenses;
• changes in our product, segment and geographic mix; and
• the impact of acquisitions, divestitures, restructurings, product
withdrawals and other unusual items, including the impact of
the possible sale or spin-off of our Consumer Healthcare
business and our ability to realize the projected benefits of our
Adapting to Scale multi-year productivity initiative.
We cannot guarantee that any forward-looking statement will be
realized, although we believe we have been prudent in our plans
and assumptions. Achievement of future results is subject to risks,
uncertainties and inaccurate assumptions. Should known or
unknown risks or uncertainties materialize, or should underlying
assumptions prove inaccurate, actual results could vary materially
from past results and those anticipated, estimated or projected.
Investors should bear this in mind as they consider forward-
looking statements.
We undertake no obligation to publicly update forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further
disclosures we make on related subjects in our Forms 10-Q, 8-K
and 10-K reports to the Securities and Exchange Commission.
Certain risks, uncertainties and assumptions are discussed here and
under the heading entitled “Risk Factors and Cautionary Factors
That May Affect Future Results” in Item 1 of our Annual Report
on Form 10-K for the year ended December 31, 2005, which will
be filed in March 2006. We note these factors for investors as
permitted by the Private Securities Litigation Reform Act of 1995.
You should understand that it is not possible to predict or identify
all such factors. Consequently, you should not consider any such
list to be a complete set of all potential risks or uncertainties.
32 2005 Financial Report
Financial Review
Pfizer Inc and Subsidiary Companies
This report includes discussion of certain clinical studies relating
to various in-line products and/or product candidates. These
studies typically are part of a larger body of clinical data relating
to such products or product candidates, and the discussion herein
should be considered in the context of the larger body of data.
Financial Risk Management
The overall objective of our financial risk management program
is to seek a reduction in the potential negative earnings effects
from changes in foreign exchange and interest rates arising in our
business activities. We manage these financial exposures through
operational means and by using various financial instruments.
These practices may change as economic conditions change.
Foreign Exchange Risk—A significant portion of our revenues and
earnings are exposed to changes in foreign exchange rates. We
seek to manage our foreign exchange risk in part through
operational means, including managing same currency revenues
in relation to same currency costs, and same currency assets in
relation to same currency liabilities.
Foreign exchange risk is also managed through the use of foreign
currency forward-exchange contracts. These contracts are used to
offset the potential earnings effects from mostly intercompany
short-term foreign currency assets and liabilities that arise from
operations. We also use foreign currency forward-exchange
contracts and foreign currency swaps to hedge the potential
earnings effects from short and long-term foreign currency
investments and loans and intercompany loans.
Foreign currency put options are sometimes purchased to reduce
a portion of the potential negative effects on earnings related to
certain of our significant anticipated intercompany inventory
purchases for up to two years. In early 2003, these purchased
options hedged Japanese yen versus the U.S. dollar.
In addition, under certain market conditions, we protect against
possible declines in the reported net assets of our Japanese yen
and certain euro functional currency subsidiaries.
Our financial instrument holdings at year-end were analyzed to
determine their sensitivity to foreign exchange rate changes.
The fair values of these instruments were determined as follows:
• foreign currency forward-exchange contracts and currency
swaps-net present values
• foreign receivables, payables, debt and loans-changes in
exchange rates
In this sensitivity analysis, we assumed that the change in one
currency’s rate relative to the U.S. dollar would not have an
effect on other currencies’ rates relative to the U.S. dollar. All other
factors were held constant.
If there were an adverse change in foreign exchange rates of 10%,
the expected effect on net income related to our financial
instruments would be immaterial. For additional details, see Notes
to Consolidated Financial Statements—Note 9D, Financial
Instruments: Derivative Financial Instruments and Hedging Activities.
Interest Rate Risk—Our U.S. dollar interest-bearing investments,
loans and borrowings are subject to interest rate risk. We are also
subject to interest rate risk on euro investments and short-term
currency swaps, and on Japanese yen short and long-term
borrowings and short-term currency swaps. We invest and borrow
primarily on a short-term or variable-rate basis. From time to
time, depending on market conditions, we will fix interest rates
either through entering into fixed rate investments and
borrowings or through the use of derivative financial instruments
such as interest rate swaps.
Our financial instrument holdings at year-end were analyzed to
determine their sensitivity to interest rate changes. The fair values
of these instruments were determined by net present values.
In this sensitivity analysis, we used the same change in interest rate
for all maturities. All other factors were held constant.
If there were an adverse change in interest rates of 10%, the
expected effect on net income related to our financial instruments
would be immaterial.
Legal Proceedings and Contingencies
We and certain of our subsidiaries are involved in various patent,
product liability, consumer, commercial, securities, environmental
and tax litigations and claims; government investigations; and
other legal proceedings that arise from time to time in the
ordinary course of our business. We do not believe any of them
will have a material adverse effect on our financial position.
We record accruals for such contingencies to the extent that we
conclude their occurrence is probable and the related damages
are estimable. If a range of liability is probable and estimable and
some amount within the range appears to be a better estimate
than any other amount within the range, we accrue that amount.
If a range of liability is probable and estimable and no amount
within the range appears to be a better estimate than any other
amount within the range, we accrue the minimum of such
probable range. Many claims involve highly complex issues relating
to causation, label warnings, scientific evidence, actual damages
and other matters. Often these issues are subject to substantial
uncertainties and, therefore, the probability of loss and an
estimation of damages are difficult to ascertain. Consequently, we
cannot reasonably estimate the maximum potential exposure or
the range of possible loss in excess of amounts accrued for these
contingencies. These assessments can involve a series of complex
judgments about future events and can rely heavily on estimates
and assumptions (see Notes to Consolidated Financial
Statements—Note 1B, Significant Accounting Policies: Estimates
and Assumptions). Our assessments are based on estimates and
assumptions that have been deemed reasonable by management.
Litigation is inherently unpredictable, and excessive verdicts do
occur. Although we believe we have substantial defenses in these
matters, we could in the future incur judgments or enter into
settlements of claims that could have a material adverse effect on
our results of operations in any particular period.
Patent claims include challenges to the coverage and/or validity
of our patents on various products or processes. Although we
believe we have substantial defenses to these challenges with
respect to all our material patents, there can be no assurance as
to the outcome of these matters, and a loss in any of these cases
could result in a loss of patent protection for the drug at issue,
which could lead to a significant loss of sales of that drug and
could materially affect future results of operations.
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Management’s Report
We prepared and are responsible for the financial statements that
appear in our 2005 Financial Report. These financial statements
are in conformity with accounting principles generally accepted
in the United States of America, and therefore, include amounts
based on informed judgments and estimates. We also accept
responsibility for the preparation of other financial information
that is included in this document.
Report on Internal Control Over Financial Reporting
The management of the Company is responsible for establishing
and maintaining adequate internal control over financial reporting
as defined in Rules 13a-15(f) and 15d-15(f) under the Securities
Exchange Act of 1934. The Company’s internal control over
financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with
generally accepted accounting principles in the United States of
America. The Company’s internal control over financial reporting
includes those policies and procedures that: (i) pertain to the
maintenance of records that, in reasonable detail, accurately and
fairly reflect the transactions and dispositions of the assets of the
Company; (ii) provide reasonable assurance that transactions are
recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the Company are
being made only in accordance with authorizations of
management and directors of the Company; and (iii) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the Company’s
assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate. Management
assessed the effectiveness of the Company’s internal control over
financial reporting as of December 31, 2005. In making this
assessment, management used the criteria set forth by the
Committee of Sponsoring Organizations of the Treadway
Commission in Internal Control-Integrated Framework. Based on
our assessment and those criteria, management believes that
the Company maintained effective internal control over financial
reporting as of December 31, 2005.
The Company’s independent auditors have issued their auditors’
report on management’s assessment of the Company’s internal
control over financial reporting. That report appears in our 2005
Financial Report under the heading, Report of Independent





Alan G. Levin Loretta V. Cangialosi
Principal Financial Officer Principal Accounting Officer
February 24, 2006
The Audit Committee reviews the Company’s financial reporting
process on behalf of the Board of Directors. Management has the
primary responsibility for the financial statements and the
reporting process, including the system of internal controls.
In this context, the Committee has met and held discussions with
management and the independent registered public accounting
firm regarding the fair and complete presentation of the
Company’s results and the assessment of the Company’s internal
control over financial reporting. The Committee has discussed
significant accounting policies applied by the Company in its
financial statements, as well as alternative treatments.
Management represented to the Committee that the Company’s
consolidated financial statements were prepared in accordance
with accounting principles generally accepted in the United States
of America, and the Committee has reviewed and discussed the
consolidated financial statements with management and the
independent registered public accounting firm. The Committee
discussed with the independent registered public accounting
firm matters required to be discussed by Statement of Auditing
Standards No. 61, Communication With Audit Committees.
In addition, the Committee has reviewed and discussed with the
independent registered public accounting firm the auditor’s
independence from the Company and its management. As part
of that review, the Committee received the written disclosures and
letter required by the Independence Standards Board Standard
No. 1, Independence Discussions with Audit Committees and by
all relevant professional and regulatory standards relating to KPMG’s
independence from the Company. The Committee also has
considered whether the independent registered public accounting
firm’s provision of non-audit services to the Company is compatible
with the auditor’s independence. The Committee has concluded
that the independent registered public accounting firm is
independent from the Company and its management.
The Committee reviewed and discussed Company policies with
respect to risk assessment and risk management.
The Committee discussed with the Company’s internal auditors and
the independent registered public accounting firm the overall scope
and plans for their respective audits. The Committee met with the
internal auditors and the independent registered public accounting
firm, with and without management present, to discuss the results
of their examinations, the evaluations of the Company’s internal
controls, and the overall quality of the Company’s financial reporting.
In reliance on the reviews and discussions referred to above, the
Committee recommended to the Board of Directors, and the Board
has approved, that the audited financial statements be included in
the Company’s Annual Report on Form 10-K for the year ended
December 31, 2005, for filing with the Securities and Exchange
Commission. The Committee has selected and the Board of Directors
has ratified, subject to shareholder ratification, the selection of




The Audit Committee’s Report shall not be deemed to be filed or
incorporated by reference into any Company filing under the
Securities Act of 1933, as amended, or the Securities Exchange Act
of 1934, as amended, except to the extent that the Company
specifically incorporates the Audit Committee’s Report by
reference therein.
Management’s Report on Internal Control
Over Financial Reporting
Audit Committee’s Report
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To the Board of Directors and Shareholders of Pfizer Inc:
We have audited the accompanying consolidated balance sheets
of Pfizer Inc and Subsidiary Companies as of December 31, 2005
and 2004, and the related consolidated statements of income,
shareholders’ equity, and cash flows for each of the years in the
three-year period ended December 31, 2005. These consolidated
financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to
above present fairly, in all material respects, the financial position
of Pfizer Inc and Subsidiary Companies as of December 31, 2005
and 2004, and the results of their operations and their cash flows
for each of the years in the three-year period ended December
31, 2005, in conformity with U.S. generally accepted accounting
principles.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
effectiveness of Pfizer Inc and Subsidiary Companies’ internal
control over financial reporting as of December 31, 2005, based
on criteria established in Internal Control—Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO), and our report dated February 24,
2006 expressed an unqualified opinion on management’s





To the Board of Directors and Shareholders of Pfizer Inc:
We have audited management’s assessment, included in the
accompanying Management’s Report on Internal Control Over
Financial Reporting, that Pfizer Inc and Subsidiary Companies
maintained effective internal control over financial reporting as
of December 31, 2005, based on criteria established in Internal
Control—Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO).
Pfizer Inc and Subsidiary Companies’ management is responsible
for maintaining effective internal control over financial reporting
and for its assessment of the effectiveness of internal control
over financial reporting. Our responsibility is to express an opinion
on management’s assessment and an opinion on the effectiveness
of the Company’s internal control over financial reporting based
on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether effective internal
control over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of
internal control over financial reporting, evaluating management’s
assessment, testing and evaluating the design and operating
effectiveness of internal control, and performing such other
procedures as we considered necessary in the circumstances. We
believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted
accounting principles. A company’s internal control over financial
reporting includes those policies and procedures that (i) pertain
to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of the assets
of the company; (ii) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of
management and directors of the company; and (iii) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the company’s
assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
In our opinion, management’s assessment that Pfizer Inc and
Subsidiary Companies maintained effective internal control over
financial reporting as of December 31, 2005, is fairly stated, in all
material respects, based on criteria established in Internal
Control—Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO).
Also, in our opinion, Pfizer Inc and Subsidiary Companies
maintained, in all material respects, effective internal control
over financial reporting as of December 31, 2005, based on criteria
established in Internal Control—Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO).
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
consolidated balance sheets of Pfizer Inc and Subsidiary Companies
as of December 31, 2005 and 2004, and the related consolidated
statements of income, shareholders’ equity, and cash flows for
each of the years in the three-year period ended December 31,
2005, and our report dated February 24, 2006 expressed an
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Consolidated Statements of Income
Pfizer Inc and Subsidiary Companies
YEAR ENDED DECEMBER 31,_______________________________________________________________
(MILLIONS, EXCEPT PER COMMON SHARE DATA) 2005 2004 2003
Revenues $51,298 $52,516 $44,736
Costs and expenses:
Cost of sales(a) 8,525 7,541 9,589
Selling, informational and administrative expenses(a) 16,997 16,903 15,108
Research and development expenses(a) 7,442 7,684 7,487
Amortization of intangible assets 3,409 3,364 2,187
Merger-related in-process research and development charges 1,652 1,071 5,052
Restructuring charges and merger-related costs 1,392 1,193 1,058
Other (income)/deductions—net 347 753 1,009
Income from continuing operations before provision for taxes on income, 
minority interests and cumulative effect of a change in accounting principles 11,534 14,007 3,246
Provision for taxes on income 3,424 2,665 1,614
Minority interests 16 10 3
Income from continuing operations before cumulative effect of a change 
in accounting principles 8,094 11,332 1,629
Discontinued operations:
(Loss)/income from discontinued operations—net of tax (31) (22) 26
Gains on sales of discontinued operations—net of tax 47 51 2,285
Discontinued operations—net of tax 16 29 2,311
Income before cumulative effect of a change in accounting principles 8,110 11,361 3,940
Cumulative effect of a change in accounting principles—net of tax (25) — (30)
Net income $ 8,085 $11,361 $ 3,910
Earnings per common share—basic
Income from continuing operations before cumulative effect of a change 
in accounting principles $ 1.10 $ 1.51 $ 0.22
Discontinued operations — — 0.32
Income before cumulative effect of a change in accounting principles 1.10 1.51 0.54
Cumulative effect of a change in accounting principles — — —
Net income $ 1.10 $ 1.51 $ 0.54
Earnings per common share—diluted
Income from continuing operations before cumulative effect of a change 
in accounting principles $ 1.09 $ 1.49 $ 0.22
Discontinued operations — — 0.32
Income before cumulative effect of a change in accounting principles 1.09 1.49 0.54
Cumulative effect of a change in accounting principles — — —
Net income $ 1.09 $ 1.49 $ 0.54
Weighted-average shares—basic 7,361 7,531 7,213
Weighted-average shares—diluted 7,411 7,614 7,286
(a) Exclusive of amortization of intangible assets, except as disclosed in Note 1K, Amortization of Intangible Assets, Depreciation and Certain
Long-Lived Assets.
See Notes to Consolidated Financial Statements which are an integral part of these statements.
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Consolidated Balance Sheets
Pfizer Inc and Subsidiary Companies
AS OF DECEMBER 31,________________________________________
(MILLIONS, EXCEPT PREFERRED STOCK ISSUED AND PER COMMON SHARE DATA) 2005 2004
Assets
Current Assets
Cash and cash equivalents $ 2,247 $ 1,808
Short-term investments 19,979 18,085
Accounts receivable, less allowance for doubtful accounts: 2005—$183; 2004—$205 9,765 9,367
Short-term loans 510 653
Inventories 6,039 6,660
Prepaid expenses and taxes 3,196 2,333
Assets held for sale 160 182
Total current assets 41,896 39,088
Long-term investments and loans 2,497 3,873
Property, plant and equipment, less accumulated depreciation 17,090 18,385
Goodwill 23,774 23,756
Identifiable intangible assets, less accumulated amortization 27,786 33,251
Other assets, deferred taxes and deferred charges 4,522 4,725
Total assets $117,565 $123,078
Liabilities and Shareholders’ Equity
Current Liabilities
Short-term borrowings, including current portion of long-term debt: 2005—$778; 2004—$907 $ 11,589 $ 11,266
Accounts payable 2,226 2,672
Dividends payable 1,772 1,418
Income taxes payable 3,617 1,963
Accrued compensation and related items 1,720 1,939
Other current liabilities 7,522 7,136
Liabilities held for sale 2 64
Total current liabilities 28,448 26,458
Long-term debt 6,347 7,279
Pension benefit obligations 2,717 2,821
Postretirement benefit obligations 1,443 1,450
Deferred taxes 10,240 12,026
Other noncurrent liabilities 2,743 4,766
Total liabilities 51,938 54,800
Shareholders’ Equity
Preferred stock, without par value, at stated value; 27 shares authorized; 
issued: 2005—4,193; 2004—4,779 169 193
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2005—8,784; 2004—8,754 439 438
Additional paid-in capital 67,622 67,098
Employee benefit trust (923) (1,229)
Treasury stock, shares at cost; 2005—1,423; 2004—1,281 (39,767) (35,992)
Retained earnings 37,608 35,492
Accumulated other comprehensive income 479 2,278
Total shareholders’ equity 65,627 68,278
Total liabilities and shareholders’ equity $117,565 $123,078
See Notes to Consolidated Financial Statements which are an integral part of these statements.
2005 Financial Report 37
Consolidated Statements of Shareholders’ Equity
Pfizer Inc and Subsidiary Companies
EMPLOYEE
ACCUM. OTHER
PREFERRED STOCK COMMON STOCK
ADDITIONAL
BENEFIT TRUST TREASURY STOCK
COMPRE-
____________________________ __________________________ PAID-IN ___________________________ ___________________________ RETAINED HENSIVE
(MILLIONS, EXCEPT PREFERRED SHARES) SHARES STATED VALUE SHARES PAR VALUE CAPITAL SHARES FAIR VALUE SHARES COST EARNINGS INC./(EXP.) TOTAL
Balance, January 1, 2003 — $ — 6,829 $341 $ 9,368 (58) $(1,786) (667) $(16,341) $30,243 $(1,875) $19,950
Comprehensive income:
Net income 3,910 3,910
Total other comprehensive
income—net of tax 2,070 2,070
Total comprehensive income 5,980
Pharmacia acquisition 6,019 242 1,817 91 55,402 55,735
Cash dividends declared—
common stock (4,764) (4,764)
preferred stock (7) (7)
Stock option transactions 52 3 1,199 5 175 (1) (20) 1,357
Purchases of common stock (407) (13,037) (13,037)
Employee benefit trust 
transactions—net 287 (1) (287) 1 — —
Preferred stock conversions 
and redemptions (574) (23) 23 — 6 6
Other 4 — 117 1 40 157
Balance, December 31, 2003 5,445 219 8,702 435 66,396 (54) (1,898) (1,073) (29,352) 29,382 195 65,377
Comprehensive income:
Net income 11,361 11,361
Total other comprehensive
income—net of tax 2,083 2,083
Total comprehensive income 13,444
Cash dividends declared—
common stock (5,243) (5,243)
preferred stock (8) (8)
Stock option transactions 47 3 886 9 323 — (16) 1,196
Purchases of common stock (208) (6,659) (6,659)
Employee benefit trust 
transactions—net (346) (1) 346 — — —
Preferred stock conversions 
and redemptions (666) (26) 27 — 9 10
Other 5 — 135 — 26 161
Balance, December 31, 2004 4,779 193 8,754 438 67,098 (46) (1,229) (1,281) (35,992) 35,492 2,278 68,278
Comprehensive income:
Net income 8,085 8,085
Total other comprehensive
expense—net of tax (1,799) (1,799)
Total comprehensive income 6,286
Cash dividends declared—
common stock (5,960) (5,960)
preferred stock (9) (9)
Stock option transactions 24 1 342 7 193 — (6) 530
Purchases of common stock (143) (3,797) (3,797)
Employee benefit trust 
transactions—net (113) (1) 113 1 — —
Preferred stock conversions 
and redemptions (586) (24) 37 — 6 19
Other 6 — 258 — 22 280
Balance, December 31, 2005 4,193 $169 8,784 $439 $67,622 (40) $ (923) (1,423) $(39,767) $37,608 $ 479 $65,627
See Notes to Consolidated Financial Statements which are an integral part of these statements.
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Consolidated Statements of Cash Flows
Pfizer Inc and Subsidiary Companies
YEAR ENDED DECEMBER 31,________________________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
Operating Activities
Net Income $ 8,085 $ 11,361 $ 3,910
Adjustments to reconcile net income to net cash provided by continuing 
operating activities:
Depreciation and amortization 5,576 5,093 4,025
Merger-related in-process research and development charges 1,652 1,071 5,052
Charge for fair value mark-up of acquired inventory sold — 40 2,747
Intangible asset impairments and other associated non-cash charges 1,240 702 —
Gains on disposal of investments, products and product lines (188) (16) (85)
Loss/(income) from discontinued operations 33 39 (43)
Gains on sales of discontinued operations (77) (75) (3,885)
Cumulative effect of a change in accounting principles 40 — 47
Deferred taxes from continuing operations (1,384) (1,579) (104)
Other deferred taxes 8 (15) 735
Other non-cash adjustments 334 558 588
Changes in assets and liabilities, net of effect of businesses acquired and divested:
Accounts receivable (803) (465) 207
Inventories 72 (542) (200)
Prepaid and other assets 582 (640) (918)
Accounts payable and accrued liabilities (729) (704) 909
Income taxes payable 172 827 (541)
Other liabilities 120 685 (717)
Net cash provided by continuing operating activities 14,733 16,340 11,727
Investing Activities
Purchases of property, plant and equipment (2,106) (2,601) (2,629)
Purchases of short-term investments (28,040) (17,499) (9,931)
Proceeds from redemptions of short-term investments 26,779 11,723 12,060
Purchases of long-term investments (687) (1,329) (1,883)
Proceeds from sales of long-term investments 1,309 1,570 356
Purchases of other assets (431) (327) (788)
Proceeds from sales of other assets 12 6 360
Proceeds from sales of businesses, product lines and other products 127 1,276 5,602
Acquisitions, net of cash acquired (2,104) (2,263) —
Cash and cash equivalents acquired through acquisition of Pharmacia — — 1,789
Other investing activities 69 22 (86)
Net cash (used in)/provided by investing activities (5,072) (9,422) 4,850
Financing Activities
Increase in short-term borrowings, net 1,124 2,466 194
Principal payments on short-term borrowings (1,427) (288) (946)
Proceeds from issuances of long-term debt 1,021 2,586 600
Principal payments on long-term debt (1,039) (664) (439)
Purchases of common stock (3,797) (6,659) (13,037)
Cash dividends paid (5,555) (5,082) (4,353)
Stock option transactions and other 451 1,012 1,072
Net cash used in financing activities (9,222) (6,629) (16,909)
Effect of exchange-rate changes on cash and cash equivalents — (1) (26)
Net increase/(decrease) in cash and cash equivalents 439 288 (358)
Cash and cash equivalents at beginning of year 1,808 1,520 1,878
Cash and cash equivalents at end of year $ 2,247 $ 1,808 $ 1,520
Supplemental Cash Flow Information
Non-cash transactions:
Acquisition of Pharmacia, net of transaction costs $ — $ — $ 55,871
Cash paid during the period for:
Income taxes $ 4,713 $ 3,388 $ 2,905
Interest 649 496 350
See Notes to Consolidated Financial Statements which are an integral part of these statements.
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Notes to Consolidated Financial Statements
Pfizer Inc and Subsidiary Companies
1. Significant Accounting Policies
A. Consolidation and Basis of Presentation
The consolidated financial statements include our parent company
and all subsidiaries, including those operating outside the U.S. and
are prepared in accordance with accounting principles generally
accepted in the United States of America (GAAP). For subsidiaries
operating outside the U.S., the financial information is included
as of and for the year ended November 30 for each year presented.
Substantially all unremitted earnings of international subsidiaries
are free of legal and contractual restrictions. All significant
transactions among our businesses have been eliminated.
We made certain reclassifications to the 2004 and 2003
consolidated financial statements to conform to the 2005
presentation.
On April 16, 2003, we completed our acquisition of Pharmacia
Corporation (Pharmacia) in a stock-for-stock transaction accounted
for under the purchase method of accounting (see Note 2A,
Acquisitions: Pharmacia Corporation). Starting at the date of
acquisition, the assets acquired and liabilities assumed were
recorded at their respective fair values and our results of
operations included Pharmacia’s product sales and expenses from
the acquisition date. Therefore, approximately 71/2 months of
results of operations of Pharmacia’s international operations and
about 81/2 months of results of operations of Pharmacia’s U.S.
operations were included in our consolidated financial statements
for the year ended December 31, 2003.
B. Estimates and Assumptions
In preparing the consolidated financial statements, we use certain
estimates and assumptions that affect reported amounts and
disclosures. For example, estimates are used when accounting for
deductions from revenues (such as rebates, discounts, incentives
and product returns), depreciation, amortization, employee
benefits, contingencies and asset and liability valuations. Our
estimates are often based on complex judgments, probabilities and
assumptions that we believe to be reasonable but that are
inherently uncertain and unpredictable. Assumptions may be
incomplete or inaccurate and unanticipated events and
circumstances may occur. It is also possible that other professionals,
applying reasonable judgment to the same facts and
circumstances, could develop and support a range of alternative
estimated amounts. We are also subject to other risks and
uncertainties that may cause actual results to differ from estimated
amounts, such as changes in the healthcare environment,
competition, foreign exchange, litigation, legislation and
regulations. These and other risks and uncertainties are discussed
in the accompanying Financial Review, which is unaudited, under
the headings “Our Business Environment” and “Forward-Looking
Information and Factors That May Affect Future Results.”
C. Contingencies
We and certain of our subsidiaries are involved in various patent,
product liability, consumer, commercial, securities, environmental
and tax litigations and claims; government investigations; and
other legal proceedings that arise from time to time in the ordinary
course of our business. We record accruals for such contingencies
to the extent that we conclude their occurrence is probable and
the related damages are estimable. We consider many factors in
making these assessments. Because litigation and other
contingencies are inherently unpredictable and excessive verdicts
do occur, these assessments can involve a series of complex
judgments about future events and can rely heavily on estimates
and assumptions (see Note 1B, Significant Accounting Policies:
Estimates and Assumptions). We record anticipated recoveries
under existing insurance contracts when assured of recovery.
D. New Accounting Standards
As of December 31, 2005, we adopted the provisions of Financial
Accounting Standards Board (FASB) Interpretation No. 47,
Accounting for Conditional Asset Retirement Obligations (FIN
47). FIN 47 clarifies that conditional obligations meet the definition
of an asset retirement obligation in Statement of Financial
Accounting Standards (SFAS) No. 143, Accounting for Asset
Retirement Obligations (SFAS 143), and therefore should be
recognized if their fair value is reasonably estimable. As a result
of adopting FIN 47, we recorded a non-cash pre-tax charge of $40
million ($25 million, net of tax). This charge was reported in
Cumulative effect of a change in accounting principles—net of tax
in the fourth quarter of 2005. As of January 1, 2003, we adopted
the provisions of SFAS 143, which broadly addresses financial
accounting requirements for retirement obligations associated
with tangible long-lived assets. As a result of adopting SFAS 143,
we recorded a non-cash pre-tax charge of $47 million ($30 million,
net of tax) for the change in accounting for costs associated with
the eventual retirement of certain manufacturing and research
facilities. This charge was reported in Cumulative effect of a
change in accounting principles—net of tax in the first quarter of
2003. In accordance with these standards, we record accruals for
legal obligations associated with the retirement of tangible long-
lived assets, including obligations under the doctrine of promissory
estoppel and those that are conditioned upon the occurrence of
future events. We recognize these obligations using management’s
best estimate of fair value.
As of January 1, 2004, we adopted the provisions of FASB
Interpretation No. 46R (FIN 46R), Consolidation of Variable Interest
Entities. FIN 46R provides additional guidance as to when certain
entities need to be consolidated for financial reporting purposes.
The adoption of FIN 46R did not have a material impact on our
consolidated financial statements.
E. Acquisitions
Our consolidated financial statements and results of operations
reflect an acquired business after the completion of the acquisition
and are not restated. We account for acquired businesses using
the purchase method of accounting which requires that the
assets acquired and liabilities assumed be recorded at the date of
acquisition at their respective fair values. Any excess of the
purchase price over the estimated fair values of the net assets
acquired is recorded as goodwill. Amounts allocated to acquired
in-process research and development (IPR&D) are expensed at the
date of acquisition. When we acquire net assets that do not
constitute a business under GAAP, no goodwill is recognized.
F. Foreign Currency Translation
For most international operations, local currencies have been
determined to be the functional currencies. The effects of
converting non-functional currency assets and liabilities into the
functional currency are recorded in Other (income)/deductions—
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net. We translate functional currency assets and liabilities to their
U.S. dollar equivalents at rates in effect at the balance sheet
date and record these translation adjustments in Shareholders’
equity—Accumulated other comprehensive income. We translate
functional currency statement of income amounts at average
rates for the period.
For operations in highly inflationary economies, we translate
monetary items at rates in effect at the balance sheet date, with
translation adjustments recorded in Other (income)/deductions—
net, and nonmonetary items at historical rates.
G. Revenues
Revenue Recognition—We record revenue from product sales
when the goods are shipped and title passes to the customer. At
the time of sale, we also record estimates for a variety of sales
deductions, such as sales rebates, discounts and incentives, and
product returns.
Deductions From Revenues—Gross product sales are subject to a
variety of deductions that are generally estimated and recorded
in the same period that the revenue is recognized.
In the U.S., we record provisions for Medicaid and contract rebates
based upon our actual experience ratio of rebates paid and actual
prescriptions during prior quarters. We apply the experience
ratio to the respective period’s sales to determine the rebate
accrual and related expense. This experience ratio is evaluated
regularly to ensure that the historical trends are as current as
practicable. As appropriate, we will adjust the ratio to better
match our current experience or our expected future experience.
In assessing this ratio, we consider current contract terms, such as
changes in formulary status and discount rates.
Our provisions for chargebacks (primarily discounts to U.S. federal
government agencies) closely approximate actual as we settle
these deductions generally within 2-3 weeks of incurring the
liability.
Outside of the U.S., the majority of our rebates are contractual or
legislatively-mandated and our estimates are based on actual
invoiced sales within each period; both of these elements help to
reduce the risk of variations in the estimation process. Some
European countries base their rebates on the government’s
unbudgeted pharmaceutical spending and we use an estimated
allocation factor based on historical payments against our actual
invoiced sales to project the expected level of reimbursement. We
obtain third-party information that helps us to monitor the
adequacy of these accruals.
We record sales incentives as a reduction of revenues at the time
the related revenues are recorded or when the incentive is offered,
whichever is later. We estimate the cost of our sales incentives
based on our historical experience with similar incentive programs.
Other current liabilities include accruals for Medicaid rebates,
contract rebates and chargebacks of $1.8 billion at December 31,
2005 and $1.7 billion at December 31, 2004.
Alliances—We have agreements to co-promote pharmaceutical
products discovered by other companies. Revenue is earned when
our co-promotion partners ship the related product and title
passes to their customer. Alliance revenue is primarily based upon
a percentage of our co-promotion partners’ net sales. Generally,
expenses for selling and marketing these products are included
in Selling, informational and administrative expenses.
H. Cost of Sales and Inventories
We value inventories at cost or fair value, if lower. Cost is
determined as follows:
• finished goods and work in process at average actual cost;
and
• raw materials and supplies at average or latest actual cost.
I. Selling, Informational and Administrative Expenses
Selling, informational and administrative costs are expensed as
incurred. Among other things, these expenses include the costs
of marketing, advertising, shipping and handling, information
technology and non-plant employee compensation.
Advertising expenses relating to production costs are expensed
as incurred and the costs of radio time, television time and space
in publications are expensed when the related advertising occurs.
Advertising expenses totaled approximately $3.5 billion in 2005
and 2004, and $2.9 billion in 2003.
J. Research and Development Expenses
Research and development (R&D) costs are expensed as incurred.
These expenses include the costs of our proprietary R&D efforts,
as well as costs incurred in connection with our third-party
collaboration efforts. Pre-approval milestone payments made by
us to third parties under contracted R&D arrangements are
expensed when the specific milestone has been achieved. Once
the product receives regulatory approval, we record any
subsequent milestone payments in Identifiable intangible assets,
less accumulated amortization and amortize them evenly over the
remaining agreement term or the expected product life cycle,
whichever is shorter. We have no third-party R&D arrangements
that result in the recognition of revenue.
K. Amortization of Intangible Assets, Depreciation and
Certain Long-Lived Assets
Long-lived assets include:
• goodwill—Goodwill represents the difference between the
purchase price of a business acquisition and the fair value of
its net assets. Goodwill is not amortized.
• identifiable intangible assets—These acquired assets are
recorded at our cost. Intangible assets with finite lives are
amortized evenly over their estimated useful lives. Intangible
assets with indefinite lives are not amortized.
• property, plant and equipment—These assets are recorded at
original cost and increased by the cost of any significant
improvements after purchase. We depreciate the cost evenly
over the assets’ estimated useful lives. For tax purposes,
accelerated depreciation methods are used as allowed by tax
laws.
Amortization expense related to acquired intangible assets that
contribute to our ability to sell, manufacture, research, market and
distribute products, compounds and intellectual property are
included in Amortization of intangible assets as they benefit
multiple business functions. Amortization expense related to
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intangible assets that are associated with a single function and
depreciation of property, plant and equipment are included in Cost
of sales, Selling, informational and administrative expenses and
Research and development expenses, as appropriate.
We review all of our long-lived assets, including goodwill and
other intangible assets, for impairment at least annually and
whenever events or circumstances present an indication of
impairment. When necessary, we record charges for impairments
of long-lived assets for the amount by which the present value of
future cash flows, or some other fair value measure, is less than
the carrying value of these assets.
L. Merger-Related In-Process Research and
Development Charges and Restructuring Charges and
Merger-Related Costs
When recording acquisitions (see Note 1E, Significant Accounting
Polices: Acquisitions), we immediately expense amounts related
to acquired IPR&D in Merger-related in-process research and
development charges.
Also, in connection with an acquisition of a business enterprise,
we may review the associated operations and implement plans to
restructure and integrate. For restructuring charges associated
with a business acquisition that are identified in the first year after
the acquisition date, the related costs are recorded as additional
goodwill as they are considered to be liabilities assumed in the
acquisition. All other restructuring charges, all integration costs
and any charges related to our pre-existing businesses impacted
by the acquisition are included in Restructuring charges and
merger-related costs.
M. Cash Equivalents
Cash equivalents include items almost as liquid as cash, such as
certificates of deposit and time deposits with maturity periods of
three months or less when purchased. If items meeting this
definition are part of a larger investment pool, we classify them
as Short-term investments.
N. Investments
Realized gains or losses on sales of investments are determined
by using the specific identification cost method.
O. Income Tax Contingencies
We account for income tax contingencies using an asset
recognition model. In our initial evaluation of tax positions taken
related to tax law, we assess the likelihood of prevailing on the
interpretation of that tax law. When we consider that a tax
position is probable of being sustained on audit based solely on
the technical merits of the position, we record the benefit. These
assessments can be complex and we often obtain assistance from
external advisors.
Under the asset recognition model, if our initial assessment fails
to result in the recognition of a tax benefit, we regularly monitor
our position and subsequently recognize the tax benefit if there
are changes in tax law or analogous case law that sufficiently raise
the likelihood of prevailing on the technical merits of the position
to probable; if the statute of limitations expires; or if there is a
completion of an audit resulting in a settlement of that tax year
with the appropriate agency.
P. Share-Based Payments
Our compensation programs can include share-based payments.
Stock options, which entitle the holder to purchase shares of
Pfizer stock at a pre-determined price at the end of a vesting term,
are accounted for under Accounting Principles Board Opinion No.
25, Accounting for Stock Issued to Employees, an elective
accounting policy permitted by SFAS No. 123, Accounting for
Stock-Based Compensation. Under this policy, since the exercise
price of stock options granted is set equal to the market price on
the date of the grant, we do not record any expense to the
income statement related to the grants of stock options, unless
certain original grant-date terms are subsequently modified.
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For disclosure purposes only, we estimated the fair value of
employee stock options, as required under GAAP, using the Black-
Scholes-Merton option-pricing model and using the assumptions
as described in Note 14E, Equity and Stock Plans: Share-Based
Payments. The following table shows the effect on results for 2005,
2004 and 2003 if we had applied the fair-value-based recognition
provisions of SFAS 123 to measure stock-based compensation
expense for the option grants:
(MILLIONS OF DOLLARS, 
YEAR ENDED DEC. 31,_____________________________________________________
EXCEPT PER COMMON SHARE DATA) 2005 2004 2003
Net income available to 
common shareholders 
used in the calculation 
of basic earnings per 
common share:
As reported under 
GAAP(a) $8,079 $11,357 $3,906
Compensation 
expense—net of tax(b) (457) (574) (541)
Pro forma $7,622 $10,783 $3,365
Basic earnings per common 
share:
As reported under 
GAAP(a) $ 1.10 $ 1.51 $ 0.54
Compensation  
expense—net of tax(b) (0.06) (0.08) (0.07)
Pro forma $ 1.04 $ 1.43 $ 0.47
Net income available to 
common shareholders 
used in the calculation of 
diluted earnings per 
common share:
As reported under 
GAAP(a) $8,080 $11,356 $3,907
Compensation
expense—net of tax(b) (457) (574) (541)
Pro forma $7,623 $10,782 $3,366
Diluted earnings per 
common share:
As reported under 
GAAP(a) $ 1.09 $ 1.49 $ 0.54
Compensation 
expense—net of tax(b) (0.06) (0.08) (0.08)
Pro forma $ 1.03 $ 1.41 $ 0.46
(a) Includes stock-based compensation expense, net of related tax
effects, of $107 million in 2005 (of which $70 million related to
Restricted Stock Units (RSUs) and a nominal amount was a result
of acceleration of vesting due to our new productivity initiative),
$38 million in 2004 and $34 million in 2003.
(b) Pro forma compensation expense related to stock options that are
subject to accelerated vesting upon retirement is recognized over
the period of employment up to the vesting date of the grant.
RSUs, which entitle the holders to receive shares of Pfizer stock
at the end of a vesting period, are recorded at fair value at the
date of grant and are generally amortized on an even basis over
the vesting term into Cost of sales, Selling, informational and
administrative expenses, and Research and development expenses,
as appropriate. 
Performance-contingent share awards, which entitle the holders
to receive shares of stock at the end of a vesting period, are
awarded based on a non-discretionary formula measuring defined
performance standards. They are recorded evenly at fair value over
the performance period of the award, based on an estimate of
probable performance. They are then adjusted for changes in the




On April 16, 2003, Pfizer acquired Pharmacia for a purchase price
of approximately $56 billion. The fair value of Pfizer’s equity
items exchanged in the acquisition was derived using an average
market price per share of Pfizer common stock of $29.81, which
was based on Pfizer’s average stock price for the period two days
before through two days after the terms of the acquisition were
agreed to and announced on July 15, 2002. Under the terms of
the merger agreement, each outstanding share of Pharmacia
common stock was exchanged for 1.4 shares of Pfizer common
stock in a tax-free transaction. Each share of Pharmacia Series C
convertible perpetual preferred stock was exchanged for a newly
created class of Pfizer Series A convertible perpetual preferred
stock with rights substantially similar to the rights of the Pharmacia
Series C convertible perpetual preferred stock.
Pharmacia’s core business was the development, manufacture
and sale of prescription pharmaceutical products as well as the
production and distribution of consumer healthcare products
and animal healthcare products.
The following table summarizes the components of the purchase
price:
(MILLIONS OF DOLLARS) FAIR VALUE
Pfizer common stock $54,177
Pfizer Series A convertible perpetual preferred stock(a) 462
Pfizer stock options(b) 1,102
Pharmacia vested share awards(c) 130
Other transaction costs 101
Total estimated purchase price $55,972
(a) The estimated fair value of shares of a newly created class of
Series A convertible perpetual preferred stock (see Note 14B,
Equity and Stock Plans: Preferred Stock) was based on the same
exchange ratio as for the Pharmacia common stock and a Pfizer
stock price of $29.81.
(b) The estimated fair value of Pfizer stock options issued as of April
16, 2003 in exchange for Pharmacia outstanding stock options was
calculated using the Black-Scholes-Merton option pricing model
with model assumptions estimated as of April 16, 2003, and a
Pfizer stock price of $29.81.
(c) The estimated fair value of unissued shares of fully vested awards
was based on the same exchange ratio as for the Pharmacia
common stock and a Pfizer stock price of $29.81. Awards can be
settled in cash or shares, at the election of the program
participant.
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Allocation of Pharmacia Purchase Price
The purchase price allocation, finalized in the early part of 2004,
was based on an estimate of the fair value of assets acquired and
liabilities assumed.
(MILLIONS OF DOLLARS) AMOUNT
Book value of net assets acquired $ 8,795
Less: Recorded goodwill and other intangible assets 1,559
Tangible book value of net assets acquired 7,236
Remaining allocation:
Increase inventory to fair value 2,939
Increase long-term investments to fair value 40
Decrease property, plant and equipment to fair value (317)
Record in-process research and development charge 5,052
Record identifiable intangible assets(a) 37,066
Increase long-term debt to fair value (370)
Increase benefit plan liabilities to fair value (1,471)




Purchase price $ 55,972
(a) See Note 12, Goodwill and Other Intangible Assets.
(b) See Note 5, Merger-Related Costs.
(c) See Note 7, Taxes on Income.
Since our interim allocation in the fourth quarter of 2003, the
significant revisions to our estimates relate primarily to fixed
assets ($756 million decrease), identifiable intangible assets ($155
million decrease) and tax adjustments ($645 million decrease). In
addition, in 2004, we recorded an additional $604 million in
restructuring charges as a component of the purchase price
allocation.
The more significant revisions to our estimates relating to our
initial allocation of the purchase price in the second quarter of
2003 include inventory ($1.3 billion increase), fixed assets ($1.1
billion decrease), identifiable intangible assets ($560 million
increase) and tax adjustments ($986 million decrease). In addition,
we recorded an additional $1.4 billion in restructuring charges.
Pro Forma Results of Pharmacia Acquisition
The following unaudited pro forma financial information presents
the combined results of operations of Pfizer and Pharmacia as if
the acquisition had occurred as of the beginning of 2003. The
unaudited pro forma financial information is not necessarily
indicative of what our consolidated statement of income actually
would have been had we completed the acquisition at the
beginning of the year. In addition, the unaudited pro forma
financial information does not attempt to project the future
results of operations of the combined company.
YEAR ENDED DEC. 31,________________________
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) (UNAUDITED) 2003
Revenues $48,292
Income from continuing operations before 




Income from continuing operations before 
cumulative effect of a change in accounting 
principles per common share—basic 1.06
Net income per common share—basic 1.36
Income from continuing operations before 
cumulative effect of a change in accounting 
principles per common share—diluted 1.05
Net income per common share—diluted 1.34
The unaudited pro forma financial information above reflects the
following:
• The elimination of transactions between Pfizer and Pharmacia,
which upon completion of the merger would be considered
intercompany. The majority of these transactions occurred
under the Celebrex and Bextra marketing agreements. This
reflects:
• the elimination of certain sales, alliance revenue and certain
co-promotion expenses
• the elimination of certain impacts of milestone payments
made by Pfizer to Pharmacia
• A decrease in interest expense of $11 million related to the
estimated fair value adjustment of long-term debt from the
purchase price allocation.
• Additional amortization and depreciation expense of
approximately $993 million related to the estimated fair value
of identifiable intangible assets and property, plant and
equipment from the purchase price allocation.
The unaudited pro forma financial information above excludes the
following material, non-recurring charges incurred in the year
ended December 31, 2003:
• Purchase accounting adjustments related to a charge for IPR&D
of $5.1 billion and the incremental charge of $2.7 billion
reported in Cost of sales for the sale of acquired inventory that
was written up to fair value.
B. Other Acquisitions
On September 14, 2005, we completed the acquisition of all of the
outstanding shares of Vicuron Pharmaceuticals, Inc. (Vicuron), a
biopharmaceutical company focused on the development of
novel anti-infectives, for approximately $1.9 billion in cash
(including transaction costs). At the date of acquisition, Vicuron
had two products under NDA review by the U.S. Food and Drug
Administration (FDA): Eraxis (anidulafungin) for fungal infections
and Zeven (dalbavancin) for Gram-positive infections. The
allocation of the purchase price includes IPR&D of approximately
$1.4 billion, which was expensed in Merger-related in-process
research and development charges, and goodwill of $243 million,
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which has been allocated to our Human Health segment. Neither
of these items is deductible for tax purposes. In February 2006,
Eraxis was approved by the FDA.
On April 12, 2005, we completed the acquisition of all outstanding
shares of Idun Pharmaceuticals, Inc. (Idun), a biopharmaceutical
company focused on the discovery and development of therapies
to control apoptosis, and on August 15, 2005, we completed the
acquisition of all outstanding shares of Bioren Inc. (Bioren), which
focuses on technology for optimizing antibodies. The aggregate
cost of these and other smaller acquisitions was approximately
$340 million in cash (including transaction costs) for 2005. In
connection with these transactions, we expensed $262 million of
IPR&D, which was included in Merger-related in-process research
and development charges.
On September 30, 2004, we completed the acquisition of
Campto/Camptosar (irinotecan), from sanofi-aventis for $525
million in cash (including transaction costs). Additional payments
of up to $63 million will be payable upon obtaining regulatory
approvals for additional indications in certain European countries.
In connection with the acquisition, we recorded an intangible asset
for developed technology rights of $445 million.
On February 10, 2004, we completed the acquisition of all the
outstanding shares of Esperion Therapeutics, Inc. (Esperion), a
biopharmaceutical company, for $1.3 billion in cash (including
transaction costs). The allocation of the purchase price includes
IPR&D of approximately $920 million, which was expensed in
Merger-related in-process research and development charges,
and goodwill of $239 million, which was allocated to our Human
Health segment. Neither of these items was deductible for tax
purposes.
In 2004, we also completed several other acquisitions. The total
purchase price associated with these transactions was
approximately $430 million. In connection with these transactions,
we expensed $151 million of IPR&D, which was included in
Merger-related in-process research and development charges,
and recorded $206 million in intangible assets, primarily brands
(indefinite-lived) and developed technology rights.
3. Dispositions
We evaluate our businesses and product lines periodically for
strategic fit within our operations. As a result of our evaluation,
we decided to sell a number of businesses and product lines and
we recorded certain of these results in Discontinued operations
for 2005, 2004 and 2003. All of the sales were completed as of
December 31, 2005.
• In the third quarter of 2005, we sold the last of three European
generic pharmaceutical businesses which we had included in our
Human Health segment and had become a part of Pfizer in April
2003 in connection with our acquisition of Pharmacia, for 4.7
million euro (approximately $5.6 million) and recorded a loss
of $3 million ($2 million, net of tax) in Gains on sales of
discontinued operations—net of tax in the consolidated
statement of income for 2005.
• In the first quarter of 2005, we sold the second of three
European generic pharmaceutical businesses which we had
included in our Human Health segment and had become a part
of Pfizer in April 2003 in connection with our acquisition of
Pharmacia, for 70 million euro (approximately $93 million)
and recorded a gain of $57 million ($36 million, net of tax) in
Gains on sales of discontinued operations—net of tax in the
consolidated statement of income for 2005. In addition, we
recorded an impairment charge of $9 million ($6 million, net
of tax) related to the third European generic business in
(Loss)/income from discontinued operations—net of tax in the
consolidated statement of income for 2005.
• In the fourth quarter of 2004, we sold the first of three
European generic pharmaceutical businesses which we had
included in our Human Health segment and had become a part
of Pfizer in April 2003 in connection with our acquisition of
Pharmacia, for 53 million euro (approximately $65 million). In
addition, we recorded an impairment charge of $61 million ($37
million, net of tax), relating to a European generic business
which was later sold in 2005, and is included in (Loss)/income
from discontinued operations—net of tax in the consolidated
statement of income for 2004.
• In the third quarter of 2004, we sold certain non-core consumer
product lines marketed in Europe by our Consumer Healthcare
segment for 135 million euro (approximately $163 million) in
cash. We recorded a gain of $58 million ($41 million, net of tax)
in Gains on sales of discontinued operations—net of tax in
the consolidated statement of income for 2004. The majority
of these products were small brands sold in single markets
only and included certain products that became a part of Pfizer
in April 2003 in connection with our acquisition of Pharmacia.
• In the second quarter of 2004, we sold our surgical ophthalmic
business for $450 million in cash. The surgical ophthalmic
business was included in our Human Health segment and
became a part of Pfizer in April 2003 in connection with our
acquisition of Pharmacia. The results of this business were
included in (Loss)/income from discontinued operations—net
of tax.
• In the second quarter of 2004, we sold our in-vitro allergy and
autoimmune diagnostics testing (Diagnostics) business, formerly
included in the “Corporate/Other” category of our segment
information, for $575 million in cash. The Diagnostics business
was acquired in April 2003 in connection with our acquisition
of Pharmacia. The results of this business were included in
(Loss)/income from discontinued operations—net of tax.
• In the second quarter of 2003, we completed the sale of the
hormone replacement therapy femhrt, formerly part of our
Human Health segment, for $160 million in cash with a right
to receive up to $63.8 million contingent on femhrt retaining
market exclusivity until the expiration of its patent. We recorded
a gain on the sale of this product of $139 million ($83 million,
net of tax) in Gains on sales of discontinued operations—net
of tax in the consolidated statement of income for 2003.
• In the first quarter of 2003, we sold the oral contraceptives
Estrostep and Loestrin, formerly part of our Human Health
segment, for $197 million in cash with a right to receive up to
$47.3 million contingent on Estrostep retaining market
exclusivity until the expiration of its patent. We recorded a gain
on the sale of these two products of $193 million ($116 million,
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net of tax) in Gains on sales of discontinued operations—net
of tax in the consolidated statement of income for 2003.
• In the first quarter of 2003, we sold the Adams confectionery
products business, formerly part of our Consumer Healthcare
segment, for $4.2 billion in cash. We recorded a gain on the sale
of this business of $3.1 billion ($1.8 billion, net of tax) in Gains
on sales of discontinued operations—net of tax in the
consolidated statement of income for 2003.
• In the first quarter of 2003, we sold the Schick-Wilkinson Sword
shaving products business, formerly part of our Consumer
Healthcare segment, for $930 million in cash. We recorded a
gain on the sale of this business of $462 million ($262 million,
net of tax) in Gains on sales of discontinued operations—net
of tax in the consolidated statement of income for 2003.
In 2005, we earned $29 million of income ($18 million, net of tax)
and in 2004, we earned $17 million of income ($10 million, net
of tax), both amounts relating to the 2003 sale of the femhrt,
Estrostep and Loestrin product lines, which was recorded in Gains
on sales of discontinued operations—net of tax in the consolidated
statement of income for the applicable year.
The significant assets and liabilities as of December 31, 2004
relating to these businesses and product lines included intangible
assets; goodwill; property, plant and equipment; inventory;
accounts receivable; accrued liabilities and deferred taxes.
The following amounts have been segregated from continuing
operations and reported as discontinued operations:
YEAR ENDED DEC. 31,_________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
Revenues $ 55 $405 $1,214
Pre-tax (loss)/income (33) (39) 43
(Benefit) from/provision 
for taxes(a) (2) (17) 17
(Loss)/income from 
discontinued operations—
net of tax (31) (22) 26
Pre-tax gains on sales of 
discontinued operations 77 75 3,885
Provision for taxes on gains(b) 30 24 1,600
Gains on sales of discontinued 
operations—net of tax 47 51 2,285
Discontinued operations—
net of tax $ 16 $ 29 $2,311
(a) Includes a deferred tax expense of $23 million in 2005, a deferred
tax benefit of $15 million in 2004 and a deferred tax expense of
$8 million in 2003.
(b) Includes a deferred tax expense of nil in 2005 and 2004, and $744
million in 2003.
Net cash flows of our discontinued operations from each of the
categories of operating, investing and financing activities were
not significant for 2005, 2004 and 2003.
4. Adapting to Scale Initiative
In the first quarter of 2005, we launched our multi-year productivity
initiative, called Adapting to Scale (AtS), to increase efficiency and
streamline decision-making across the Company. This initiative,
announced in April 2005, follows the integration of Warner-Lambert
and Pharmacia, which resulted in the tripling of Pfizer’s revenues
over the past six years. The integration of those two companies
resulted in the achievement of significant annual cost savings.
In connection with the AtS productivity initiative, Pfizer
management has performed a comprehensive review of our
processes, organizations, systems and decision-making procedures,
in a company-wide effort to improve performance and efficiency.
This initiative is expected to yield substantial annual cost savings
by 2008. We expect the costs associated with this multi-year effort
to continue through 2008 and to total approximately $4 billion to
$5 billion, on a pre-tax basis. The actions associated with the AtS
productivity initiative will include about $2.8 billion to $3.5 billion
in restructuring charges, such as asset impairments, exit costs and
severance costs (including any related impacts to our benefit
plans, such as settlements and curtailments) and about $1.2 billion
to $1.5 billion in associated implementation costs, such as
accelerated depreciation charges, primarily associated with plant
network optimization efforts, and expenses associated with system
and process standardization and the expansion of shared services.




(MILLIONS OF DOLLARS) 2005
Implementation costs(a) $330
Restructuring charges(b) 450
Total AtS costs $780
(a) Included in Cost of sales ($124 million), Selling, informational and
administrative expenses ($156 million), and Research and
development expenses ($50 million).
(b) Included in Restructuring charges and merger-related costs.
Through December 31, 2005, the restructuring charges primarily
relate to employee termination costs at our manufacturing
facilities in North America and in our U.S. marketing and
worldwide research operations, and the implementation costs
primarily relate to system and process standardization, as well as
the expansion of shared services.
The components of restructuring charges associated with AtS
follow:
UTILIZATION ACCRUAL
COSTS THROUGH AS OF 
INCURRED DEC. 31, DEC. 31,__________ ___________ ___________
(MILLIONS OF DOLLARS) 2005 2005 2005(a)
Employee termination costs $305 $166 $139
Asset impairments 131 131 —
Other 14 3 11
$450 $300 $150
(a) Included in Other current liabilities.
Through December 31, 2005, Employee termination costs
represent the reduction of the workforce by 2,602 employees,
mainly in manufacturing, sales and research. We notified affected
individuals and 2,425 employees were terminated as of December
31, 2005. Employee termination costs are recorded as incurred and
include accrued severance benefits, pension and postretirement
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Restructuring Costs Associated with Legacy 
Pharmacia — Capitalized
We recorded, through April 15, 2004, restructuring costs
associated primarily with employee terminations and exiting
certain activities of legacy Pharmacia. These costs were recognized
as liabilities assumed in the purchase business combination.
Accordingly, the restructuring costs incurred in the first year
after the acquisition are considered part of the purchase price of
Pharmacia and have been recorded as an increase to goodwill.
These restructuring costs also include costs associated with
relocation. Restructuring costs after April 15, 2004 that are
associated with legacy Pharmacia are charged to the results of
operations. Changes to previous estimates of restructuring costs
included as part of the purchase price allocation of Pharmacia are
recorded as a reduction to goodwill or as an expense to
operations, as appropriate. The components of the restructuring
costs capitalized as a cost of the acquisition of Pharmacia follow:
UTILIZATION ACCRUAL
THROUGH AS OF
COSTS INCURRED DEC. 31,(a) DEC. 31,(b)___________________________________________________________________





termination costs $246 $1,289 $1,535 $1,504 $ 31
Other 335 289 624 523 101
$581 $1,578 $2,159 $2,027 $132
(a) Includes insignificant adjustments to original amounts
established.
(b) Included in Other current liabilities.
The majority of the restructuring costs related to employee
terminations. Through December 31, 2005, employee termination
costs represent the approved reduction of the legacy Pharmacia
work force by 12,768 employees mainly in corporate,
manufacturing, distribution, sales and research. We notified
affected individuals and 12,589 employees were terminated as of
December 31, 2005. Employee termination costs include accrued
severance benefits and costs associated with change-in-control
provisions of certain Pharmacia employment contracts.
Restructuring Costs Associated with Legacy Pfizer and
Legacy Pharmacia — Expensed
We have recorded restructuring costs associated with exiting
certain activities of legacy Pfizer and legacy Pharmacia (from
April 16, 2004), including severance, costs of vacating duplicative
facilities, contract termination and other exit costs. These costs
have been recorded as a charge to the results of operations and
are included in Restructuring charges and merger-related costs.
The components of the restructuring costs associated with the
acquisition of Pharmacia, which were expensed, follow:
UTILIZATION ACCRUAL
THROUGH AS OF
PROVISIONS DEC. 31, DEC. 31,(a)_________________________ ___________________
(MILLIONS OF DOLLARS) 2005 2004 2003 TOTAL 2005 2005
Employee 
termination 
costs $108 $377 $140 $ 625 $ 538 $ 87
Asset 
impairments 234 269 21 524 524 —
Other 48 58 16 122 90 32
$390 $704 $177 $1,271 $1,152 $119
(a) Included in Other current liabilities
benefits. Asset impairments primarily include charges to write off
inventory and write down property, plant and equipment. Other
primarily includes costs to exit certain activities.
5. Merger-Related Costs
We incurred the following merger-related charges primarily in
connection with our acquisition of Pharmacia which was
completed on April 16, 2003:
YEAR ENDED DEC. 31,_________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
Integration costs:
Pharmacia $538 $ 475 $ 838
Other 12 21 33
Restructuring costs:
Pharmacia 390 704 177
Other 3 (7) 10
Total merger-related costs—
expensed(a) $943 $1,193 $1,058
Total merger-related costs—
capitalized $ — $ 581 $1,578
(a) Included in Restructuring charges and merger-related costs.
A. Integration Costs
Integration costs represent external, incremental costs directly
related to an acquisition, including expenditures for consulting
and systems integration.
B. Restructuring Costs — Pharmacia
In connection with the acquisition of Pharmacia, Pfizer
management approved plans to restructure the operations of both
legacy Pfizer and legacy Pharmacia to eliminate duplicative
facilities and reduce costs. As of December 31, 2005, the
restructuring of our operations as a result of our acquisition of
Pharmacia is substantially complete. Restructuring charges
included severance, costs of vacating duplicative facilities, contract
termination and other exit costs.
Total merger-related expenditures (income statement and balance
sheet) incurred during 2002-2005 to achieve these synergies were
$5.4 billion, on a pre-tax basis.
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7. Taxes on Income
A. Taxes on Income
Income from continuing operations before provision for taxes on
income, minority interests and the cumulative effect of a change
in accounting principles consists of the following:
YEAR ENDED DEC. 31,_____________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
United States $ 1,296 $ 4,361 $ (209)
International 10,238 9,646 3,455
Total income from 
continuing operations 
before provision for taxes 
on income, minority 
interests and cumulative 
effect of a change in 
accounting principles $11,534 $14,007 $3,246
The decrease in domestic income from continuing operations
before taxes in 2005 compared to 2004 is due primarily to non-
cash IPR&D charges in 2005 of $1.7 billion, primarily related to our
acquisition of Vicuron and Idun, the Bextra impairment, changes
in product mix and adverse changes in product volume, among
other factors, partially offset by IPR&D charges recorded in 2004
for the acquisition of Esperion ($920 million).
Domestic and international income from continuing operations
before taxes in 2003 includes several non-cash charges associated
with the Pharmacia acquisition (IPR&D and the charge for the fair-
value mark-up of acquired inventory sold); an increase in merger-
related costs incurred in connection with our acquisition of
Pharmacia; and the provision for two legacy Warner-Lambert
legal matters.
The provision for taxes on income from continuing operations
before minority interests and the cumulative effect of a change
in accounting principles consists of the following:
YEAR ENDED DEC. 31,_____________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
United States:
Taxes currently payable:
Federal $ 1,369 $ 1,892 $ 29
State and local 122 352 115
Deferred income taxes 12 (1,042) 502
Total U.S. tax provision 1,503 1,202 646
International:
Taxes currently payable 3,317 2,000 1,574
Deferred income taxes (1,396) (537) (606)
Total international tax 
provision 1,921 1,463 968
Total provision for taxes 
on income $ 3,424(a) $ 2,665 $1,614
(a) Excludes federal, state and local, and international benefits of
$127 million primarily related to the resolution of certain tax
positions related to Pharmacia, which were credited to Goodwill.
In 2005, we recorded an income tax charge of $1.7 billion, included
in Provision for taxes on income, in connection with our decision
to repatriate approximately $37 billion of foreign earnings in
accordance with the American Jobs Creation Act of 2004 (the Jobs
Through December 31, 2005, Employee termination costs represent
the approved reduction of the legacy Pfizer and legacy Pharmacia
(from April 16, 2004) work force by 4,476 employees, mainly in
corporate, manufacturing, distribution, sales and research. We
notified affected individuals and 4,082 employees were terminated
as of December 31, 2005. Employee termination costs include
accrued severance benefits and costs associated with change-in-
control provisions of certain Pharmacia employment contracts.
Asset impairments primarily include charges to write down
property, plant and equipment. Other primarily includes costs to
exit certain activities of legacy Pfizer and legacy Pharmacia (from
April 16, 2004).
6. Other (Income)/Deductions — Net
The components of Other (income)/deductions—net follow:
YEAR ENDED DEC. 31,__________________________________________________
(MILLIONS OF DOLLARS) 2005 2004 2003
Interest income $(740) $(346) $ (346)
Interest expense 488 359 290
Interest expense capitalized (17) (12) (20)
Net interest (income)/expense (269) 1 (76)
Various litigation matters(a) 2 369 1,435
Impairment of long-lived 
assets(b) 1,158 702 —
Royalty income (369) (288) (255)
Contingent income earned 
from the prior year sale of 
a product-in-development — (100) —
Net gains on disposals of 
investments, products and 
product lines(c) (188) (16) (85)
Net exchange (gains)/losses (10) 81 1
Other, net 23 4 (11)
Other (income)/
deductions—net $ 347 $ 753 $1,009
(a) In 2004, we recorded charges totaling $369 million related to the
resolution of claims against Quigley Company, Inc., a wholly-
owned subsidiary of Pfizer. See Note 18B, Legal Proceedings and
Contingencies: Product Liability Matters. In 2003, we recorded
charges totaling $1.4 billion for the resolution of two legacy
Warner-Lambert litigation matters relating to Rezulin personal
injury claims and a government investigation of marketing
practices relating to Neurontin.
(b) In 2005, we recorded charges totaling $1.2 billion in connection
with the decision to suspend sales and marketing of Bextra. In
2004, we recorded an impairment charge of $691 million related
to the Depo-Provera brand. See Note 12B, Goodwill and Other
Intangible Assets: Other Intangible Assets.
(c) In 2005, gross realized gains were $171 million and gross realized
losses were $14 million on sales of available-for-sale securities.
Gross realized gains and gross realized losses on sales of available-
for-sale securities were not significant for 2004 and 2003. 
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Act). The Jobs Act created a temporary incentive for U.S.
corporations to repatriate accumulated income earned abroad by
providing an 85% dividend-received deduction for certain
dividends from controlled foreign corporations, subject to various
limitations and restrictions including qualified U.S. reinvestment
of such earnings. In addition, in 2005, we recorded a tax benefit
of $586 million related to the resolution of certain tax positions
(see Note 7D, Taxes on Income: Tax Contingencies).
Amounts are reflected in the preceding tables based on the location
of the taxing authorities. As of December 31, 2005, we have not
made a U.S. tax provision on approximately $27 billion of
unremitted earnings of our international subsidiaries. As of
December 31, 2005, these earnings are intended to be permanently
reinvested overseas. Because of complexity, it is not practical to
compute the estimated deferred tax liability on these permanently
reinvested earnings. On January 23, 2006, the IRS issued final
regulations on Statutory Mergers and Consolidations, which impact
certain prior period transactions. The regulations could result in
benefits ranging from approximately $75 million to $214 million
in the first quarter of 2006 subject to certain management decisions.
B. Tax Rate Reconciliation
Reconciliation of the U.S. statutory income tax rate to our effective
tax rate for continuing operations before the cumulative effect
of a change in accounting principles follows:
YEAR ENDED DEC. 31,__________________________________________________
2005 2004 2003(a)
U.S. statutory income tax rate 35.0% 35.0% 35.0%
Earnings taxed at other than 
U.S. statutory rate (19.5) (18.3) (53.2)
U.S. research tax credit (0.7) (0.6) (3.1)
Repatriation of foreign 
earnings 14.4 — —
Resolution of certain tax 
positions (5.1) — —
Acquired IPR&D 5.0 2.7 54.2
Litigation settlement 
provisions — — 13.7
All other—net 0.6 0.2 3.1
Effective tax rate for income 
from continuing operations 
before cumulative effect of 
a change in accounting 
principles 29.7% 19.0% 49.7%
(a) The large component percentages in 2003 reflect lower income
from continuing operations in 2003 due to the impact of the
Pharmacia acquisition. 
We operate manufacturing subsidiaries in Puerto Rico and Ireland.
We benefit from Puerto Rican incentive grants that expire
between 2013 and 2023. Under the grants, we are partially
exempt from income, property and municipal taxes. Under Section
936 of the U.S. Internal Revenue Code, Pfizer is a “grandfathered”
entity and is entitled to the benefits under such statute until
September 30, 2006. In Ireland, we benefit from an incentive tax
rate effective through 2010 on income from manufacturing
operations.
The U.S. research tax credit is effective through December 31, 2005.
For tax years beginning after December 31, 2005, the research
credit has been suspended. For a discussion about the repatriation
of foreign earnings, see Note 7A, Taxes on Income: Taxes on
Income and for a discussion about the resolution of certain tax
positions, see Note 7D, Taxes on Income: Tax Contingencies. The
charges for acquired IPR&D in 2005, 2004 and 2003 are not
deductible. In addition, the litigation settlement provisions of $1.4
billion recorded in 2003 either are not deductible or are deductible
at rates lower than the U.S. statutory rate. 
C. Deferred Taxes
Deferred taxes arise because of different treatment between
financial statement accounting and tax accounting, known as
“temporary differences.” We record the tax effect of these
temporary differences as “deferred tax assets” (generally items
that can be used as a tax deduction or credit in future periods)
or “deferred tax liabilities” (generally items for which we received
a tax deduction, but that have not yet been recorded in the
consolidated statement of income).
The tax effects of the major items recorded as deferred tax assets
and liabilities as of December 31 are:
2005 2004
DEFERRED TAX DEFERRED TAX_____________________________ _____________________________
(MILLIONS OF DOLLARS) ASSETS (LIABILITIES) ASSETS (LIABILITIES)
Prepaid/deferred 
items $1,318 $ (753) $1,085 $ (579)
Intangibles 857 (8,748) 270 (9,991)
Inventories 583 — 693 —
Property, plant 
and equipment 87 (1,183) 279 (1,402)
Employee 
benefits 2,282 (1,376) 2,314 (891)
Restructurings 
and other 
charges 729 (118) 619 (74)
Net operating
loss/credit
carryforwards 406 — 353 —
Unremitted 
earnings — (2,651) — (3,063)
All other 950 (335) 973 (581)
Subtotal 7,212 (15,164) 6,586 (16,581)
Valuation 
allowance (142) — (177) —
Total deferred 
taxes $7,070 $(15,164) $6,409 $(16,581)
Net deferred 
tax liability $ (8,094) $(10,172)
The net deferred tax liability position is primarily due to the deferred
taxes recorded in connection with our acquisition of Pharmacia.
We have carryforwards primarily related to net operating losses
which are available to reduce future U.S. federal and state, as well
as international income, expiring at various times between 2006
and 2025.
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Valuation allowances are provided when we believe that our
deferred tax assets are not recoverable based on an assessment
of estimated future taxable income that incorporates ongoing,
prudent, feasible tax planning strategies. 
Deferred tax assets and liabilities in the preceding table, netted
by taxing jurisdiction, are in the following captions in the
consolidated balance sheet:
AS OF DEC. 31,__________________________________
(MILLIONS OF DOLLARS) 2005 2004
Current deferred tax asset(a) $ 2,231 $ 1,461
Noncurrent deferred tax asset(b) 721 397
Current deferred tax liability(c) (806) (4)
Noncurrent deferred tax liability(d) (10,240) (12,026)
Net deferred tax liability $ (8,094) $(10,172)
(a) Included in Prepaid expenses and taxes.
(b) Included in Other assets, deferred taxes and deferred charges.
(c) Included in Other current liabilities.
(d) Included in Deferred taxes.
A reclassification was made in 2004 to conform to the 2005
presentation, as well as to better reflect jurisdictional netting.
D. Tax Contingencies
We are subject to income tax in many jurisdictions and a certain
degree of estimation is required in recording the assets and
liabilities related to income taxes. Tax accruals are provided when
we believe that it is not probable that the Company’s position will
be sustained if challenged.
In 2005, we recorded a tax benefit of $586 million primarily related
to the resolution of certain tax positions of the Pfizer Inc. tax
returns for the years 1999 through 2001 and the Warner-Lambert
Company tax returns for the years 1999 through the date of the
merger with Pfizer (June19, 2000). In connection with those audits,
as of December 31, 2005, we were in the process of appealing one
matter related to the tax deductibility of a breakup fee paid by
Warner-Lambert Company in 2000. On January 25, 2006, the Company
was notified by the Internal Revenue Service (IRS) Appeals Division that
resolution had been reached on the Warner-Lambert Company break-
up fee issue. This resolution finalizes the IRS’ audit of the Company’s
tax returns for Pfizer Inc. for the years 1999 through 2001 and Warner-
Lambert Company for the years 1999 through the date of merger. As
a result, in the first quarter of 2006 we will record favorable
adjustments of approximately $450 million related to the resolution
of this issue.
The IRS is currently conducting audits of the Pfizer Inc. tax returns for
the years 2002, 2003 and 2004. The 2005 and 2006 tax years are also
currently under audit under the IRS Compliance Assurance Process
(CAP).
As previously disclosed, with respect to Pharmacia (formerly known
as Monsanto Company), the IRS is currently conducting audits of the
tax returns for the years 2000 through the date of merger with
Pfizer (April 16, 2003).
We believe that our accruals for tax liabilities are adequate for all
open years. We consider many factors in making these assessments,
including past history, recent interpretations of tax law, and the
specifics of each matter. Because tax regulations are subject to
interpretation and tax litigation is inherently uncertain, these
assessments can involve a series of complex judgments about future
events and can rely heavily on estimates and assumptions (see Note
1B, Significant Accounting Policies: Estimates and Assumptions). Our
assessments are based on estimates and assumptions that have been
deemed reasonable by management. However, if our estimates are
not representative of actual outcomes, our results could be materially
affected. Because of complexity, we cannot estimate the range of
reasonably possible loss in excess of amounts recorded.
8. Other Comprehensive Income
Changes, net of tax, in accumulated other comprehensive income/(expense) follow:
NET UNREALIZED NET UNREALIZED ACCUMULATED
CURRENCY GAINS/(LOSSES) GAIN/(LOSS) OTHER COM-
TRANSLATION ON DERIVATIVE ON AVAILABLE- MINIMUM PREHENSIVE
ADJUSTMENT FINANCIAL FOR-SALE PENSION INCOME/
(MILLIONS OF DOLLARS) AND OTHER INSTRUMENTS SECURITIES LIABILITY (EXPENSE)
Balance, January 1, 2003 $(1,448) $ 10 $ 70 $(507) $(1,875)
Period change 2,028 42 68 (68) 2,070
Balance, December 31, 2003 580 52 138 (575) 195
Period change 2,014 (53) 128 (6) 2,083
Balance, December 31, 2004 2,594 (1) 266 (581) 2,278
Period change (1,481) (106) (183) (29) (1,799)
Balance, December 31, 2005 $ 1,113 $(107) $ 83 $(610) $ 479
Income taxes related to the above components of other
comprehensive income/(expense) are not significant in any year.
Income taxes are not provided for foreign currency translation
relating to permanent investments in international subsidiaries.
Reclassification adjustments for realized gains on available-for-sale
securities included in net income, net of tax, were $169 million
in 2005 (largely due to the sale of certain equity investments), $15
million in 2004 and $6 million in 2003. All other reclassification
adjustments are not significant in any year.
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9. Financial Instruments
A. Investments in Debt and Equity Securities
Information about our investments as of December 31 follows:
(MILLIONS OF DOLLARS) 2005 2004
Trading investments(a) $ 286 $ 395
Amortized cost and fair value of 
available-for-sale debt securities:(b)
Western European and other 
government debt 8,739 4,270
Western European and other 
government agency debt 4,794 4,358
Corporate debt 4,546 7,947
Supranational debt 2,227 1,230
Certificates of deposit 323 613
Corporate asset-backed securities 58 1,712
Total available-for-sale debt securities 20,687 20,130
Amortized cost and fair value of 
held-to-maturity debt securities:(b)
Certificates of deposit and other 1,401 967
Total held-to-maturity debt securities 1,401 967
Cost of available-for-sale equity securities 270 176
Gross unrealized gains 189 441
Gross unrealized losses (12) (8)
Fair value of available-for-sale equity 
securities 447 609
Total investments $22,821 $22,101
(a) Trading investments are held in trust for legacy Pharmacia
severance benefits.
(b) Gross unrealized gains and losses are not significant.
These investments were in the following captions in the
consolidated balance sheet as of December 31:
(MILLIONS OF DOLLARS) 2005 2004
Cash and cash equivalents $ 1,203 $ 881
Short-term investments 19,979 18,085
Long-term investments and loans 1,639 3,135
Total investments $22,821 $22,101
The contractual maturities of the available-for-sale and held-to-
maturity debt securities as of December 31, 2005 follow:
YEARS_______________________________________________________
OVER 1 OVER 5 OVER









agency debt 4,619 50 125 — 4,794
Corporate 
debt 4,014 218 314 — 4,546
Supranational debt 2,100 127 — — 2,227
Certificates of 
deposit 320 — 3 — 323
Corporate 
asset-backed 




deposit and other 1,390 4 — 7 1,401





On an ongoing basis, we evaluate our investments in debt and
equity securities to determine if a decline in fair value is other-
than-temporary. When a decline in fair value is determined to be
other-than-temporary, an impairment charge is recorded and a
new cost basis in the investment is established. The aggregate cost
and related unrealized losses related to non-traded equity
investments are not significant.
B. Short-Term Borrowings
Short-term borrowings include amounts for commercial paper of
$10.6 billion and $9.1 billion at December 31, 2005 and 2004. Our
commercial paper borrowings were made by international
subsidiaries and they are guaranteed as to principal and interest
by Pfizer Inc. through the maturity date of the borrowings. The
weighted average effective interest rate on short-term borrowings
outstanding was 3.7% and 2.5% at December 31, 2005 and 2004.
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At December 31, 2005, we had access to $3.0 billion of lines of
credit, of which $1.1 billion expire within one year. Of these lines
of credit, $2.8 billion are unused, of which our lenders have
committed to loan us $1.7 billion at our request. $1.5 billion of
the unused lines of credit, which expire in 2010, may be used to
support our commercial paper borrowings.
C. Long-Term Debt
Information about our long-term debt as of December 31 follows:
(MILLIONS OF DOLLARS) MATURITY DATE 2005 2004
Senior unsecured notes:
LIBOR-based floating-rate January 2007 $1,000 $ —
LIBOR-based floating-rate January 2006 — 1,000
5.625%(a) February 2006 — 771
6.6%(a) December 2028 763 749
4.5%(a) February 2014 728 742
2.5%(a) March 2007 682 686
5.625%(a) April 2009 618 644
6.5%(a) December 2018 522 528
0.80% Japanese yen March 2008 513 586
4.65%(a) March 2018 293 294
3.3%(a) March 2009 288 294
6.0%(a) January 2008 255 266
Other:
Debentures, notes, 
borrowings and mortgages(a) 685 719
Total long-term debt $6,347 $7,279
Current portion not included above(a) $ 778 $ 907
(a) Includes unrealized gains and losses for debt with fair value
hedges in 2005 and/or 2004 (see Note 9D, Financial Instruments:
Derivative Financial Instruments and Hedging Activities).
In November 2005, Pfizer issued $1 billion of senior unsecured
floating-rate notes at LIBOR, less a nominal amount, with an
initial maturity of 13 months. The debt holders have the option
to extend the term of the notes by one month, each month,
during the five-year maximum term of the notes. In addition, the
adjustment to LIBOR increases each December by a nominal
amount. The notes are callable by us at par plus accrued interest
to date every six months, with a notice of not less than thirty days,
but not more than sixty days. The LIBOR-based floating-rate
notes bear an interest rate of 4.33% as of December 31, 2005. The
floating-rate notes were issued through an international
subsidiary. They are guaranteed as to principal and interest by
Pfizer Inc. though the maturity date of the notes. These notes were
issued to fund certain international subsidiaries’ intercompany
dividends paid in 2005 in connection with the Jobs Act.
In July 2005, we decided to exercise Pfizer’s option to call, at par-
value plus accrued interest, $1 billion of senior unsecured floating-
rate notes, which were included in Long-term debt at December
31, 2004. Notice to call was given to the Trustees and the notes
were redeemed in September 2005.
Long-term debt outstanding at December 31, 2005 matures in the
following years:
AFTER
(MILLIONS OF DOLLARS) 2007 2008 2009 2010 2010
Maturities $1,688 $979 $956 $2 $2,722
On February 22, 2006, we issued the following Japanese yen
fixed-rate bonds, which will be used for current general corporate
purposes:
• $508 million equivalent, senior unsecured notes, due February
2011, which pay interest semi-annually, beginning on August 22,
2006, at a rate of 1.2%; and
• $466 million equivalent, senior unsecured notes, due February
2016, which pay interest semi-annually, beginning on August 22,
2006, at a rate of 1.8%.
The notes were issued under a $5 billion debt shelf registration
filed with the SEC in November 2002. Such yen debt is designated
as a hedge of our yen net investments.
At February 24, 2006, we had the ability to borrow $1 billion by
issuing debt securities under our existing debt shelf registration
statement filed with the SEC in November 2002.
D. Derivative Financial Instruments and Hedging
Activities
Foreign Exchange Risk—A significant portion of revenues,
earnings and net investments in foreign affiliates is exposed to
changes in foreign exchange rates. We seek to manage our
foreign exchange risk in part through operational means,
including managing expected same currency revenues in relation
to same currency costs and same currency assets in relation to
same currency liabilities. Depending on market conditions, foreign
exchange risk is also managed through the use of derivative
financial instruments and foreign currency debt. These financial
instruments serve to protect net income and net investments
against the impact of the translation into U.S. dollars of certain
foreign exchange denominated transactions.
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PRIMARY NOTIONAL AMOUNT
BALANCE SHEET HEDGE (MILLIONS OF DOLLARS) MATURITY______________________________
INSTRUMENT(a) CAPTION(b) TYPE(c) HEDGED OR OFFSET ITEM 2005 2004 DATE
Forward Prepaid CF Euro available-for-sale investments $7,371 $ — 2006
Forward OCL CF Euro available-for-sale investments — 3,415 2005
Forward OCL — Short-term foreign currency assets and liabilities 
(d)
6,509 — 2006
Forward OCL — Short-term foreign currency assets and liabilities 
(d)
— 6,737 2005
ST yen borrowings STB NI Yen net investments 1,620 — 2006
ST yen borrowings STB NI Yen net investments — 1,854 2005
Swaps OCL NI Euro net investments 1,233 — 2006
Forward Prepaid CF Danish krone available-for-sale investments 810 — 2006
Forward OCL CF Danish krone available-for-sale investments — 551 2005
Swaps ONCL CF U.K. pound intercompany loan 717 793 2006
Swaps OCL NI Yen net investments 662 — 2006
Swaps ONCL NI Yen net investments — 758 2006
LT yen debt LTD NI Yen net investments 512 585 2008
Forward OCL CF Swedish krona available-for-sale investments 486 — 2006
Forward OCL CF Swedish krona available-for-sale investments — 194 2005
(a) Forward = Forward-exchange contracts; ST yen borrowings = Short-term yen borrowings; LT yen debt = Long-term yen debt
(b) The primary balance sheet caption indicates the financial statement classification of the fair value amount associated with the financial
instrument used to hedge or offset foreign exchange risk. The abbreviations used are defined as follows: Prepaid = Prepaid expenses and taxes;
STB = Short-term borrowings, including current portion of long-term debt; OCL = Other current liabilities; LTD = Long-term debt; and ONCL =
Other noncurrent liabilities.
(c) CF = Cash flow hedge; NI = Net investment hedge
(d) Forward-exchange contracts used to offset short-term foreign currency assets and liabilities were primarily for intercompany transactions in
euros, U.K. pounds, Australian dollars, Canadian dollars, Swedish krona, Japanese yen and Swiss franc for the year ended December 31, 2005
and, euros, U.K. pounds, Swedish krona, Japanese yen and Australian dollars for the year ended December 31, 2004.
We entered into financial instruments to hedge or offset by the
same currency an appropriate portion of the currency risk and the
timing of the hedged or offset item. At December 31, 2005 and
2004, the more significant financial instruments employed to
manage foreign exchange risk follow:
All derivative contracts used to manage foreign currency risk are
measured at fair value and reported as assets or liabilities on the
balance sheet. Changes in fair value are reported in earnings or
deferred, depending on the nature and effectiveness of the
offset or hedging relationship, as follows:
• We recognize the earnings impact of foreign currency swaps
and foreign currency forward-exchange contracts designated
as cash flow hedges in Other (income)/deductions—net upon
the recognition of the foreign exchange gain or loss on the
translation to U.S. dollars of the hedged items.
• We recognize the earnings impact of foreign currency forward-
exchange contracts that are used to offset foreign currency
assets or liabilities in Other (income)/deductions—net during the
terms of the contracts, along with the earnings impact of the
items they generally offset.
• We recognize the earnings impact of foreign currency swaps
designated as a hedge of our net investments in Other
(income)/deductions—net in three ways: over time—for the
periodic net swap payments; immediately—to the extent of any
change in the difference between the foreign exchange spot
rate and forward rate; and upon sale or substantial liquidation
of our net investments—to the extent of change in the foreign
exchange spot rates.
Any ineffectiveness in a hedging relationship is recognized
immediately into earnings. There was no significant ineffectiveness
in 2005, 2004 or 2003.
Interest Rate Risk—Our interest-bearing investments, loans and
borrowings are subject to interest rate risk. We invest, loan and
borrow primarily on a short-term or variable-rate basis. From
time to time, depending on market conditions, we will fix interest
rates either through entering into fixed-rate investments and
borrowings or through the use of derivative financial instruments. 
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All derivative contracts used to manage interest rate risk are 
measured at fair value and reported as assets or liabilities on the
balance sheet. Changes in fair value are reported in earnings or
deferred, depending on the nature and effectiveness of the
offset or hedging relationship, as follows:
• We recognize the earnings impact of interest rate swaps
designated as fair value hedges in Other (income)/deductions—
net upon the recognition of the change in fair value for interest
rate risk related to the hedged items.
• We recognize the earnings impact of interest rate swaps
designated as cash flow hedges in Other (income)/deductions—
net upon the recognition of the interest related to the hedged
items.
Any ineffectiveness in a hedging relationship is recognized
immediately into earnings. There was no significant ineffectiveness
in 2005, 2004 or 2003.
E. Fair Value
The following methods and assumptions were used to estimate
the fair value of derivative and other financial instruments at the
balance sheet date:
• short-term financial instruments (cash equivalents, accounts
receivable and payable, held-to-maturity debt securities and
debt)—we use cost or contract value because of the short
maturity period
• available-for-sale debt securities—we use a valuation model that
uses observable market quotes and credit ratings of the
securities
• available-for-sale equity securities—we use observable market
quotes
• derivative contracts—we use valuation models that use
observable market quotes and our view of the creditworthiness
of the derivative counterparty
• loans—we use cost because of the short interest-reset period
• held-to-maturity long-term investments and long-term debt—
we use valuation models that use observable market quotes
The differences between the estimated fair values and 
carrying values of our financial instruments were not significant
at December 31, 2005 and 2004.
F. Credit Risk
On an ongoing basis, we review the creditworthiness of
counterparties to foreign exchange and interest rate agreements
and do not expect to incur a loss from failure of any counterparties
to perform under the agreements.
There are no significant concentrations of credit risk related to our
financial instruments with any individual counterparty. At
December 31, 2005, we had $3.2 billion due from a broad group
of banks around the world.
In general, there is no requirement for collateral from customers.
However, derivative financial instruments are executed under
master netting agreements with financial institutions. These
agreements contain provisions that provide for the ability for
collateral payments, depending on levels of exposure and the
credit rating of the counterparty and us.
10. Inventories
The components of inventories as of December 31 follow:
(MILLIONS OF DOLLARS) 2005 2004
Finished goods $2,303 $2,643
Work-in-process 2,379 2,703
Raw materials and supplies 1,357 1,314
Total inventories $6,039 $6,660
A reclassification was made in 2004 from Finished Goods to Work-
in-process to better reflect the stage of completion.
PRIMARY NOTIONAL AMOUNT
FINANCIAL BALANCE SHEET HEDGE (MILLIONS OF DOLLARS) MATURITY______________________________
INSTRUMENT CAPTION(a) TYPE(b) HEDGED ITEM 2005 2004 DATE
Swaps ONCL FV U.S. dollar fixed rate debt(c) $5,141 $5,147 2006-
2028
Swaps OCL CF Yen LIBOR interest rate related to forecasted issuances 
of short-term debt(d) 1,182 — 2006
Swaps ONCL CF Yen LIBOR interest rate related to forecasted issuances 
of short-term debt(d) — 1,353 2006
(a) The primary balance sheet caption indicates the financial statement classification of the fair value amount associated with the financial
instrument used to hedge interest rate risk. The abbreviations used are defined as follows: OCL = Other current liabilities and ONCL = Other
noncurrent liabilities.
(b) CF = Cash flow hedge; FV = Fair value hedge.
(c) Serve to reduce exposure to long-term U.S. dollar interest rates by effectively converting fixed rates associated with long-term debt obligations
to floating rates (see Note 9C, Financial Instruments: Long-Term Debt for details of maturity dates).
(d) Serve to reduce variability by effectively fixing the maximum rates on short-term debt at 0.8%.
We entered into derivative financial instruments to hedge the
fixed or variable interest rates on the hedged item, matching the
amount and timing of the hedged item. At December 31, 2005 and
2004, the more significant derivative financial instruments
employed to manage interest rate risk follow:
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11. Property, Plant and Equipment




(MILLIONS OF DOLLARS) (YEARS) 2005 2004
Land — $ 645 $ 688
Buildings 331⁄3-50 9,735 9,771
Machinery and equipment 8-20 9,453 9,395
Furniture, fixtures and 
other 3-121⁄2 4,540 4,670
Construction in progress — 2,244 2,395
26,617 26,919
Less: accumulated depreciation 9,527 8,534
Total property, plant and equipment $17,090 $18,385
12. Goodwill and Other Intangible Assets
A. Goodwill
The changes in the carrying amount of goodwill by segment for
the years ended December 31, 2005 and 2004 follow:
HUMAN CONSUMER ANIMAL 
(MILLIONS OF DOLLARS) HEALTH HEALTHCARE HEALTH OTHER TOTAL
Balance, 
January 1, 2004 $19,487 $2,615 $ 78 $ 85 $22,265
Pharmacia goodwill 
adjustments(a) 816 155 (14) (1) 956
Other(b) 663 (69) 15 (74) 535
Balance,
December 31, 2004 20,966 2,701 79 10 23,756
Other(b) (47) 88 (23) — 18
Balance, 
December 31, 2005 $20,919 $2,789 $ 56 $ 10 $23,774
(a) Refer to Note 2A, Acquisitions: Pharmacia Corporation for the
primary factors impacting the Pharmacia goodwill adjustments.
None of the Pharmacia goodwill was deductible for tax purposes.
(b) Includes additions from acquisitions (primarily Vicuron in 2005
and Esperion in 2004), reductions to goodwill as a result of
adjusting certain purchase accounting liabilities in 2005,
reclassifications to Assets held for sale (including those
subsequently sold) in 2004 and the impact of foreign exchange.
B. Other Intangible Assets




CARRYING ACCUMULATED CARRYING ACCUMULATED




technology rights $30,781 $(8,819) $33,137 $(5,967)
Brands 1,022 (60) 1,037 (14)
License agreements 160 (30) 158 (17)
Trademarks 152 (91) 134 (90)
Other(a) 452 (207) 390 (186)
Total amortized 
finite-lived intangible 
assets 32,567 (9,207) 34,856 (6,274)
Indefinite-lived 
intangible assets:
Brands 3,864 — 4,012 —
License agreements 296 — 356 —
Trademarks 227 — 235 —
Other(b) 39 — 66 —
Total indefinite-lived 
intangible assets 4,426 — 4,669 —
Total identifiable 





(a) Includes patents, non-compete agreements, customer contracts
and other intangible assets.
(b) Includes pension-related intangible assets.
Developed technology rights represent the amortized value
associated with developed technology, which has been acquired
from third parties and which can include the right to develop, use,
market, sell and/or offer for sale the product, compounds and
intellectual property that we have acquired with respect to
products, compounds and/or processes that have been completed.
We possess a well-diversified portfolio of hundreds of developed
technology rights across therapeutic categories primarily
representing the amortized value of the commercialized products
included in our Human Health segment that we acquired in
connection with our Pharmacia acquisition. While the Arthritis and
Pain therapeutic category represents about 28% of the total
amortized value of developed technology rights at December 31,
2005, the balance of the amortized value is evenly distributed
across the following Human Health therapeutic product
categories: Ophthalmology; Oncology; Urology; Infectious and
Respiratory Diseases; Endocrine Disorders categories; and, as a
group, the Cardiovascular and Metabolic Diseases; Central Nervous
System Disorders and All Other categories. The significant
components include values determined for Celebrex, Detrol,
Xalatan, Genotropin, Zyvox, and Campto/Camptosar. Also included
in this category are the post-approval milestone payments made
under our alliance agreements for certain Human Health products,
such as Rebif, Spiriva, Celebrex (prior to our acquisition of
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Pharmacia) and Macugen. These rights are all subject to our
impairment review process explained in Note 1K, Amortization
of Intangible Assets, Depreciation and Certain Long-Lived Assets.
The weighted-average life of our total finite-lived intangible
assets is approximately 9 years, which includes developed
technology rights at 9 years. Total amortization expense for
finite-lived intangible assets was $3.5 billion in 2005, $3.4 billion
in 2004 and $2.4 billion in 2003.
Brands represent the amortized value associated with tradenames,
as the products themselves no longer receive patent protection.
Most of these assets are associated with our Human Health and
Consumer Healthcare segments and the significant components
include values determined for Depo-Provera contraceptive, Xanax,
Medrol and tobacco dependence products.
In 2005, we recorded an impairment charge of $1.1 billion in Other
(income)/deductions—net related to the developed technology
rights for Bextra, a selective COX-2 inhibitor (included in our
Human Health segment) in connection with the decision to
suspend sales and marketing of Bextra. This decision resulted
from an April 7, 2005 request from the FDA, as part of its safety
review of all selective COX-2 medicines. In addition, in connection
with the suspension, we also recorded $5 million related to the
write-off of machinery and equipment included in Other
(income)/deductions—net, $73 million in write-offs of inventory
and exit costs, included in Cost of sales; $8 million related to the
costs of administering the suspension of sales, included in Selling,
informational and administrative expenses; and $212 million for
an estimate of customer returns, primarily included against
Revenues.
In 2004, we recorded an impairment charge of $691 million in
Other (income)/deductions—net related to the Depo-Provera
brand (included in our Human Health segment), a contraceptive
injection, due to the unexpected entrance of a generic competitor
in the U.S. market and an adverse labeling change. In addition,
the asset was reclassified as a finite-lived intangible asset.
The annual amortization expense expected for the years 2006
through 2010 is as follows:
(MILLIONS OF DOLLARS) 2006 2007 2008 2009 2010
Amortization expense $3,343 $3,299 $2,646 $2,371 $2,363
13. Benefit Plans
We provide defined benefit pension plans and defined
contribution plans for the majority of our employees worldwide.
In the U.S., we have both qualified and supplemental (non-
qualified) defined benefit plans. A qualified plan meets the
requirements of certain sections of the Internal Revenue Code and,
generally, contributions to qualified plans are tax deductible. A
qualified plan typically provides benefits to a broad group of
employees and may not discriminate in favor of highly
compensated employees in its coverage, benefits or contributions.
We also provide benefits through supplemental (non-qualified)
retirement plans to certain employees. In addition, we provide
medical and life insurance benefits to retirees and their eligible
dependents through our postretirement plans.
We use a measurement date of December 31 for a majority of our
U.S. pension and postretirement plans and November 30 for a
majority of our international plans. In December 2003, the
Medicare Prescription Drug Improvement and Modernization
Act of 2003 (the Act) was enacted. The Act introduced a
prescription drug benefit under Medicare (Medicare Part D) as well
as a federal subsidy to sponsors of retiree healthcare benefit
plans that provide a benefit that is at least actuarially equivalent
to Medicare Part D. During the third quarter of 2004, in accordance
with FASB Staff Position No.106-2 (FSP 106-2), Accounting and
Disclosure Requirements Related to the Medicare Prescription
Drug Improvement and Modernization Act of 2003, the Company
began accounting for the effect of the federal subsidy under
the Act; the associated reduction to the benefit obligations of
certain of our postretirement benefit plans and the related
benefit cost was not significant.
A. Acquisitions and Divestitures
We acquired certain pension and postretirement plans from
Pharmacia on April 16, 2003. The related obligations and plan
assets acquired at fair value included global pension benefit
obligations of $3.7 billion and pension plan assets of $1.9 billion
and other postretirement benefit obligations of $966 million
and postretirement plan assets of $172 million.
During 2003, pursuant to the divestitures of the Adams, Schick-
Wilkinson Sword and Tetra businesses, pension plan assets and
accumulated benefit obligations were transferred to the
purchasers of those businesses.
B. Components of Net Periodic Benefit Costs
The annual cost of the U.S. qualified and international pension plans and the postretirement plans for the years ended December 31,
2005, 2004 and 2003, follow:
PENSION PLANS
U.S. QUALIFIED INTERNATIONAL POSTRETIREMENT PLANS
(MILLIONS OF DOLLARS) 2005 2004 2003 2005 2004 2003 2005 2004 2003
Service cost $ 318 $ 277 $ 229 $ 293 $ 264 $ 212 $ 38 $ 39 $ 31
Interest cost 410 391 354 309 288 224 113 113 101
Expected return on plan assets (594) (569) (384) (297) (278) (213) (23) (20) (11)
Amortization of:
Prior service costs/(gains) 10 17 17 (2) 5 7 1 1 14
Net transition obligation — — — 1 1 1 — — —
Actuarial losses 101 99 115 95 59 43 21 15 20
Curtailments and settlements—net 12 37 6 19 (9) 13 — — 1
Special termination benefits 5 — — 29 21 — 2 (1) —
Net periodic benefit costs $ 262 $ 252 $ 337 $ 447 $ 351 $ 287 $152 $147(a) $156
(a) Includes a credit of $21 million relating to the adoption of FSP 106-2 in 2004.
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The increase in the 2005 international pension plans’ net periodic
benefit cost was largely driven by changes in assumptions used,
such as the decline in the discount rate and the expected return
on plan assets. The increase in the 2004 international pension
plans’ net periodic cost reflects the decline of the discount rate
assumption.
The decline in the 2004 U.S. qualified pension plans’ net periodic
benefit cost was largely driven by higher expected returns on plan
assets due to the 2003 voluntary tax-deductible contributions of
$1.4 billion and by higher than assumed 2003 investment returns,
partially offset by the decline in the discount rate assumed.
The net periodic benefit cost for the U.S. supplemental (non-
qualified) pension plans was $140 million in 2005, $131 million in
2004 and $127 million in 2003.
C. Actuarial Assumptions
The following table provides the weighted-average actuarial
assumptions:
(PERCENTAGES) 2005 2004 2003
Weighted-average assumptions used 
to determine benefit obligations:
Discount rate:
U.S. qualified pension plans 5.8% 6.0% 6.3%
U.S. non-qualified pension plans 5.8 6.0 6.3
International pension plans 4.3 4.7 5.0
Postretirement plans 5.8 6.0 6.3
Rate of compensation increase:
U.S. qualified pension plans 4.5 4.5 4.5
U.S. non-qualified pension plans 4.5 4.5 4.5
International pension plans 3.6 3.6 3.6
Weighted-average assumptions used 
to determine net benefit cost(a) :
Discount rate:
U.S. qualified pension plans 6.0 6.3 6.8
U.S. non-qualified pension plans 6.0 6.3 6.7
International pension plans 4.7 5.0 5.2
Postretirement plans 6.0 6.3 6.6
Expected return on plan assets:
U.S. qualified pension plans 9.0 9.0 9.0
International pension plans 6.9 7.3 7.0
Postretirement plans 9.0 9.0 9.0
Rate of compensation increase:
U.S. qualified pension plans 4.5 4.5 4.5
U.S. non-qualified pension plans 4.5 4.5 4.5
International pension plans 3.6 3.6 3.6
(a) The 2003 net benefit cost assumptions for legacy Pharmacia plans
were as of April 16, 2003.
The assumptions above are used to develop the benefit obligations
at fiscal year-end and to develop the net periodic benefit cost for
the subsequent fiscal year. Therefore, the assumptions used to
determine net periodic benefit cost for each year are established
at the end of each previous year, while the assumptions used to
determine benefit obligations were established at each year-end.
The net periodic benefit cost and the benefit obligations are
based on actuarial assumptions that are reviewed on an annual
basis. We revise these assumptions based on an annual evaluation
of long-term trends, as well as market conditions, that may have
an impact on the cost of providing retirement benefits.
The expected rate of return on plan assets for our U.S. qualified,
international and postretirement plans represents our long-term
assessment of return expectations, which we will change based
on significant shifts in economic and financial market conditions.
The 2005 expected rates of return for these plans reflect our
long-term outlook for a globally diversified portfolio which is
influenced by a combination of return expectations for individual
asset classes, actual historical experience and our diversified
investment strategy. The historical returns are one of the inputs
used to provide context for the development of our expectations
for future returns. Using this information, we develop ranges of
returns for each asset class and a weighted-average expected
return for our targeted portfolio, which includes the impact of
portfolio diversification and actively managed strategies.
The healthcare cost trend rate assumptions for our U.S.
postretirement benefit plans are as follows:
2005 2004
Healthcare cost trend rate assumed 
for next year 9.8% 10.0%
Rate to which the cost trend rate is 
assumed to decline 5.0 5.0
Year that the rate reaches the ultimate 
trend rate 2013 2012
A one-percentage-point increase or decrease in the healthcare cost
trend rate assumed for postretirement benefits would have the
following effects as of December 31, 2005:
(MILLIONS OF DOLLARS) INCREASE DECREASE
Effect on total service and interest 
cost components $ 17 $ (14)
Effect on postretirement benefit obligation 220 (187)
The decline in the 2005 U.S. qualified pension plans projected
benefit obligations (PBO) funded status was primarily the result
of the 0.2 percentage-point decline in the discount rate and the
adoption of updated mortality assumptions.
The unrecognized actuarial losses primarily represent the
cumulative difference between the actuarial assumptions and
actual return on plan assets, changes in discount rates and plan
experience. These actuarial losses are largely deferred and a
portion of this loss is currently being amortized for all U.S. and
international plans’ net periodic benefit cost over an average
period of 14 years. The 2005 increase in the unrecognized actuarial
losses in the U.S. qualified pension plans and the postretirement
plans was driven by the 0.2 percentage-point decline in the
discount rate, the adoption of updated mortality assumptions and
plan experience.
The U.S. supplemental (non-qualified) pension plans are not
generally funded as no tax or other incentives exist and these
obligations are paid from cash generated from operations, which
is substantially greater than the annual cash outlay for these
liabilities. Company contributions to U.S. supplemental (non-
qualified) pension plans amounted to $135 million in 2005 and
$141 million in 2004, which were used for settlement and benefit
payments. The PBO for the U.S. supplemental (non-qualified)
pension plans were $1.1 billion in both 2005 and 2004. The net
liability for U.S. supplemental (non-qualified) pension plans was
$393 million in 2005 and $385 million in 2004. The unrecognized
actuarial losses in the U.S. supplemental (non-qualified) pension
plans amounted to $775 million in 2005 and $666 million in 2004.
For U.S. supplemental (non-qualified) pension plans the
unrecognized actuarial losses represent the cumulative difference
between actuarial assumptions and actual results primarily related
to changes in discount rates and plan experience.
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D. Obligations and Funded Status
The following table presents an analysis of the changes in 2005 and 2004 in the benefit obligations, the plan assets and the funded
status of our U.S. qualified and international pension plans and our postretirement plans:
PENSION PLANS
U.S. QUALIFIED INTERNATIONAL POSTRETIREMENT
(MILLIONS OF DOLLARS) 2005 2004 2005 2004 2005 2004
Change in benefit obligation:
Benefit obligation at beginning of year(a) $7,108 $6,492 $ 6,969 $ 5,681 $ 1,920 $ 2,053
Service cost 318 277 293 264 38 39
Interest cost 410 391 309 288 113 113
Employee contributions — — 23 22 28 22
Plan amendments (82) — 15 (80) 5 —
Increases/(decreases) arising primarily from changes in 
actuarial assumptions 671 490 459 488 332 (136)
Foreign exchange impact — — (793) 621 — 1
Acquisitions — — 18 23 — 1
Divestitures — — — (36) — —
Curtailments — — (3) (19) — —
Settlements (33) (27) (56) (35) — —
Special termination benefits 5 — 29 21 2 —
Benefits paid (414) (515) (295) (269) (186) (173)
Benefit obligation at end of year(a) $7,983 $7,108 $ 6,968 $ 6,969 $ 2,252 $ 1,920(b)
Change in plan assets:
Fair value of plan assets at beginning of year $6,820 $6,593 $ 4,277 $3,410 $ 253 $ 225
Actual gain on plan assets 625 688 687 339 23 28
Company contributions 52 81 439 428 158 152
Employee contributions — — 23 22 28 22
Foreign exchange impact — — (490) 384 (1) (1)
Acquisitions — — 10 8 — —
Divestitures — — — (10) — —
Settlements (33) (27) (56) (35) — —
Benefits paid (414) (515) (295) (269) (186) (173)
Fair value of plan assets at end of year $7,050 $6,820 $ 4,595 $ 4,277 $ 275 $ 253
Funded status (plan assets less than benefit obligation) $ (933) $ (288) $(2,373) $(2,692) $(1,977) $(1,667)
Unrecognized:
Net transition obligation — — 3 4 2 2
Actuarial losses 2,364 1,837 1,715 1,958 525 212
Prior service costs/(benefits) 54 146 (6) (30) 7 3
Net asset/(liability) recorded in consolidated balance sheet $1,485 $1,695 $ (661) $ (760) $(1,443) $(1,450)
(a) For the U.S. and international pension plans, the benefit obligation is the projected benefit obligation. For the postretirement plans, the
benefit obligation is the accumulated projected benefit obligation.
(b) Includes a credit of $157 million relating to the adoption of FSP 106-2 in 2004.
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The components of the net asset/(liability) recorded in the
consolidated balance sheet as of December 31 follow:
PENSION PLANS
U.S. QUALIFIED INTERNATIONAL POSTRETIREMENT
(MILLIONS OF DOLLARS) 2005 2004 2005 2004 2005 2004
Prepaid benefit 
cost(a) $1,625 $1,858 $ 532 $ 624 $ — $ —
Accrued benefit 
liability(b) (140) (163) (1,734) (1,967) (1,443) (1,450)
Intangible asset(c) — — 21 21 — —
Accumulated 
other compre-





balance sheet $1,485 $1,695 $ (661)$ (760) $(1,443)$(1,450)
(a) Included in Other assets, deferred taxes and deferred charges.
(b) Included in Pension benefit obligations and Postretirement
benefit obligations, as appropriate.
(c) Included in Identifiable intangible assets, less accumulated
amortization.
The accrued benefit liability for U.S. supplemental (non-qualified)
pension plans was $843 million in 2005 and $812 million in 2004.
The accumulated other comprehensive income related to U.S.
supplemental (non-qualified) pension plans was $450 million in 2005
and $405 million in 2004. There was no identifiable intangible
asset related to U.S. supplemental (non-qualified) pension plans in
2005. The identifiable intangible asset related to U.S. supplemental
(non-qualified) pension plans was $22 million in 2004.
The accumulated benefit obligations (ABO) for our U.S. qualified
pension plans was $6.4 billion in 2005 and $5.8 billion in 2004. The
ABO for our U.S. supplemental (non-qualified) pension plans was
$843 million in 2005 and $812 million in 2004. The ABO for our
international pension plans was $6.0 billion in both 2005 and 2004.
The 2005 increase in the U.S. qualified pension plans’ ABO was
primarily driven by the 0.2 percentage-point decline in the discount
rate, and in the adoption of updated mortality assumptions.
Information related to both U.S. qualified and international
pension plans as of December 31 follows:
U.S. INTERNATIONAL
QUALIFIED PLANS PLANS
(MILLIONS OF DOLLARS) 2005 2004 2005 2004
Pension plans with an 
accumulated benefit 
obligation in excess 
of plan assets:
Fair value of plan assets $ 387 $ 344 $1,849 $1,699
Accumulated benefit 
obligation 458 445 3,494 3,553
Pension plans with a 
projected benefit 
obligation in excess 
of plan assets:
Fair value of plan assets 4,249 4,151 4,355 4,045
Projected benefit obligation 5,376 4,625 6,738 6,741
In the aggregate, our U.S. qualified pension plans had assets greater
than their ABO and less than their PBO at December 31, 2005. U.S.
supplemental (non-qualified) pension plans with PBOs in excess of
plan assets had PBO balances of $1.1 billion in both 2005 and 2004.
E. Plan Assets
The following table presents the weighted-average long-term
target asset allocations and the percentages of the fair value of
plan assets for our U.S. qualified pension and postretirement




(PERCENTAGES) 2005 2005 2004
U.S. qualified pension plans:
Global equity securities 65.0 66.8 69.0
Debt securities 25.0 23.9 23.1
Alternative investments(a) 10.0 8.9 7.3
Cash — 0.4 0.6
Total 100.0 100.0 100.0
International pension plans:
Global equity securities 63.8 63.9 61.9
Debt securities 28.0 26.0 28.4
Alternative investments(b) 7.9 8.8 8.4
Cash 0.3 1.3 1.3
Total 100.0 100.0 100.0
U.S. postretirement plans(c):
Global equity securities 75.0 75.4 73.8
Debt securities 25.0 24.6 26.2
Total 100.0 100.0 100.0
(a) Private equity, venture capital, private debt and real estate.
(b) Real estate, insurance contracts and other investments.
(c) Reflects postretirement plan assets which support a portion of our
U.S. retiree medical plans.
All long-term asset allocation targets reflect our asset class return
expectations and tolerance for investment risk within the context
of the respective plans’ long-term benefit obligations. The long-
term asset allocation is supported by an analysis that incorporates
historical and expected returns by asset class, as well as volatilities
and correlations across asset classes and our liability profile. This
analysis, referred to as an asset-liability analysis, also provides an
estimate of expected returns on plan assets, as well as a forecast
of potential future asset and liability balances. Due to market
conditions and other factors, actual asset allocations may vary from
the target allocation outlined above. For the U.S. qualified pension
plans, the year-end 2005 alternative investments allocation of
8.9% was below the target allocation primarily due to the timing
of our contributions to the U.S. qualified plans and the cash
allocation of 0.4% was above the target allocation due to the need
to fund certain expected benefit payments. The assets are
periodically rebalanced back to the target allocation.
The U.S. qualified pension plans held approximately 10.3 million
shares (fair value of approximately $240 million representing
3.5% of U.S. plan assets) at December 31, 2005 and approximately
10.3 million shares (fair value of approximately $277 million
representing 4.0% of U.S. plan assets) at December 31, 2004 of
our common stock. The plans received approximately $8 million
in dividends on these shares in 2005 and approximately $7 million
in dividends on these shares in 2004.
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F. Cash Flows
It is our practice to fund amounts for our qualified pension plans
at least sufficient to meet the minimum requirements set forth
in applicable employee benefit laws and local tax laws. Liabilities
for amounts in excess of these funding levels are included in our
consolidated balance sheet, to the extent required by GAAP.
The following table presents expected cash flow information:
FOR THE YEAR ENDED POST-
DECEMBER 31 U.S. QUALIFIED INTERNATIONAL RETIREMENT
(MILLIONS OF DOLLARS) PENSION PLANS PENSION PLANS BENEFITS
Employer Contributions:
2006 (estimated) $ 3 $ 339 $150
Expected Benefit Payments:
2006 $ 321 $ 260 $150
2007 342 271 152
2008 361 286 153
2009 394 303 155
2010 422 310 155
2011—2015 2,717 1,827 769
Employer contributions for U.S. supplemental (non-qualified)
pension plans for 2006 are estimated to be $69 million with
expected benefit payments for 2006 through 2010 estimated to
be $69 million, $74 million, $81 million, $63 million and $68
million, respectively, and for 2011 through 2015 totaling $398
million.
The table reflects the total U.S. plan benefits projected to be paid
from the plans or from the Company’s general assets under the
current actuarial assumptions used for the calculation of the
projected benefit obligation and therefore, actual benefit
payments may differ from projected benefit payments. Under the
provisions of the Medicare Prescription Drug Improvement and
Modernization Act of 2003, the expected benefit payments for our
U.S. postretirement plans were reduced by $156 million through
2015.
G. Defined Contribution Plans
We have savings and investment plans in several countries
including the U.S., Puerto Rico and Japan. For the U.S. and Puerto
Rico plans, employees may contribute a portion of their salaries
and bonuses to the plans, and we match, largely in company
stock, a portion of the employee contributions. Employees are
permitted to diversify a portion of the company stock match
contribution, subject to certain plan limits. The contribution
match for certain legacy Pfizer U.S. participants are held in an
employee stock ownership plan. We recorded charges related to
our plans of $234 million in 2005, $313 million in 2004 and $180
million in 2003.
14. Equity and Stock Plans
A. Common Stock
We purchase our common stock via privately negotiated
transactions or in open market purchases as circumstances and
prices warrant. Purchased shares under each of the share-purchase
programs, which are authorized by our Board of Directors, are
available for general corporate purposes.
A summary of common stock purchases follows:
FOR THE YEAR ENDED DECEMBER 31, SHARES OF AVERAGE TOTAL COST OF
(MILLIONS OF SHARES AND COMMON STOCK PER-SHARE COMMON STOCK
DOLLARS EXCEPT PER SHARE DATA) PURCHASED PRICE PAID PURCHASED
2005:
June 2005 program(a) 22 $22.38 $ 493
October 2004 program(b) 122 $27.20 3,304
Total 144 $ 3,797
2004:
October 2004 program(b) 63 $26.79 $ 1,696
December 2003 program(c) 145 $34.14 4,963
Total 208 $ 6,659
2003:
December 2003 program(c) 1 $34.57 $ 37
July 2002 program(d) 406 $31.99 13,000
Total 407 $13,037
(a) In June 2005, we announced a new $5 billion share-purchase
program.
(b) In October 2004, we announced a $5 billion share-purchase
program, which we completed in June 2005.
(c) In December 2003, we announced a $5 billion share-purchase
program, which we completed in October 2004.
(d) In July 2002, we announced a $16 billion share-purchase program,
which we completed in November 2003.
B. Preferred Stock
In connection with our acquisition of Pharmacia in 2003, we issued
a newly created class of Series A convertible perpetual preferred
stock (7,500 shares designated) in exchange for and with rights
substantially similar to Pharmacia’s Series C convertible perpetual
preferred stock. The Series A convertible perpetual preferred stock
is held by an Employee Stock Ownership Plan (“Preferred ESOP”)
Trust and provides dividends at the rate of 6.25% which are
accumulated and paid quarterly. The per-share stated value is
$40,300 and the preferred stock ranks senior to our common stock
as to dividends and liquidation rights. Each share is convertible, at
the holder’s option, into 2,574.87 shares of our common stock
with equal voting rights. The conversion option is indexed to our
common stock and requires share settlement, and therefore, is
reported at the fair value at the date of issuance. The Company may
redeem the preferred stock, at any time or upon termination of the
Preferred ESOP, at its option, in cash, in shares of common stock or
a combination of both at a price of $40,300 per share.
C. Employee Stock Ownership Plans
In connection with our acquisition of Pharmacia, we assumed two
employee stock ownership plans (collectively the “ESOPs”), a
Preferred ESOP and another that held Pharmacia common stock
that upon acquisition was exchanged for the common stock of the
Company (“Common ESOP”). A portion of the matching
contributions for legacy Pharmacia U.S. savings plan participants
is funded through the ESOPs.
Legacy Pharmacia guaranteed a note relating to the ESOPs for the
original principal amount of $80 million (8.13%). This guarantee
continued after Pfizer’s acquisition of Pharmacia. At December 31,
2005, the balance of the note was $2 million, which was classified
as current. Compensation expense related to the ESOPs totaled
approximately $42 million in 2005 and $45 million in 2004. The
Preferred ESOP has access to up to $95 million in financing at the
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rate of 7.00% per annum, of which $22 million was utilized prior
to our acquisition of Pharmacia and remains outstanding as of
December 31, 2005.
Allocated shares held by the Common ESOP are considered
outstanding for the earnings per share (EPS) calculations and
the eventual conversion of allocated preferred shares held by the
Preferred ESOP is assumed in the diluted EPS calculation. At
December 31, 2005, the Preferred ESOP held preferred shares
convertible into approximately 11 million shares of our common
stock and the Common ESOP held approximately 26 thousand
shares. The value of the shares held in the Preferred ESOP at
December 31, 2005 was approximately $169 million.
D. Employee Benefit Trust
The Pfizer Inc Employee Benefit Trust (EBT) was established in 1999
to fund our employee benefit plans through the use of its holdings
of Pfizer Inc stock. The consolidated balance sheets reflect the fair
value of the shares owned by the EBT as a reduction of
Shareholders’ equity.
E. Share-Based Payments
The Company’s shareholders approved the Pfizer Inc. 2004 Stock
Plan (the 2004 Plan) at the Annual Meeting of Shareholders held
on April 22, 2004 and, effective upon that approval, new stock
option and other share-based awards may be granted only under
the 2004 Plan. The 2004 Plan allows a maximum of 3 million shares
to be awarded to any employee per year and 475 million shares in
total. Whole share awards count as three shares and stock options
count as one share under the 2004 Plan toward the maximums. 
In the past, we had various employee stock and incentive plans
under which stock options and other share-based awards were
granted. Stock options and other share-based awards that were
granted under the prior plans and were outstanding on April 22,
2004 continue in accordance with the terms of the respective
plans.
The following shares (in thousands) were available for award as
of:
• December 31, 2005 402,540*
• December 31, 2004 487,993*
• December 31, 2003 152,173*
* Includes 16,610 shares in 2005, 13,139 shares in 2004 and 20,827 shares
in 2003 available for award under the legacy Pharmacia Long-Term
Incentive Plan, which reflects award cancellations returned to the pool
of available shares for legacy Pharmacia commitments.
We may grant stock options to employees, including officers.
Options are exercisable after five years or less, subject to
continuous employment and certain other conditions, and
generally expire 10 years after the grant date. Once options are
exercisable, the employee can purchase shares of our common
stock at the market price on the date we granted the option.
Former Pharmacia and Warner-Lambert plans provided that, in the
event of a change in control, stock options already granted
became immediately exercisable.
The table below summarizes information concerning options
outstanding under the plans as of December 31, 2005:
____________________________________________________________________________________________________________________
(THOUSANDS OF SHARES)___________________________________________________________________________ ___________________________________




RANGE OF NUMBER REMAINING PRICE NUMBER PRICE
EXERCISE OUTSTANDING CONTRACTUAL (TOTAL EXERCISABLE (EXERCISABLE
PRICES AT 12/31/05 TERM (YEARS) OPTIONS) AT 12/31/05 OPTIONS)
$ 0 – $19.99 51,339 1.2 $15.38 51,339 $15.38
20 – 29.99 171,953 6.8 27.47 63,372 26.70
30 – 34.99 101,788 4.6 32.67 85,656 32.96
35 – 39.99 126,401 6.3 36.59 44,615 35.57
40 – 41.99 59,897 6.2 41.30 56,069 41.30
42 – 44.99 53,475 3.3 42.07 53,460 42.07
over 45 62,551 5.1 45.40 60,539 45.40
Total 627,404 415,050




(THOUSANDS OF SHARES) SHARES PER SHARE
Balance, January 1, 2003 431,981 $31.45












Balance, December 31, 2005 627,404 $33.51
The decline in the number of options granted in 2005 reflects a
change in the compensation strategy of the Company.
The tax benefits related to certain stock option transactions were
$137 million in 2005, $261 million in 2004, and $238 million in 2003.
The weighted average fair value per stock option granted was $5.15
for 2005, $6.88 for 2004 and $7.35 for 2003. We estimated the fair
values using the Black-Scholes-Merton option pricing model and
using the assumptions below. In the first quarter of 2005, we
changed our method of estimating expected dividend yield from
historical patterns of dividend payments to a method that reflects
a constant dividend yield during the expected term of the option.
In the first quarter of 2004, we changed our method of estimating
expected stock price volatility to reflect market-based inputs under
emerging stock option valuation considerations.
2005 2004 2003
Expected dividend yield 2.90% 2.90% 3.15%
Risk-free interest rate 3.96% 3.32% 2.75%
Expected stock price volatility 21.93% 22.15% 33.05%
Expected term until exercise (years) 5.75 5.75 5.58
We may grant restricted stock units (RSUs) to employees. RSUs
entitle the holders to receive shares of Pfizer stock at the end of
a vesting period, which include dividend equivalents paid on
such units. RSUs generally vest in equal portions each year over
a five-year period. The total number of RSUs granted in 2005 was
11 million shares with a weighted average fair value of $26.20.
We may grant performance-contingent share awards to
employees. The 2004 Plan limitations on the maximum amount of
share-based awards apply to all awards including performance-
contingent share awards. In 2001, our shareholders approved the
2001 Performance-Contingent Share Award Plan (the 2001 Plan),
allowing a maximum of 12.5 million shares to be awarded to all
participants. This maximum was applied to awards for performance
periods beginning after January 1, 2002 through 2004. Awards
prior to that date were made under the Performance-Contingent
Award Program (the 1993 Program), allowing a maximum of 120
million shares. The 2004 Plan is the only plan under which any stock
award may be given in the future.
Performance-contingent share awards vest and are paid based on
a non-discretionary formula, which measures our performance
using relative total shareholder return and relative growth in
diluted EPS, over a performance period relative to an industry peer
group. If our minimum performance in both measures is below
the threshold level relative to the peer group, then no
performance-contingent awards will be paid.
The performance period for the 1993 Program and the 2001 Plan
typically covers five years; however, in certain limited circumstances
two, three and four year performance periods were permitted.
The performance period for the 2004 Plan typically covers five
years; however, for new entrants into the program on January 1,
2005, three and four year performance periods were established.
At December 31, 2005, a summary of the performance-contingent





AWARDED SHARES INOUTSTANDING DEC. 31,
(MILLIONS OF SHARES) AWARDS 2005 2005 2004 2003
The 2004 Plan 2.6 — — — —
The 2001 Plan 11.0 0.2 0.1 — —
The 1993 Program* 1.8 12.2 1.4 0.6 1.4
* Includes some awards granted under the prior Stock and Incentive
Plan.
Compensation expense relating to the performance-contingent
share awards totaled approximately $37 million in 2005, $42
million in 2004 and $41 million in 2003.
We entered into forward-purchase contracts that partially offset
the potential impact on net income of our liability under the 1993
Program, the 2001 Plan and the 2004 Plan. At settlement date we
will, at the option of the counterparty to each of the contracts,
either receive our own stock or settle the contracts for cash. At
December 31, 2005 and 2004, forward-purchase contracts for 3.0
million shares at $33.84 per share were outstanding and had a
maximum maturity of 0.4 years.
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The financial statements include the following items related to
these contracts:
Prepaid expenses and taxes includes:
• fair value of these contracts
Other (income)/deductions—net includes:
• changes in the fair value of these contracts
Other share-based awards include restricted (unvested) stock,
which include dividend equivalents paid on such stock. Such
awards were not significant.
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15. Earnings Per Common Share
Basic and diluted earnings per common share were computed
using the following common share data:
YEAR ENDED DEC. 31,
(MILLIONS) 2005 2004 2003
EPS Numerator—Basic:
Income from continuing operations 
before cumulative effect of a change 
in accounting principles $8,094 $11,332 $1,629
Less: Preferred stock dividends—net of tax 6 4 4
Income available to common share-
holders from continuing operations 
before cumulative effect of a change 
in accounting principles 8,088 11,328 1,625
Discontinued operations:
(Loss)/income from discontinued 
operations—net of tax (31) (22) 26
Gains on sales of discontinued 
operations—net of tax 47 51 2,285
Discontinued operations—net of tax 16 29 2,311
Income available to common share-
holders before cumulative effect of 
a change in accounting principles 8,104 11,357 3,936
Cumulative effect of a change in 
accounting principles—net of tax (25) — (30)
Net income available to common 
shareholders $8,079 $11,357 $3,906
EPS Denominator—Basic:
Weighted average number of 
common shares outstanding 7,361 7,531 7,213
EPS Numerator—Diluted:
Income from continuing operations 
before cumulative effect of a change 
in accounting principles $8,094 $11,332 $1,629
Less: ESOP contribution—net of tax 5 5 3
Income available to common share-
holders from continuing operations 
before cumulative effect of a change 
in accounting principles 8,089 11,327 1,626
Discontinued operations:
Income/(loss) from discontinued 
operations—net of tax (31) (22) 26
Gains on sales of discontinued 
operations—net of tax 47 51 2,285
Discontinued operations—net of tax 16 29 2,311
Income available to common share-
holders before cumulative effect of 
a change in accounting principles 8,105 11,356 3,937
Cumulative effect of a change in 
accounting principles—net of tax (25) — (30)
Net income available to common 
shareholders $8,080 $11,356 $3,907
EPS Denominator—Diluted:
Weighted-average number of 
common shares outstanding 7,361 7,531 7,213
Common share equivalents—stock 
options, stock issuable under 
employee compensation plans and 
convertible preferred stock 50 83 73
Weighted-average number of 
common shares outstanding 
and common share equivalents 7,411 7,614 7,286
Stock options and stock issuable under employee compensation
plans representing equivalents of 557 million shares of common
stock during 2005, 359 million shares of common stock during 2004
and 331 million shares of common stock during 2003 had exercise
prices greater than the annual average market price of Pfizer
common stock. These common stock equivalents were outstanding
during 2005, 2004 and 2003, but were not included in the
computation of diluted earnings per common share for those years
because their inclusion would have had an anti-dilutive effect.
16. Lease Commitments
We lease properties and equipment for use in our operations. In
addition to rent, the leases may require us to pay directly for taxes,
insurance, maintenance and other operating expenses, or to pay
higher rent when operating expenses increase. Rental expense,
net of sublease income, was $449 million in 2005, $452 million in
2004 and $487 million in 2003. This table shows future minimum
rental commitments under noncancellable operating leases at
December 31 for the following years:
AFTER
(MILLIONS OF DOLLARS) 2006 2007 2008 2009 2010 2010
Lease commitments $231 $217 $181 $141 $103 $376
17. Insurance
Our insurance coverage reflects market conditions (including cost
and availability) existing at the time it is written, and our decision
to obtain insurance coverage or to self-insure varies accordingly.
The cost of insurance has risen substantially and the availability of
insurance has become more restrictive. Thus, depending upon
the cost of insurance and the nature of the risk involved, the
amount of self-insurance may be significant. We consider the
impact of these changes as we assess our future insurance needs.
If we incur substantial liabilities that are not covered by insurance
or substantially exceed insurance coverage and that are in excess
of existing accruals, there could be a material adverse effect on our
results of operations in any particular period (see Note 18, Legal
Proceedings and Contingencies).
18. Legal Proceedings and Contingencies
We and certain of our subsidiaries are involved in various patent,
product liability, consumer, commercial, securities, environmental
and tax litigations and claims; government investigations; and
other legal proceedings that arise from time to time in the
ordinary course of our business. We do not believe any of them
will have a material adverse effect on our financial position.
We record accruals for such contingencies to the extent that we
conclude their occurrence is probable and the related damages are
estimable. If a range of liability is probable and estimable and some
amount within the range appears to be a better estimate than any
other amount within the range, we accrue that amount. If a
range of liability is probable and estimable and no amount within
the range appears to be a better estimate than any other amount
within the range, we accrue the minimum of such probable range.
Many claims involve highly complex issues relating to causation,
label warnings, scientific evidence, actual damages and other
matters. Often these issues are subject to substantial uncertainties
and, therefore, the probability of loss and an estimation of
damages are difficult to ascertain. Consequently, we cannot
reasonably estimate the maximum potential exposure or the
range of possible loss in excess of amounts accrued for these
contingencies. These assessments can involve a series of complex
judgments about future events and can rely heavily on estimates
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and assumptions (see Note 1B, Significant Accounting Policies:
Estimates and Assumptions). Our assessments are based on
estimates and assumptions that have been deemed reasonable by
management. Litigation is inherently unpredictable, and excessive
verdicts do occur. Although we believe we have substantial
defenses in these matters, we could in the future incur judgments
or enter into settlements of claims that could have a material
adverse effect on our results of operations in any particular period.
Patent claims include challenges to the coverage and/or validity
of our patents on various products or processes. Although we
believe we have substantial defenses to these challenges with
respect to all our material patents, there can be no assurance as
to the outcome of these matters, and a loss in any of these cases
could result in a loss of patent protection for the drug at issue,
which could lead to a significant loss of sales of that drug and
could materially affect future results of operations.
Among the principal matters pending to which we are a party are
the following:
A. Patent Matters
We are involved in a number of patent suits, the majority of which
involve claims by generic drug manufacturers that patents covering
our products, processes or dosage forms are invalid and/or do not
cover the product of the generic manufacturer. Pending suits include
generic challenges to patents covering, among other products,
amlodipine (Norvasc), atorvastatin (Lipitor), tolterodine (Detrol)
and celecoxib (Celebrex). Also, counterclaims as well as various
independent actions have been filed claiming that our assertions
of, or attempts to enforce, our patent rights with respect to certain
products constitute unfair competition and/or violations of the
antitrust laws. In addition to the challenges to the U.S. patents on
a number of our products that are discussed below, we note that
the patent rights to certain of our products, including without
limitation Lipitor, are being challenged in various other countries.
Norvasc (amlodipine)
Between 2002 and 2005, we brought patent infringement suits in
various federal courts against several manufacturers that have
filed abbreviated new drug applications with the FDA seeking to
market a generic version of amlodipine besylate, which is the salt
form contained in Norvasc. Our patent for amlodipine besylate is
being challenged in all of the suits, and our basic patent for
amlodipine also is being challenged in certain of the suits. In the
first of these actions to go to trial, which involved only our
amlodipine besylate patent, in January 2006 the U.S. District Court
for the Northern District of Illinois held that our amlodipine besylate
patent is valid and infringed by the generic manufacturer Apotex
Inc.’s product. The court issued an injunction prohibiting Apotex
from marketing its generic amlodipine besylate product before the
expiration of our amlodipine besylate patent (including the
additional six-month pediatric exclusivity period) in September
2007. The decision is subject to possible appeal. The cases against
other manufacturers are expected to go to trial later this year.
Lipitor (atorvastatin)
The generic manufacturer Ranbaxy Laboratories Limited filed an
abbreviated new drug application with the FDA for atorvastatin
(Lipitor) in 2002 and amended the application in 2003 to allege
that its product would not infringe our basic product patent for
atorvastatin. Shortly thereafter, Ranbaxy also asserted that our
patent covering the active enantiomeric form of the drug is
invalid. Our basic patent for Lipitor, including the additional six-
month pediatric exclusivity period, expires in March 2010. Our
enantiomer patent, including the six-month pediatric exclusivity
period, expires in June 2011.
In 2003, we filed suits in the U.S. District Court for the District of
Delaware against Ranbaxy for infringement of both our basic
product patent and our patent covering the active enantiomeric form
of the drug. The trial of this matter was held in late 2004. In late 2005,
the court held that both patents are valid and infringed by Ranbaxy’s
generic atorvastastin product, and it issued an injunction prohibiting
Ranbaxy from marketing a generic version of atorvastatin before
June 2011. Ranbaxy appealed the decision in January 2006, and the
appeal is scheduled to be heard in May 2006.
As noted, our patent rights to Lipitor are being challenged in
various countries. On October 12, 2005, in an action brought by
Ranbaxy, the United Kingdom’s High Court of Justice upheld our
basic U.K. patent for Lipitor, which expires in November 2011, but
ruled that a second patent covering the calcium salt of
atorvastatin, which expires in July 2010, is invalid. Both sides
have appealed the decision, and the appeal is scheduled to be
heard in June 2006. If upheld on appeal, the decision will prohibit
Ranbaxy from marketing a generic version of atorvastatin in the
U.K. before the expiration of our basic patent in November 2011.
Detrol (tolterodine)
In February 2004, a generic manufacturer notified us that it had
filed an abbreviated new drug application with the FDA seeking
approval to market tolterodine (Detrol). We filed a patent
infringement suit against the generic manufacturer in the U.S.
District Court for the District of New Jersey in March 2004.
Celebrex (celecoxib)
In January 2004, a generic manufacturer notified us that it had
filed an abbreviated new drug application with the FDA seeking
approval to market a product containing celecoxib and asserting
the non-infringement and invalidity of our patents relating to
celecoxib. In February 2004, we filed suit against the generic
manufacturer in the U.S. District Court for the District of New
Jersey asserting infringement of our patents relating to celecoxib.
B. Product Liability Matters
Rezulin
Rezulin was a medication that treated insulin resistance and was
effective for many patients whose diabetes had not been
controlled with other medications. Rezulin was voluntarily
withdrawn by Warner-Lambert in March 2000 following approval
of two newer medications, which the FDA considered to have
similar efficacy and fewer side effects.
In 2003, we took a charge to earnings of $975 million, before tax
($955 million, after tax), in connection with all known personal
injury cases and claims relating to Rezulin, and we settled many of
those cases and claims. Warner-Lambert continues to defend
vigorously the remaining personal injury cases and claims.
Warner-Lambert is also a defendant in a number of suits, including
purported class actions, relating to Rezulin that seek relief other
than damages for alleged personal injury. These suits are not
covered by the charge to earnings that we took in 2003. Motions
to certify statewide classes of Rezulin users or purchasers who
allegedly incurred economic loss have been denied by state courts
in California and Texas and granted by state courts in Illinois and
West Virginia. The Illinois action was settled in 2004.
In April 2001, Louisiana Health Service Indemnity Company and
Eastern States Health and Welfare Fund filed a consolidated
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complaint against Warner-Lambert in the U.S. District Court for the
Southern District of New York purportedly on behalf of a class
consisting of all health benefit providers that paid for or reimbursed
patients for the purchase of Rezulin between February 1997 and
April 2001. The action seeks to recover amounts paid for Rezulin
by the health benefit providers on behalf of their plan participants
during the specified period. In September 2005, the court granted
Warner-Lambert’s motion for summary judgment and dismissed the
complaint. In November 2005, the plaintiffs appealed the decision.
In addition, in May 2005, an action was filed in the U.S. District Court
for the Eastern District of Louisiana purportedly on behalf of a
nationwide class of third-party payors that asserts claims and seeks
damages that are substantially similar to those in the New York suit.
An action also was filed in July 2005 by the Attorney General of the
State of Louisiana in the Civil District Court for Orleans Parish,
Louisiana, against Warner-Lambert and Pfizer seeking to recover
amounts paid by the Louisiana Medicaid program for Rezulin and
for medical services to treat persons allegedly injured by Rezulin.
In 2005, the actions filed in the Eastern District of Louisiana and the
Civil District Court for Orleans Parish, Louisiana, were transferred
for consolidated pre-trial proceedings to a Multi-District Litigation
(In re Rezulin Products Liability Litigation MDL-1348) in the U.S.
District Court for the Southern District of New York, where the
action filed in April 2001 by Louisiana Health and Eastern States
Health had been brought.
Asbestos
• Quigley
Quigley Company, Inc. (Quigley), a wholly owned subsidiary, was
acquired by Pfizer in 1968 and sold small amounts of products
containing asbestos until the early 1970s. In September 2004, Pfizer
and Quigley took steps which, if approved by the courts and
claimants, will resolve all pending and future claims against Pfizer
and Quigley in which the claimants allege personal injury from
exposure to Quigley products containing asbestos, silica or mixed
dust. We took a charge of $369 million before-tax ($229 million after-
tax) to third quarter 2004 earnings in connection with these matters.
In September 2004, Quigley filed a petition in the U.S. Bankruptcy
Court for the Southern District of New York seeking reorganization
under Chapter 11 of the U.S. Bankruptcy Code. In March 2005,
Quigley filed a reorganization plan in the Bankruptcy Court that
must be approved by both the Bankruptcy Court and the U.S.
District Court for the Southern District of New York after receipt
of the vote of 75 percent of the claimants. In connection with that
filing, Pfizer entered into settlement agreements with lawyers
representing more than 80 percent of the individuals with claims
related to Quigley products against Quigley and Pfizer. The
agreements provide for a total of $430 million in payments, of
which $215 million became due in December 2005 and is being
paid to claimants upon receipt by the Company of certain required
documentation from each of the claimants. The reorganization
plan, the approval of which is considered probable, will establish
a Trust for the payment of all remaining pending claims as well
as any future claims alleging injury from exposure to Quigley
products. Pfizer will contribute $405 million to the Trust through
a note, which has a present value of $172 million, as well as
approximately $100 million in insurance, and will forgive a $30
million secured loan to Quigley. If approved by the courts and the
claimants, the reorganization plan will result in a permanent
injunction directing all future claims alleging personal injury
from exposure to Quigley products to the Trust.
In a separately negotiated transaction with an insurance company,
we agreed to a settlement related to certain insurance coverage
which provides for the payment to us over 10 years of an amount
with a present value of $263 million.
• Other Matters
Between 1967 and 1982, Warner-Lambert owned American
Optical Corporation, which manufactured and sold respiratory
protective devices and asbestos safety clothing. In connection
with the sale of American Optical in 1982, Warner-Lambert agreed
to indemnify the purchaser for certain liabilities, including certain
asbestos-related and other claims. As of December 31, 2005,
approximately 145,400 claims naming American Optical and
numerous other defendants were pending in various federal and
state courts seeking damages for alleged personal injury from
exposure to asbestos and other allegedly hazardous materials. We
are actively engaged in the defense of, and will continue to
explore various means to resolve, these claims. Several of the
insurance carriers that provided coverage for the American Optical
asbestos and other claims have denied coverage. We believe that
these carriers’ position is without merit and are pursuing legal
proceedings against such carriers. Separately, there is a small
number of lawsuits pending against Pfizer in various federal and
state courts seeking damages for alleged personal injury from
exposure to products containing asbestos and other allegedly
hazardous materials sold by Gibsonburg Lime Products Company,
which was acquired by Pfizer in the 1960s and which sold small
amounts of products containing asbestos until the early 1970s.
There also is a small number of lawsuits pending in various federal
and state courts seeking damages for alleged exposure to asbestos
in facilities owned or formerly owned by Pfizer or its subsidiaries.
Hormone-Replacement Therapy
Pfizer Inc.; Pharmacia Corporation (a direct, wholly owned
subsidiary of Pfizer Inc.); Pharmacia & Upjohn LLC and Warner-
Lambert Company LLC (limited liability companies wholly owned
by Pfizer Inc.); and Greenstone Ltd. (an indirect, wholly owned
subsidiary of Pfizer Inc.), along with several other pharmaceutical
manufacturers, have been named as defendants in a number of
lawsuits in various federal and state courts alleging personal
injury resulting from the use of certain estrogen and progestin
medications prescribed for women to treat the symptoms of
menopause. Plaintiffs in these suits allege a variety of personal
injuries, including breast cancer, stroke and heart disease. Certain
co-defendants in some of these actions have asserted
indemnification rights against Pfizer and its affiliated companies.
The cases against Pfizer and its affiliated companies involve the
products femhrt (which Pfizer divested in 2003), Activella and
Vagifem (which are Novo Nordisk products that were marketed
by a Pfizer affiliate from 2000 to 2004), and Provera, Ogen, Depo-
Estradiol, Estring and generic MPA, all of which remain approved
by the FDA for use in the treatment of menopause. The federal
court cases have been transferred for consolidated pre-trial
proceedings to a Multi-District Litigation (In re Prempro Products
Liability Litigation MDL-1507) in the U.S. District Court for the
Eastern District of Arkansas.
This litigation originally included both individual actions as well
as various purported nationwide and statewide class actions.
However, each of the purported class actions, except one
purported statewide class action filed in the Supreme Court of the
State of New York, County of New York, either has been
voluntarily dismissed in its entirety or has had its class action
allegations stricken by the plaintiffs.
2005 Financial Report 65
Notes to Consolidated Financial Statements
Pfizer Inc and Subsidiary Companies
Viagra
A number of lawsuits, including purported class actions, have been
filed against us in various federal and state courts alleging that
Viagra causes certain types of visual injuries. The plaintiffs in the
purported class actions seek to represent nationwide and certain
statewide classes of Viagra users. All of the actions seek damages
for personal injury, and the purported class actions also seek
medical monitoring. In January 2006, the federal court cases
were transferred for consolidated pre-trial proceedings to a
Multi-District Litigation (In re Viagra Products Liability Litigation
MDL-1724) in the U.S. District Court for the District of Minnesota.
Zoloft
A number of individual lawsuits have been filed against us in various
federal and state courts alleging personal injury, including suicide and
suicide attempt in certain cases, as a result of ingesting Zoloft.
C. Consumer and Commercial Matters
Neurontin
A number of lawsuits, including purported class actions, have been
filed against us in various federal and state courts alleging claims
arising from the promotion and sale of Neurontin. The plaintiffs
in the purported class actions seek to represent nationwide and
certain statewide classes consisting of persons, including
individuals, health insurers, employee benefit plans and other
third-party payors, who purchased or reimbursed patients for
the purchase of Neurontin that allegedly was used for indications
other than those included in the product labeling approved by the
FDA. In October 2004, many of the suits pending in federal courts,
including individual actions as well as purported class actions, were
transferred for consolidated pre-trial proceedings to a Multi-
District Litigation (In re Neurontin Marketing, Sales Practices and
Product Liability Litigation MDL-1629) in the U.S. District Court for
the District of Massachusetts. Purported class actions also have
been filed against us in various Canadian provincial courts alleging
claims arising from the promotion and sale of Neurontin.
A number of individual lawsuits also have been filed against us
in various U.S. federal and state courts and in certain other
countries alleging personal injury, including suicide and suicide
attempt in certain cases, as a result of ingesting Neurontin.
Certain of the federal court actions have been transferred for
consolidated pre-trial proceedings to the same Multi-District
Litigation referred to in the preceding paragraph.
Lipitor
Since September 2005, three purported class actions have been filed
against us in various federal courts alleging claims relating to the
promotion of Lipitor. In January 2006, two of the actions were
voluntarily dismissed without prejudice. In the remaining action,
which is pending in the U.S. District Court for the Southern District
of Florida, the plaintiffs seek to represent a nationwide class
consisting of women (regardless of age) and men over age 65
who in each case had no history of heart disease or diabetes and
who purchased Lipitor within four years before the filing of the
action. The plaintiffs allege that the Company engaged in false and
misleading advertising in violation of state consumer protection
laws by allegedly promoting Lipitor for the prevention of heart
disease in the aforementioned two groups. The action seeks
monetary and injunctive relief, including treble damages. In
addition, a purported class action on behalf of residents of the
Province of Quebec has been filed against us in Canada that asserts
claims under Canadian law and seeks relief substantially similar to
the claims asserted and the relief sought in the U.S. action.
Average Wholesale Price Litigation
A number of states and counties have sued Pharmacia, Pfizer and
other pharmaceutical manufacturers alleging that they sold
certain products at prices lower than the published average
wholesale price (AWP). The AWP is used to determine
reimbursement levels under Medicare Part B and under many
private-sector insurance policies and medical plans. Several of the
suits also allege that Pharmacia and/or Pfizer did not report to the
states its best price for certain products under the Medicaid
program. Each of these suits alleges, among other things,
deceptive trade practices and fraud and seeks monetary and
other relief, including civil penalties and treble damages.
In addition, Pharmacia, Pfizer and other pharmaceutical
manufacturers are defendants in a number of purported class
action suits in various federal and state courts brought by
employee benefit plans and self-styled public interest groups
that assert claims similar to those in the state and county actions.
These suits allege, among other things, fraud, unfair competition
and unfair trade practices and seek monetary and other relief,
including civil penalties and treble damages.
All of these state, county and purported class action suits were
transferred for consolidated pre-trial proceedings to a Multi-
District Litigation (In re Pharmaceutical Industry Average Wholesale
Price Litigation MDL-1456) in the U.S. District Court for the District
of Massachusetts. Certain of the state suits and one of the private
suits have been remanded to their respective state courts.
D. Celebrex and Bextra Matters
In 2003, several purported class action complaints were filed in the
U.S. District Court for the District of New Jersey by persons who claim
to have been purchasers of publicly traded securities of Pharmacia
during the period from April 17, 2000 through August 22, 2001 (the
Purported Class Period). Named as defendants in the actions are
Pharmacia, Pfizer and certain former officers of Pharmacia. The
complaints allege that the defendants violated federal securities laws
by misrepresenting the data from a study concerning the
gastrointestinal effects of Celebrex. These cases have been
consolidated for pre-trial proceedings in the District of New Jersey
(Alaska Electrical Pension Fund et al. v. Pharmacia Corporation et al.).
Plaintiffs purport to represent a class of all persons who purchased
Pharmacia securities during the Purported Class Period and were
damaged as a result of the decline in the price of Pharmacia’s
securities allegedly attributable to the misrepresentations. Plaintiffs
seek damages in an unspecified amount.
Pfizer is a defendant in product liability suits, including purported
class actions, in various U.S. federal and state courts and in certain
other countries alleging personal injury as a result of the use of
Celebrex and/or Bextra. These suits include a purported class
action filed in 2001 in the U.S. District Court for the Eastern
District of New York as well as actions that have been filed since
late 2004. In addition, beginning in late 2004, purported class
actions have been filed against Pfizer in various U.S. federal and
state courts and in certain other countries alleging consumer
fraud as the result of alleged false advertising of Celebrex and
Bextra and the withholding of information from the public
regarding the alleged safety risks associated with Celebrex and
Bextra. The plaintiffs in these consumer fraud actions seek
damages in unspecified amounts for economic loss. In September
2005, the U.S. federal product liability and consumer fraud actions
were transferred for consolidated pre-trial proceedings to a
Multi-District Litigation (In re Celebrex and Bextra Marketing, Sales
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Practices and Product Liability Litigation MDL-1699) in the U.S.
District Court for the Northern District of California.
Beginning in late 2004, actions, including purported class and
shareholder derivative actions, have been filed in various federal
and state courts against Pfizer, Pharmacia and certain current and
former officers, directors and employees of Pfizer and Pharmacia.
These actions include: (i) purported class actions alleging that
Pfizer and certain officers of Pfizer violated federal securities laws
by misrepresenting the safety of Celebrex and Bextra; (ii) purported
shareholder derivative actions alleging that certain of Pfizer’s
current and former officers and directors breached fiduciary duties
by causing Pfizer to misrepresent the safety of Celebrex and, in
certain of the cases, Bextra; and (iii) purported class actions filed
by persons who claim to be participants in the Pfizer or Pharmacia
Savings Plan alleging that Pfizer and certain officers, directors and
employees of Pfizer or, where applicable, Pharmacia and certain
former officers, directors and employees of Pharmacia, violated
certain provisions of the Employee Retirement Income Security
Act of 1974 (ERISA) by selecting and maintaining Pfizer stock as an
investment alternative when it allegedly no longer was a suitable
or prudent investment option. In June 2005, the federal securities,
fiduciary duty and ERISA actions were transferred for consolidated
pre-trial proceedings to a Multi-District Litigation (In re Pfizer Inc.
Securities, Derivative and “ERISA” Litigation MDL-1688) in the U.S.
District Court for the Southern District of New York.
In July 2005, an action was filed by the Attorney General of the
State of Louisiana in the Civil District Court for Orleans Parish,
Louisiana, against Pfizer seeking to recover amounts paid by the
Louisiana Medicaid program for Celebrex and Bextra and for
medical services to treat persons allegedly injured by Celebrex or
Bextra. The action also seeks injunctive relief to prevent the sale
of Celebrex and any resumption of the sale of Bextra in Louisiana.
E. Other Matters
Monsanto-Related Matters
In 1997, Monsanto Company (Former Monsanto) contributed
certain chemical manufacturing operations and facilities to a
newly formed corporation, Solutia Inc. (Solutia), and spun off the
shares of Solutia. In 2000, Former Monsanto merged with
Pharmacia & Upjohn to form Pharmacia Corporation (Pharmacia).
Pharmacia then transferred its agricultural operations to a newly
created subsidiary, named Monsanto Company (New Monsanto),
which it spun off in a two-stage process that was completed in
2002. Pharmacia was acquired by Pfizer in 2003 and is now a
wholly owned subsidiary of Pfizer.
In connection with its spin-off that was completed in 2002, New
Monsanto assumed, and agreed to indemnify Pharmacia for, any
liabilities related to Pharmacia’s former agricultural business.
New Monsanto is defending and indemnifying Pharmacia for
various claims and litigation arising out of or related to the
agricultural business.
In connection with its spin-off in 1997, Solutia assumed, and
agreed to indemnify Pharmacia for, liabilities related to Former
Monsanto’s chemical businesses. As a result, while Pharmacia
remains a defendant in various legal proceedings involving Former
Monsanto’s chemical businesses, Solutia manages the litigation
and is responsible for all costs and expenses and any judgment or
settlement amounts. In addition, in connection with its spin-off
that was completed in 2002, New Monsanto assumed, and agreed
to indemnify Pharmacia for, any liabilities primarily related to
Former Monsanto’s chemical businesses, including any such
liabilities that Solutia assumed. Solutia’s and New Monsanto’s
assumption of and agreement to indemnify Pharmacia for these
liabilities apply to pending actions and any future actions related
to Former Monsanto’s chemical businesses in which Pharmacia is
named as a defendant, including, without limitation, actions
asserting environmental claims, including alleged exposure to
polychlorinated biphenyls.
In December 2003, Solutia filed a petition in the U.S. Bankruptcy
Court for the Southern District of New York seeking reorganization
under Chapter 11 of the U.S. Bankruptcy Code. Solutia asked the
Bankruptcy Court to relieve it from liabilities related to Former
Monsanto’s chemical businesses that were assumed by Solutia in
1997. In addition, motions were filed by Solutia in the Chapter 11
proceeding and other actions were filed in the Bankruptcy Court
by Solutia and by a committee representing the interests of Solutia’s
shareholders that seek to avoid all or a portion of Solutia’s
obligations to Pharmacia. Should the Bankruptcy Court grant such
relief, New Monsanto would be responsible for such liabilities
under its indemnification agreement with Pharmacia.
In December 2003, Solutia filed an action, also in the U.S.
Bankruptcy Court for the Southern District of New York, seeking
a determination that Pharmacia rather than Solutia is responsible
for an estimated $475 million in health care benefits for certain
Solutia retirees. A similar action was filed in May 2004 in the
same Bankruptcy Court against Pharmacia and New Monsanto by
a committee appointed to represent Solutia retirees in the
Bankruptcy Court proceedings. The parties have agreed to a
standstill of these actions. In the event that the standstill
terminates, Pharmacia and New Monsanto will vigorously defend
these actions. Under its indemnification agreement with Pharmacia,
New Monsanto will be responsible for the costs and expenses
and any judgment or settlement amounts in these actions.
On February 14, 2006, Solutia filed its plan of reorganization in the
Bankruptcy Court. The plan, which must be approved by the
Bankruptcy Court, provides that all lawsuits filed against Pharmacia
in the Bankruptcy court by Solutia, the committee representing
Solutia retirees and the committee representing Solutia’s
shareholders will be dismissed or withdrawn with prejudice.
The plan provides that Solutia’s indemnity obligations to Pharmacia
that arose in connection with Solutia’s 1997 spin-off will be shared
between Solutia and New Monsanto. New Monsanto will be
financially responsible for all environmental remediation costs at
certain sites that Solutia never owned or operated. Solutia will
continue to be financially responsible for all environmental
remediation costs at sites that Solutia has owned or operated. New
Monsanto and Solutia will share the environmental remediation
costs of certain other sites. The plan also provides that Solutia will
indemnify Pharmacia for any environmental remediation costs
that Solutia continues to be liable for under the plan. In addition,
the plan provides that New Monsanto will be financially responsible
for all current and future personal injury tort claims related to
Former Monsanto’s chemical businesses that Solutia assumed in
connection with the 1997 spin-off. 
The plan also will implement a settlement entered into between
Solutia and the committee representing Solutia retirees. Under the
settlement, the retirees will agree to certain modifications to
their benefit plan. The settlement also provides that New Monsanto
will contribute $175 million to help Solutia fund certain legacy
healthcare, life and disability insurance benefits. The retirees will
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will provide Pharmacia with a release of all retiree benefit claims.
Solutia will continue to be liable for retiree benefits, as modified.
The plan does not in any way affect the obligations undertaken
by New Monsanto to indemnify Pharmacia for all liabilities that
Solutia originally assumed in connection with the 1997 spin-off.
Importation Cases
In 2004, a number of purported class actions were filed in the U.S.
District Court for the District of Minnesota alleging that Pfizer and
several other pharmaceutical manufacturers violated federal and
state civil antitrust laws by conspiring to prevent the importation
of brand-name prescription drugs from Canada. These suits were
consolidated into a single action in the District of Minnesota (In
re Canadian Import Antitrust Litigation), which seeks to represent
a nationwide class consisting of all persons who purchased or
reimbursed patients for the purchase of prescription drugs
manufactured and marketed by defendants that also are available
in Canada. Plaintiffs claim that, as a result of the alleged
conspiracy, U.S. prices for defendants’ prescription drugs are
higher than they otherwise would be. Plaintiffs seek monetary
relief, including treble damages and a refund of the allegedly
unlawful profits received by defendants, and injunctive relief. In
August 2005, the court granted the defendants’ motion to dismiss
this action, and the plaintiffs have appealed the decision.
Also in 2004, a number of independent pharmacists in California
filed an action in California Superior Court, Alameda County,
against Pfizer and several other pharmaceutical manufacturers. The
complaint, as amended, asserts that the defendants conspired to
fix the prices of their prescription drugs in California, using the prices
at which such drugs are sold in Canada as the minimum prices, in
violation of California antitrust and unfair business practices laws.
Environmental Matters
We will be required to submit a corrective measures study report
to the U.S. Environmental Protection Agency with regard to
Pharmacia’s discontinued industrial chemical facility in North
Haven, Connecticut.
We are a party to a number of other proceedings brought under
the Comprehensive Environmental Response Compensation and
Liability Act of 1980, as amended, (CERCLA or Superfund) and
other state, local or foreign laws in which the primary relief
sought is the cost of past and/or future remediation.
F. Government Investigations and Requests for
Information
Like other pharmaceutical companies, we are subject to extensive
regulation by national, state and local government agencies in the
U.S. and in the other countries in which we operate. As a result,
we have interactions with government agencies on an ongoing
basis. The principal pending investigations and requests for
information by government agencies are as follows:
We received requests for information and documents from the
Department of Justice in 2003 concerning the marketing of
Genotropin as well as certain managed care payments, and in 2005
concerning certain physician payments budgeted to our
prescription pharmaceutical products.
In 2003 and 2004, we received requests for information and
documents concerning the marketing and safety of Bextra and
Celebrex from the Department of Justice and a group of state
attorneys general. In 2005, we received a similar request from the
staff of the Securities and Exchange Commission.
In 2005, the Department of Justice informed us that it is
investigating Pharmacia’s former contractual relationship with a
health care intermediary.
The Company has voluntarily provided the Department of Justice
and the Securities and Exchange Commission information
concerning certain potentially improper payments made in
connection with foreign sales activities in certain countries. In Italy,
Pfizer Italia S.r.l., an indirect, wholly owned subsidiary of Pfizer
Inc., has been notified that it is under criminal investigation by
the Public Attorney’s office in Bari, Italy, with respect to gifts and
payments allegedly provided to certain doctors operating within
Italy’s national healthcare system. Pfizer Italia intends to continue
to fully cooperate with the Public Attorney’s office.
We received a letter from the Office of the Attorney General of
the State of New York in 2004 requesting documents and
information concerning clinical trials of certain of our
pharmaceutical products for indications other than those approved
by the FDA and concerning possible promotion of those products
for such indications. We also received a letter from the Office of
the Attorney General of the State of Connecticut in 2004
requesting similar materials concerning Zoloft.
G. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale
of assets and businesses, we often indemnify our counterparties
against certain liabilities that may arise in connection with the
transaction or related to activities prior to the transaction. These
indemnifications typically pertain to environmental, tax, employee
and/or product-related matters. If the indemnified party were to
make a successful claim pursuant to the terms of the
indemnification, we would be required to reimburse the loss.
These indemnifications are generally subject to threshold amounts,
specified claim periods and other restrictions and limitations.
Historically, we have not paid significant amounts under these
provisions and at December 31, 2005, recorded amounts for the
estimated fair value of these indemnifications are not material.
19. Segment, Geographic and 
Revenue Information
Business Segments
We operate in the following business segments:
• Human Health
— The Human Health segment, which represents our
pharmaceutical business, includes treatments for
cardiovascular and metabolic diseases, central nervous
system disorders, arthritis and pain, infectious and
respiratory diseases, urogenital conditions, cancer, eye
disease, endocrine disorders and allergies.
• Consumer Healthcare
— The Consumer Healthcare segment includes self-medications
for oral care, upper-respiratory health, tobacco dependence,
gastrointestinal health, skin care, eye care and hair growth.
• Animal Health
— The Animal Health segment includes prevention and
treatments for diseases in livestock and companion animals.
We operate several other businesses, including the manufacture
of empty soft-gelatin capsules, contract manufacturing and bulk
pharmaceutical chemicals. Due to the size of these businesses, they
are grouped into the “Corporate/Other” category.
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For our reportable operating segments (i.e., Human Health,
Consumer Healthcare, Animal Health), segment profit/(loss) is
measured based on income from continuing operations before
provision for taxes on income, minority interests and the
cumulative effect of a change in accounting principles and before
certain costs, such as significant impacts of purchase accounting
for acquisitions and merger-related costs. This methodology is
utilized by management to evaluate each business.
Certain income/(expense) items that are excluded from the
operating segments’ profit/(loss) are considered corporate items
and are included in Corporate/Other. These items include interest
income/(expense), corporate expenses (e.g., corporate
administration costs), other income/(expense) items (e.g., realized
gains and losses attributable to our investments in debt and
equity securities), certain performance-based compensation
expenses not allocated to the business segments, significant
impacts of purchase accounting for acquisitions, certain milestone
payments, merger-related costs, intangible asset impairments
and costs related to our new productivity initiative.
Each segment is managed separately and offers different products
requiring different marketing and distribution strategies.
We sell our products primarily to customers in the wholesale
sector. In 2005, sales to our three largest U.S. wholesaler customers
represented approximately 18%, 13% and 10% of total revenues
and, collectively, represented approximately 25% of accounts
receivable at December 31, 2005. In 2004, sales to the three
largest U.S. wholesalers represented approximately 18%, 14% and
13% of total revenues and, collectively, represented approximately
25% of accounts receivable at December 31, 2004. These sales and
related accounts receivable were concentrated in the Human
Health segment.
Revenues exceeded $500 million in each of 12 countries outside
the U.S. in 2005 and each of ten countries outside the U.S. in 2004.
The U.S. was the only country to contribute more than 10% of
total revenues in each year.
The 2005, 2004 and 2003 financial statement elements highlighted
below reflect the impact of our acquisition of Pharmacia on
April 16, 2003.
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The following tables present segment, geographic and revenue information:
Segment
FOR/AS OF THE YEAR ENDED DEC. 31,
(MILLIONS OF DOLLARS) 2005 2004 2003
Revenues
Human Health $44,284 $46,133 $39,425
Consumer Healthcare 3,878 3,516 2,949
Animal Health 2,206 1,953 1,598
Corporate/Other(a) 930 914 764
Total revenues $51,298 $52,516 $44,736
Segment profit/(loss)(b)
Human Health $19,594 $20,927 $16,719
Consumer Healthcare 698 667 613
Animal Health 405 353 247
Corporate/Other(a) (9,163)(c) (7,940)(d) (14,333)(e)
Total profit/(loss) $11,534 $14,007 $3,246
Identifiable assets
Human Health $74,406 $81,651 $80,952
Consumer Healthcare 6,060 5,886 5,602
Animal Health 2,098 1,992 1,870
Corporate/Other(a) 35,001 33,549 28,351
Total identifiable assets $117,565 $123,078 $116,775
Property, plant and equipment additions(f)
Human Health $1,755 $2,268 $2,127
Consumer Healthcare 136 76 98
Animal Health 61 95 57
Corporate/Other(a) 154 162 347
Total property, plant and equipment additions $2,106 $2,601 $2,629
Depreciation and amortization(f)
Human Health $1,901 $1,490 $1,427
Consumer Healthcare 57 64 70
Animal Health 59 57 58
Corporate/Other(a) 3,559(g) 3,482(g) 2,470(g)
Total depreciation and amortization $5,576 $5,093 $4,025
(a) Corporate/Other includes our other businesses, which include the
manufacturing of empty soft-gelatin capsules, contract
manufacturing and bulk pharmaceutical chemicals.
Corporate/Other also includes interest income/(expense), corporate
expenses (e.g., corporate administration costs), other
income/(expense) (e.g., realized gains and losses attributable to
our investments in debt and equity securities), certain
performance-based compensation expenses not allocated to the
business segments, significant impacts of purchase accounting for
acquisitions, certain milestone payments, merger-related costs,
intangible asset impairments and costs related to our new
productivity initiative.
(b) Segment profit/(loss) equals income from continuing operations
before provision for taxes on income, minority interests and the
cumulative effect of a change in accounting principles and
before certain costs, such as significant impacts of purchase
accounting for acquisitions, merger-related costs and costs
related to our new productivity initiative. This methodology is
utilized by management to evaluate each business.
(c) In 2005, Corporate/Other includes (i) significant impacts of
purchase accounting for acquisitions of $5.0 billion, including
acquired IPR&D, incremental intangible asset amortization and
other charges, (ii) merger-related costs of $943 million, (iii)
restructuring charges and implementation costs associated with
the Adapting to Scale initiative of $780 million, and (iv) costs
associated with the suspension of Bextra’s sales and marketing
of $1.2 billion.
(d) In 2004, Corporate/Other includes (i) significant impacts of purchase
accounting for acquisitions of $4.4 billion, including acquired IPR&D,
incremental intangible asset amortization and other charges, and
the sale of acquired inventory written up to fair value, (ii) merger-
related costs of $1.2 billion, (iii) an impairment charge of $691
million for Depo-Provera, (iv) a $369 million charge for litigation-
related matters, (v) contingent income earned from the 2003 sale of
a product-in-development of $100 million, (vi) the operating results
of a divested legacy Pharmacia research facility of $64 million, and
(vii) other legacy Pharmacia intangible asset impairments of $11
million.
(e) In 2003, Corporate/Other includes (i) significant impacts of purchase
accounting for acquisitions of $10.1 billion including acquired
IPR&D, the sale of acquired inventory written up to fair value and
incremental intangible asset amortization and other charges, (ii)
merger-related costs of $1.1 billion, and (iii) litigation charges of
$1.4 billion.
(f) Certain production facilities are shared by various segments.
Property, plant and equipment, as well as capital additions and
depreciation, are allocated based on physical production.
Corporate assets are primarily cash, short-term investments, long-
term loans and investments and assets held for sale.
(g) In 2005, 2004 and 2003, Corporate/Other includes charges
associated with purchase accounting.
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Geographic
FOR/AS OF THE YEAR ENDED DEC. 31,
(MILLIONS OF DOLLARS) 2005 2004 2003
Revenues
United States(a) $26,664 $29,539 $26,795
Japan 3,578 3,250 2,626
All other countries 21,056 19,727 15,315
Consolidated $51,298 $52,516 $44,736
Long-lived assets(b)
United States(a) $25,825 $29,069 $31,806
Japan 391 502 630
All other countries 18,660 22,065 21,311
Consolidated $44,876 $51,636 $53,747
(a) Includes operations in Puerto Rico.
(b) Long-lived assets include identifiable intangible assets (excluding goodwill) and property, plant and equipment.
Revenues by Therapeutic Area
FOR/AS OF THE YEAR ENDED DEC. 31,
(MILLIONS OF DOLLARS) 2005 2004 2003
Human Health
Cardiovascular and metabolic diseases $18,732 $17,412 $15,846
Central nervous system disorders 6,391 8,092 7,378
Arthritis and pain 2,376 5,203 3,046
Infectious and respiratory diseases 4,766 4,715 4,677
Urology 2,684 2,634 2,457
Oncology 1,996 1,502 875
Ophthalmology 1,373 1,227 668
Endocrine disorders 1,049 925 550
All other 3,852 3,702 3,169
Alliance revenue 1,065 721 759
Total Human Health 44,284 46,133 39,425
Consumer Healthcare 3,878 3,516 2,949
Animal Health 2,206 1,953 1,598
Other 930 914 764
Total revenues $51,298 $52,516 $44,736
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QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2005
Revenues $13,091 $12,425 $12,189 $13,592
Costs and expenses 9,960 8,834 8,295 9,631
Merger-related in-process research and development charges 2 260 1,390 —
Restructuring charges and merger-related costs 219 270 307 596
Income from continuing operations before provision for taxes 
on income, and minority interests 2,910 3,061 2,197 3,365
Provision/(benefit) for taxes on income 2,635 (413) 591 610
Minority interests 3 2 4 7
Income from continuing operations 272 3,472 1,602 2,748
Discontinued operations:
(Loss) income from discontinued operations—net of tax (12) (9) (16) 6
Gains on sales of discontinued operations—net of tax 41 — 3 3
Discontinued operations—net of tax 29 (9) (13) 9
Cumulative effect of a change in accounting principles — — — (25)
Net income $ 301 $ 3,463 $ 1,589 $ 2,732
Earnings per common share—basic:
Income from continuing operations $ 0.04 $ 0.47 $ 0.22 $ 0.37
Discontinued operations—net of tax — — — —
Cumulative effect of a change in accounting principles — — — —
Net income $ 0.04 $ 0.47 $ 0.22 $ 0.37
Earnings per common share—diluted:
Income from continuing operations $ 0.04 $ 0.47 $ 0.22 $ 0.37
Discontinued operations—net of tax — — — —
Cumulative effect of a change in accounting principles — — — —
Net income $ 0.04 $ 0.47 $ 0.22 $ 0.37
Cash dividends paid per common share $ 0.19 $ 0.19 $ 0.19 $ 0.19
Stock prices
High $ 27.75 $ 29.21 $ 27.82 $ 25.57
Low $ 23.80 $ 25.52 $ 24.67 $ 20.27
Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc and Subsidiary Companies
Merger-related in-process research and development charges
primarily includes amounts incurred in connection with our
acquisition of Vicuron and Idun (see Note 2B, Acquisitions: Other
Acquisitions).
Restructuring charges and merger-related costs include
integration and restructuring costs primarily related to our
acquisition of Pharmacia (see Note 5, Merger-Related Costs) and
the restructuring charges related to our AtS initiative (see Note 4,
Adapting to Scale Initiative).
As of January 31, 2006, there were 254,564 record holders of our
common stock (symbol PFE).
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QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2004
Revenues $12,487 $12,274 $12,831 $14,924
Costs and expenses 8,156 8,557 8,690 10,842
Merger-related in-process research and development charges 955 — — 116
Restructuring charges and merger-related costs 247 289 190 467
Income from continuing operations before provision for taxes 
on income, and minority interests 3,129 3,428 3,951 3,499
Provision for taxes on income 809 582 650 625
Minority interests 2 2 3 3
Income from continuing operations 2,318 2,844 3,298 2,871
Discontinued operations:
Income/(loss) from discontinued operations—net of tax 13 17 (3) (49)
Gains on sales of discontinued operations—net of tax — 2 46 3
Discontinued operations—net of tax 13 19 43 (46)
Net income $ 2,331 $ 2,863 $ 3,341 $ 2,825
Earnings per common share—basic:
Income from continuing operations $ 0.31 $ 0.38 $ 0.44 $ 0.39
Discontinued operations—net of tax — — 0.01 (0.01)
Net income $ 0.31 $ 0.38 $ 0.45 $ 0.38
Earnings per common share—diluted:
Income from continuing operations $ 0.30 $ 0.38 $ 0.43 $ 0.39
Discontinued operations—net of tax — — 0.01 (0.01)
Net income $ 0.30 $ 0.38 $ 0.44 $ 0.38
Cash dividends paid per common share $ 0.17 $ 0.17 $ 0.17 $ 0.17
Stock prices
High $ 38.89 $ 37.90 $ 34.63 $ 31.50
Low $ 33.50 $ 33.82 $ 29.60 $ 21.99
All financial information reflects the following as discontinued
operations: our in-vitro allergy and autoimmune diagnostics
testing, surgical ophthalmics, certain European generics, as well as
certain non-core consumer healthcare product lines (primarily
marketed in Europe) and the femhrt, Loestrin and Estrostep
women’s health product lines (see Note 3, Dispositions).
Merger-related in-process research and development charges
primarily includes amounts incurred in connection with our
acquisition of Esperion (see Note 2B, Acquisitions: Other
Acquisitions).
Restructuring charges and merger-related costs include
integration and restructuring costs primarily related to our
acquisition of Pharmacia (see Note 5, Merger-Related Costs).
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AS OF/FOR THE YEAR ENDED DECEMBER 31
(MILLIONS, EXCEPT PER COMMON SHARE DATA) 2005 2004 2003 2002 2001 2000
Revenues(a) $51,298 $52,516 $44,736 $32,294 $28,947 $25,958
Research and development expenses(b) 7,442 7,684 7,487 5,208 4,982 4,374
Other costs and expenses 29,278 28,561 27,893 14,690 13,183 12,890
Merger-related in-process research and development charges(c) 1,652 1,071 5,052 — — —
Restructuring charges and merger-related costs(d) 1,392 1,193 1,058 630 819 3,223
Income from continuing operations before provision for taxes 
on income, minority interests and cumulative effect of a change 
in accounting principles 11,534 14,007 3,246 11,766 9,963 5,471
Provision for taxes on income (3,424) (2,665) (1,614) (2,599) (2,426) (1,936)
Income from continuing operations before cumulative effect of 
a change in accounting principles 8,094 11,332 1,629 9,161 7,523 3,522
Discontinued operations—net of tax 16 29 2,311 375 265 204
Cumulative effect of a change in accounting principles—net of tax(e) (25) — (30) (410) — —
Net income 8,085 11,361 3,910 9,126 7,788 3,726
Effective tax rate—continuing operations 29.7% 19.0% 49.7% 22.1% 24.4% 35.4%
Depreciation and amortization 5,576 5,093 4,025 1,030 965 877
Property, plant and equipment additions 2,106 2,601 2,629 1,758 2,105 2,073
Cash dividends paid 5,555 5,082 4,353 3,168 2,715 2,197
Working capital(f) 13,448 12,630 6,768 6,242 5,502 6,073
Property, plant and equipment—net 17,090 18,385 18,156 10,712 9,783 8,757
Total assets(f) 117,565 123,078 116,775 46,356 39,153 33,510
Long-term debt 6,347 7,279 5,755 3,140 2,609 1,123
Long-term capital(g) 82,291 87,646 84,203 23,505 21,348 17,575
Shareholders’ equity 65,627 68,278 65,377 19,950 18,293 16,076
Earnings per common share—basic:
Income from continuing operations before cumulative effect of 
a change in accounting principles 1.10 1.51 0.22 1.49 1.21 0.57
Discontinued operations—net of tax — — 0.32 0.06 0.04 0.03
Cumulative effect of a change in accounting principles—net of tax(e) — — — (0.07) — —
Net income 1.10 1.51 0.54 1.48 1.25 0.60
Earnings per common share—diluted:
Income from continuing operations before cumulative effect of 
a change in accounting principles 1.09 1.49 0.22 1.47 1.18 0.56
Discontinued operations—net of tax — — 0.32 0.06 0.04 0.03
Cumulative effect of a change in accounting principles—net of tax(e) — — — (0.07) — —
Net income 1.09 1.49 0.54 1.46 1.22 0.59
Market value per share (December 31) 23.32 26.89 35.33 30.57 39.85 46.00
Return on shareholders’ equity 12.1% 17.0% 9.2% 47.7% 45.3% 24.8%
Cash dividends paid per common share 0.76 0.68 0.60 0.52 0.44 0.36
Shareholders’ equity per common share 8.96 9.19 8.63 3.27 2.95 2.58
Current ratio 1.47:1 1.48:1 1.28:1 1.34:1 1.40:1 1.50:1
Weighted average shares used to calculate:
Basic earnings per common share amounts 7,361 7,531 7,213 6,156 6,239 6,210
Diluted earnings per common share amounts 7,411 7,614 7,286 6,241 6,361 6,368
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2004 — Integration costs of $475 million and restructuring charges
of $704 million related to our acquisition of Pharmacia in 2003.
2003 — Integration costs of $838 million and restructuring charges
of $177 million related to our acquisition of Pharmacia in 2003.
2002 — Integration costs of $345 million and restructuring
charges of $187 million related to our merger with Warner-
Lambert in 2000 and pre-integration costs of $98 million related
to our pending acquisition of Pharmacia.
2001 — Integration costs of $456 million and restructuring
charges of $363 million related to our merger with Warner-
Lambert in 2000.
2000 — Transaction costs directly related to our merger with
Warner-Lambert of $226 million; costs related to Warner-
Lambert’s termination of the Warner-Lambert/American Home
Products merger of $1.8 billion; integration costs of $242 million
and restructuring charges of $917 million.
(e) In 2005, as a result of adopting FIN 47, Accounting for Conditional
Asset Retirement Obligations, we recorded a non-cash pre-tax
charge of $40 million ($25 million, net of tax). In 2003, as a result
of adopting SFAS No.143, Accounting for Asset Retirement
Obligations, we recorded a non-cash pre-tax charge of $47 million
($30 million, net of tax).
In 2002, as a result of adopting SFAS No.142, Goodwill and Other
Intangible Assets, we recorded pre-tax charges of $565 million
($410 million, net of tax).
(f) For 2004, 2003, 2002, 2001 and 2000, includes assets held for sale
of our in-vitro allergy and autoimmune diagnostic testing, surgical
ophthalmic, certain European generics, confectionery and shaving
businesses (and the Tetra business in 2001 and 2000) as well as
certain non-core consumer healthcare products (primarily
marketed in Europe) and the femhrt, Loestrin and Estrostep
women’s health product lines.
(g) Defined as long-term debt, deferred taxes, minority interests and
shareholders’ equity.
On April 16, 2003, Pfizer acquired Pharmacia Corporation, in a transaction
accounted for as a purchase. All financial information reflects the
following as discontinued operations: our in-vitro allergy and autoimmune
diagnostic testing, certain European generics, surgical ophthalmic,
confectionery, shaving and fish-care products businesses as well as certain
non-core consumer healthcare product lines (primarily marketed in
Europe) and the femhrt, Loestrin and Estrostep women’s health product
lines, as applicable.
In addition, depreciation and amortization includes amortization of
goodwill prior to our adoption of SFAS No.142, Goodwill and Other
Intangible Assets, in 2002.
(a) In 2001, we brought the accounting methodology pertaining to
accruals for estimated liabilities related to Medicaid discounts and
contract rebates of Warner-Lambert into conformity with our
historical method. This adjustment increased revenues in 2001 by
$175 million. 2001 and 2000 data reflect reclassifications between
Revenues and Other costs and expenses of $108 million in 2001,
and $105 million in 2000 as a result of the January 1, 2002
adoption of EITF Issue No.00-25, Vendor Income Statement
Characterization of Consideration Paid to a Reseller of the
Vendor’s Products.
(b) Research and development expenses includes co-promotion
charges and milestone payments for intellectual property rights of
$156 million in 2005; $160 million in 2004; $380 million in 2003;
$32 million in 2002; and $206 million in 2001.
(c) In 2005, 2004 and 2003, we recorded charges for the estimated
portion of the purchase price of acquisitions allocated to in-
process research and development.
(d) Restructuring charges and merger-related costs primarily includes
the following:
2005 — Integration costs of $538 million and restructuring
charges of $390 million related to our acquisition of Pharmacia in
2003 and restructuring charges of $450 million related to our AtS
productivity initiative.
